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SUMMARY 
Essentially all biological processes depend on protein-protein interactions (PPIs). Timing of 
such interactions is crucial for regulatory function. Although circadian (~24 hrs) clocks 
constitute fundamental cellular timing mechanisms regulating important physiological 
processes PPI dynamics on this timescale are largely unknown. 
To elucidate so far unknown regulatory mechanisms within the circadian clockwork, I have 
systematically mapped PPIs among 46 circadian components using high-throughput yeast-
two-hybrid (Y2H) interaction experiments. I have identified 109 so far uncharacterized 
interactions and successfully validated a sub-fraction via co-immunoprecipitation experiments 
in human cells. Among the novel PPIs, I have identified modulators of CLOCK/BMAL1 
function and further characterized the role of protein phosphatase 1 (PP1) in the dynamic 
regulation of BMAL1 abundance. Furthermore, to generate a more comprehensive circadian 
PPI network, the experimental network was enriched and extended with additional 
interactions and interaction partners from literature, some of which turned out to be essential 
for normal circadian dynamics. The integration of circadian mRNA expression profiles 
allowed us to determine the interaction dynamics within our network. Systematic genetic 
perturbation studies (RNAi and overexpression in oscillating human cells) revealed a crucial 
role of dynamic regulation (via rhythmic PPIs) for the molecular clockwork. Furthermore, 
dynamic modular organization as a pervasive circadian network feature likely contributes to 
time-of-day dependent control of many cellular processes. Global analysis of the proteome 
regarding circadian regulation of biological processes via rhythmic PPIs revealed time-of-day 
dependent organization of the human interactome. Circadian PPIs dynamically connect many 
important cellular processes like signal transduction and cell cycle, which contribute to 
temporal organization of cellular physiology. 
Overall, these data provide a global view and valuable resource on the circadian 
control of protein-protein interactions that is not only important for the circadian oscillator but 
also for the temporal orchestration of many essential cellular processes. 
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ZUSAMMENFASSUNG 
Die dynamische Regulation von Protein-Protein Interaktionen (PPIs) ist wichtig für den 
Ablauf von biologischen Prozessen. Die circadiane Uhr, die einen ~24 Stunden Rhythmus 
generiert und eine Vielzahl von physiologischen Parametern steuert kann auch die Dynamik 
von PPIs regulieren. Obwohl es für einige der PPIs innerhalb des circadianen Oszillators 
Informationen über ihr tageszeitspezifisches Auftreten gibt, fehlt jedoch diese temporale 
Auflösung für die meisten PPIs.  
Um neue Erkenntnisse über regulatorische Mechanismen innerhalb des molekularen 
Oszillators zu gewinnen, habe ich zunächst alle möglichen PPIs zwischen 46 circadianen 
Komponenten mittels eines systematischen yeast-two-hybid (Y2H) Screens bestimmt. Dabei 
habe ich 109 bis dahin noch unbekannte PPIs identifiziert und einen repräsentativen Anteil 
mittels Co-Immunopräzipitationsexperimenten in humanen Zellen validiert. Unter den neuen 
PPIs habe ich bis dahin unbekannte Modulatoren der CLOCK/BMAL1 Transaktivierung 
identifiziert und dabei die Rolle der Proteinphosphatase 1 (PP1) als dynamischen Regulator 
der BMAL1 Stabilität funktionell charakterisiert. Das experimentelle PPI Netzwerk wurde mit 
bereits aus der Literatur bekannten PPIs und Interaktionspartnern ergänzt. Eine systematische 
RNAi Studie belegte außerdem die Relevanz der aus der Literatur stammenden Interaktoren 
für die ~24 Stunden Periodizität. Um eine Aussage über die Dynamik der PPIs im Netzwerk 
treffen zu können, wurden circadiane mRNA Expressionsdaten in das PPI Netzwerk 
integriert. Systematische Perturbationsstudien, in denen alle Komponenten des 
experimentellen Netzwerkes mittels RNAi herunterreguliert oder überexprimiert wurden, 
zeigten eine essentielle Bedeutung für die dynamischen PPIs innerhalb des circadianen 
Oszillators auf. Desweiteren wurden im circadianen PPI Netzwerk funktionelle Module 
identifiziert, welche dynamisch organsiert sind. Durch eine systemweite Analyse des 
humanen Proteoms wurden viele dynamische PPIs identifiziert, die biologische Prozesse wie 
z.B. Signaltransduktion und Zellzyklus miteinander verbinden. Rhythmische PPIs sind daher 
von Bedeutung für die zeitliche Organisation zellulärer Physiologie. 
Insgesamt wurden hier neue Erkenntnisse über die circadiane Dynamik von PPIs gewonnen, 
was zu einem erweiterten Verständnis der circadianen Uhr und ihrer Regulations-
mechanismen führt. 
Introduction             1 
 
1 INTRODUCTION 
1.1 Circadian Rhythms and Chronohistory 
On the first look, the beauty of life seems to be so simple and one could assume it is based on 
many circumstances that decide about the fate and development of organisms on our planet. 
But on the second look, life only could create such diversity because many processes 
important within an organism’s life as well as among different species are precisely timed due 
to adaption to environmental settings.  
In its ecliptic route around the sun, the earth rotates around its axis and, at every given 
moment, one half of the earth is in light while the other half is in darkness. These light-dark 
cycles define the length of day and night and are the strongest rhythmic stimuli on our planet 
creating the basis for a fundamental adjustment. Circadian rhythms (circadian is derived from 
Latin circa – about – and dies – day) are biological cycles of about 24 hours (hrs), which are 
conserved in nearly all living organisms from bacteria to humans. 
In the past, circadian rhythms were assumed to be a passive response to the light-dark cycle, 
today, it is known that they are genetically determined and endogenously generated [1-3].  
The first proof for the existence of intrinsic circadian rhythms and therefore their persistence 
under constant conditions was done in the 18th century by the French astronomer de Mairan. 
Observing plants kept in darkness he recorded leaf movements that continued with a daily 
periodicity in absence of a light-dark cycle [4]. However, it took again two centuries to prove 
the genetic character of circadian rhythms by demonstrating that the period length is heritable 
using bean plants as a model organism by experiments of Bünning in the 1930s [5].  
Since the second part of the 20th century, scientist could demonstrate the existence of 
circadian rhythms in other species reaching from single-cell eukaryotes (Sweeny and Hastings 
1957) [6], birds (Kramer 1952) [7], and humans (Aschoff and Wever 1962) [8, 9] but the 
genes that program the circadian system still remained obscure. The discovery of clock 
mutants in the fruit fly Drosophila melanogaster by Ronald Konopka and Seymour Benzer in 
1971 was the beginning of the understanding of the molecular mechanisms underlying a 
circadian phenotype. In a mutagenesis screen, one gene was identified that when mutated led 
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to an altered circadian free-running period in pupal eclosion and locomotor activity [10]. The 
affected flies were called per mutants (per for period). Almost simultaneously the frq (frq for 
frequency) gene was discovered in the filamentous fungus Neurospora crassa that is a crucial 
regulator of conidiation rhythms [11].  
The extensive knowledge of Drosophila and Neurospora genetics, together with novel 
molecular approaches resulted in a rapid progression unraveling the molecular mechanisms 
for circadian function. Although some differences exist between the model organisms the 
basic molecular principles resulting in circadian phenotype are common even for the 
mammalian molecular oscillator. 
Besides circadian rhythms, many other biological rhythms can co-exist within an individual 
organism like rhythms in neuronal activity and seasonal or annual cycles that are present 
within the animal kingdom and human society (Figure 1). 
 
 
Figure 1. Examples of Biological Rhythms of Different Species and Their Periodicity.  
Taken from [12].  
1.2 Characteristics of Circadian Rhythms    
Circadian rhythms have three principal properties: 
(i) they can be entrained or synchronized to the light-dark cycle with a stable phase 
relationship, 
(ii) they are self-sustained and persist in constant conditions like in the absence of a light-dark 
cycle (constant darkness) with a endogenous period that only differs slightly from 24 hrs 
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(free-running period), and 
(iii) they are temperature compensated, i.e. they show only minor changes in response to 
changes in external temperature.  
1.3 Circadian Rhythms in Human Physiology 
The circadian clock affects the daily rhythm of many physiological processes. In humans, e.g. 
the sleep-wake cycle, body temperature, cognitive and motoric performance, secretion of 
hormones and immune function are regulated in a circadian manner [2, 13, 14].  
Even though circadian rhythms have a propensity to be synchronized by cycles of light and 
dark (the strongest synchronization stimuli or zeitgeber for the circadian system), other factors 
– such as temperature, food intake, stress and also exercise – can effect circadian timing [15-
17]. 
1.4 Hierarchical Organization of Circadian Oscillators  
In mammals, there is a hierarchical organization of biological oscillators. The master 
oscillator or pacemaker that orchestrates the circadian program is located in the 
suprachiasmatic nucleus (SCN) in the anterior hypothalamus. The SCN is a paired nucleus of 
small neurons above the optic chiasm on each side of the third ventricle. The SCN receives 
optic input from the retina by the retinohypothalamic tractus resulting in the synchronization 
of SCN neurons. The entrained or synchronized SCN than coordinates the timing of so called 
“slave” oscillators e.g. in other brain areas like the cortex and in peripheral tissues like kidney 
and liver (Figure 2) [2].  
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Figure 2. Hierarchical Organization of Circadian Clocks in Mammals. 
The suprachiasmatic nucleus (SCN) consists of two compact cell groups above the optic chiasm and at the base 
of the third ventricle. The SCN receives optic input signals through the rethinohypothalamic tractus (RHT) and 
synchronizes circadian clocks in peripheral tissues (from [2]). 
1.5 The Circadian Timing System – Input and Output Pathways  
The general properties of an about 24 hrs oscillation require a system that is composed of 
three components (Figure 3):  
(i) photoreceptors and their input to the pacemaker,  
(ii) the ~24 hrs clocks/pacemakers, and 
(iii) the output from the pacemakers that leads to the robust regulation of circadian 
physiology.  
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Figure 3. Overview on the Basic Organization of the Mammalian Circadian Timing System.  
Taken from [18]. SCN (suprachiasmatic nucleus), CNS (central nervous system). 
1.6 Molecular Clocks 
In mammals and other species, the circadian oscillator is composed of interconnected 
transcriptional translational negative and positive feedback-loops, which generate circadian 
rhythms at the molecular level. Within this gene-regulatory network, a precise timing of gene 
expression, protein-protein interactions (PPIs) as well as posttranscriptional and post-
translational modifications is essential for sustaining circadian rhythms with normal dynamics 
[1-3]. The interaction between the transcription factors CLOCK and BMAL1 (= ARNTL), 
which has been discovered in a Y2H screen [19], is crucial for the activation of the Period 
(Per) and Cryptochrome (Cry) genes. PER and CRY proteins form large complexes that 
inhibit their own transcription by binding directly to the CLOCK/BMAL1 complex during the 
late night (Figure 4) [20]. This fundamental principle of the negative feedback mechanism is 
conserved in many species and required for keeping circadian periodicity.  
In the last years, many novel clock genes and modifiers have been discovered leading to a 
better understanding of the circadian oscillator. Especially posttranslational modifications of 
individual clock proteins and complexes have been recognized as crucial for circadian rhythm 
generation. E.g. effects mediated by kinases like Casein kinase 1 and 2 (CSNK1E/D isoforms, 
CSNK2A and CSNK2B subunits) as well as F-box proteins like FBXL3 are essential for 
complex formation, sub-cellular localization and degradation of circadian proteins [21-23].  
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Figure 4. Basic Principle of the Mammalian Molecular Clock. 
Circadian rhythms are generated via interconnected transcriptional and translational negative-feedback loops 
within various cells and tissues. At the core, the positive regulators CLOCK and BMAL1 activate the 
transcription of their own repressors (PERs and CRYs) by binding to enhancer elements (E-boxes) within their 
promoters. Later in the circadian cycle, PER and CRY proteins undergo posttranslational events and as a result, 
feed back with a crucial delay to inhibit their own transcription. In addition, the transcription of CLOCK and 
BMAL1 is regulated by ROR transcriptional activators and the REV-ERB repressors via binding to ROR 
response elements (RRE). Furthermore, the activators DBP (D site of albumin promoter (albumin D-box) 
binding protein) and E4BP4 (E4 promoter-binding protein 4) together regulate the expression of D-box 
containing genes as PER and other clock output genes (from [3]). 
Although transcription, translation and protein-protein interactions events in concert generate 
the circadian pace recent studies indicate that circadian rhythms can sustain even without 
transcriptional regulation e.g. in the unicellular pico-eukaryotic alga Ostreococcus tauri and 
in human red blood cells. In these cells about 24-hrs redox cycles of peroxiredoxins 
(antioxidant proteins) show all properties of a circadian oscillation without transcription being 
necessary. These rhythms are highly conserved in Bacteria, Archaea and Eukaryota 
suggesting that redox homeostasis has co-evolved within this organisms and therefore 
probably is a valid universal bio-marker for circadian rhythms and circadian clock evolution 
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after the Great Oxidation Event (GOE) on our planet (Figure 5) [24-26].  
 
Figure 5. Evolution of the Circadian Oscillator. 
Top: Timeline and geological area of illustrated species. Middle: Phylogenetic tree represents the genetic origins 
of the depicted phyla descending from the last universal common ancestor (LUCA). Bottom: Bars mark the time 
from which the depicted oscillator systems with their characteristic components have evolved. Atmospheric 
oxygen levels are given in percent (from [24]). Byr (billion years), cAMP (Cyclic adenosine monophosphate), 
CCA1 (circadian clock associated 1 circadian clock associated 1), CK1/2 (casein kinase 1/2), FRQ (frequency), 
GOE (Great Oxidative Event), GSK3 (glycogen synthase kinase 3), PER (period), PRX (peroxiredoxins), ROS 
(reactive oxygen species), SOD (superoxide dismutase), TOC1 (timing of CAB expression 1). 
1.7 Systems-Level Understanding of Circadian Clocks 
The molecular clock regulates a multiplicity of cellular functions. E.g. circadian rhythms in 
gene expression – 2-10% of the transcriptome in a given tissue – is under circadian control 
(Figure 6) [13, 27-29]. Consequently, also a large fraction of the proteome is thought to be 
regulated in a time-of-day dependent manner. However, large-scale data sets of the circadian 
proteome are still rare [29].  
Recent publications using circadian microarray data derived from different mammalian 
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tissues provide systematic analysis of the rhythmic regulation of transcription on a systems-
wide level being essential for the clock controlled regulation of cellular output processes [29, 
30]. In addition, circadian metabolome analyses have uncovered that many essential 
physiological processes are dependent on circadian regulation indicated by e.g. the circadian 
oscillation of a variety of metabolites including the clock controlled regulation of the uracil 
salvage pathway [14, 31, 32].   
 
Figure 6. Circadian Microarray Transcriptome Analysis of Mouse Liver. 
Lines represent individual transcript profiles. Expression data were sorted in respect to the circadian phase (from 
[27]). Gray bar: subjective day; black bar: subjective night.  
In the last decade, different Systems Biology approaches were applied to generate a more 
comprehensive view of processes that result in a circadian phenotype. Transcriptome as well 
as proteome analyses were used to characterize circadian parameters of a multiplicity of genes 
in different organisms and tissues. Furthermore, large scale forward and reverse genetics 
screens have identified new components and modulators important for the robustness and fine 
tuning of circadian timing and linked the circadian clock to other biological processes like the 
control of immune response [13, 22, 27, 33-35]. In addition, recent studies have uncovered 
proportionality and paralog compensation as crucial circadian network features essentially 
contributing to its robustness (see Figure 7) [36, 37].  
However, with the rapid progression in systems identification leading to the discovery of 
many novel molecular clock or clock associated components a comprehensive network view 
of the circadian oscillator is still missing.  
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Figure 7. Four Different Levels of Systems Biology for the Molecular Oscillator. 
Systems Biology can be considered as Biology after identification reaching from system analysis and control to 
system design (from [38]).  
Another goal to understand a complex system is to map protein-protein interactions within, 
which represent molecular links for further functional characterization. Global human 
interactomes have been created using high-throughput Y2H interaction mapping providing a 
framework for interactors that participate in specific cellular processes and pathways or are 
linked to disease associated factors [39-41]. Such a network linked uncharacterized gene 
products and human disease proteins (ataxia) resulting in the identification of novel 
modulators of Wnt signaling [41]. Furthermore, a combination of a classical library and 
matrix (using a selection of putative interactors) based Y2H screens led to the identification 
and resulting mechanistic characterization of GIT1 (G protein-coupled receptor kinase-
interacting protein), an enhancer of Huntingtin aggregation to Huntington’s disease (HD) 
[39]. Experimental derived large-scale protein-protein interaction networks are the basis for 
the determination of a variety of topological parameters (e.g. network organization with 
highly connected components – so called `hubs´ – and the identification of functional modules 
etc.). In addition, the integration of further experimental data of network components (e.g. 
gene silencing information and expression profiles) is leading to a better understanding of the 
dynamic behavior of a biological network [42, 43]. Several studies propose that essentiality of 
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a network component correlates with its degree (number of interactions) [44]. However, these 
statements are currently controversially discussed since different experimental techniques and 
large-scale or low-scale interaction mapping do not really allow a comprehensive analysis of 
different network types [45]. 
Recently, the integration of dynamic transcriptome information of different cell cycle states in 
yeast or circadian transcript profiles form a hepatic cell line with protein-protein interaction 
data led to the identification of functional modules and their timely resolved dynamics [46, 
47].  
Although protein-protein interaction networks contain a large variety of information they are 
in the most cases static and still far away from saturation [43]. It is obvious that due to 
technical limitations of approaches used for interaction detection (like high-throughput Y2H 
mapping or mass spectrometry analysis) there will always remain a risk of false positive and 
negative signals. Therefore, validation of interaction screen data with an independent system 
turned out to be essential for network construction [43, 48].  
1.8 Dynamics of Protein-Protein Interactions within the Mammalian Circadian 
Gene-Regulatory Network 
Cellular functions are increasingly recognized to be regulated by protein complexes, thus, 
PPIs and their timing are predicted to be crucial for many physiological processes [49]. In 
most cases, in which PPIs exert a regulatory function, such interactions are transient and 
occur only under specific conditions, e.g. as a response to a signal, after binding of a co-factor 
or when the expression of one or both partners is induced in response to a changing cellular 
condition. Circadian clock regulation of cellular functions via PPIs can be accomplished by 
restricting important interactions to specific times of the day. In the circadian oscillator, many 
of the known PPIs also happen predominantly at specific times of the day, e.g. PER/CRY 
complexes bind to CLOCK/BMAL1 in the late night to inhibit transactivation [20]. Here, the 
temporal binding profile correlates with the abundance profiles of PER and CRY proteins. 
While these examples demonstrate the fundamental importance of precisely timed PPIs for 
the circadian clockwork we are still far from a comprehensive view of the PPI network among 
circadian oscillator proteins and their dynamics. Furthermore, the extent of a regulation of 
circadian output processes via time-of-day dependent PPIs is largely unknown. 
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1.9 Aim of the Study 
Since the complexity of the circadian oscillator is increasing because of the identification of 
many new clock components and modulators in the last years, I firstly wanted to map PPIs 
among these components (46 candidates at the beginning of my study, July 2007) using a 
high-throughput interaction mapping approach in yeast. With this experimental information, I 
wanted to generate a more comprehensive view on the circadian protein-protein interaction 
network that allows me to uncover new mechanisms that are probably important for the 
regulation of circadian periodicity and cellular physiology.  
In the second part of my study, I wanted to investigate the circadian network 
organization/topology and the underlying interaction dynamics on the circadian time scale via 
integration of circadian expression as well as genetic perturbation data for each network 
component. In addition, I wanted to focus on the identification of clock controlled regulation 
of cellular physiology by rhythmic PPIs. 
Expected significance: 
Since the large fraction of regulatory enzymes (kinases, phosphatases and F-box proteins, 22 
in total) and circadian clock components or associated core clock factors (24 in total) that I 
have included for the construction of the circadian PPI network the interaction mapping 
should lead to the identification of new PPIs probably also mediating posttranslational 
modifications. In the last years, phosporylation of clock proteins was recognized as crucial for 
setting the speed of the circadian clock but not much is known about the role of phosphatases 
within the mammalian system. Therefore, I have included phosphatase 1 (PP1) and 
phosphatase 2 (PP2) subunits as candidates in my interaction experiments. My approach 
should lead to the discovery of many so far uncharacterized interactions and therefore serve as 
a valuable resource for the circadian clock community helping us to understand the 
mammalian molecular clockwork at the systems-level. In addition, by integrating circadian 
expression information to the circadian PPI network data (with the highest available temporal 
resolution), it should be able to create the first comprehensive view on PPI dynamics on a 
~24-hrs timescale.  
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2 MATERIALS 
2.1 Materials and Suppliers 
2.1.1 Chemicals 
All used chemicals were provided by the following companies: 
Sigma-Aldrich (Taufkirchen, Germany) 
Merck KGaA (Darmstadt, Germany) and  
Carl Roth GmbH & Co (Karlsruhe, Germany). 
2.1.2 Reagents 
Acris     (Acris Antibodies GmbH, Herfort, Germany) 
Applied Biosystems   (Forster City, USA) 
Bio-Rad     (Bio-Rad Laboratories GmbH, Munch, Germany) 
Calbiochem    (EMD Biosciences/Merck Biosciences, Darmstadt, Germany) 
Fermentas     (GmbH, S. Leon, USA) 
GIBCO     (Invitrogen Corporation, Karlsruhe, Germany) 
Invitrogen     (Invitrogen Corporation, Carlsbad, California, USA) 
Molecular Probes   (Invitrogen Corporation, Eugene, Oregon, USA) 
MWG Biotech AG   (Ebersberg, Germany) 
New England Biolabs   (New England Biolabs Inc., Ipswich, Massachusetts, USA) 
NOVOUS     (Novous Biologicals, Littleton, USA) 
Open Biosystems  (Thermo Fischer, St. Leon-Rot, Germany) 
PIERCE     (Pierce Biotechnology Inc., Rockford, Illinois, USA) 
Promega     (Promega Corporation, Madison, Wisconsin, USA) 
QIAGEN     (QIAGEN GmbH, Hilden, Germany) 
Roche     (Roche Diagnostics, Manheim, Germany) 
SantaCruz     (Santa Cruz Biotechnology Inc., Santa Cruz, USA) 
Stratagene     (La Jolla, California, USA) 
2.2 Enzymes 
2.2.1 Restriction Endonucleases 
ApaI:     (NEB, Cat. no. R0114S) 
Recognition site:     
 
Materials              13 
 
BamHI:     (NEB, Cat. no. R0136 S) 
Recognition site:    
 
BsrGI:    (NEB, Cat. no. R0575 S) 
Recognition site:      
  
EcoRI:    (NEB, Cat. no. R0101 S) 
Recognition site:    
 
HindIII:     (NEB, Cat. no. R0104 S) 
Recognition site:    
 
SacI:     (NEB, Cat. no. R0156 S) 
Recognition site:    
 
XhoI:     (NEB, Cat. no. R0146 S) 
Recognition site:    
2.2.2 PCR Enzymes 
Platinum-Pfx-Polymerase:     (Invitrogen, Cat. no. 11708-013) 
DeepVent-DNAPolymerase:    (New England Biolabs, Cat. no. M0258L) 
SuperscriptRNaseH:     (Invitrogen, Cat. no. 18053-017) 
2.3 Technical Equipment 
ABI PRISM 7000 (Applied Biosystems) 
Betascout luminometer (PerkinElmar) 
Centrifuges (Eppendorf) 
ChemoCam  (Intas) 
ELISA platereader (Berthold Technologies) 
Gyrorocker shaker (Labnet International) 
Infinite F200Pro  (TECAN) 
Lumi Imager (Roche) 
LumiCyle (ActiMetrix) 
Microscope (Laica) 
Multichannal pipettes (Eppendorf) 
NANODrop (Roche) 
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OrionII (Berthold Detection Systems) 
Pipettes (Eppendorf) 
Pipetting robot  (Biomek FX)  
Spotting robot (KBiosystems) 
TOPCount (PerkinElmar) 
XCell Sure Lock Sytem (Invitrogen) 
2.4 Buffers and Solutions 
RIPA buffer:    1x PBS 
1% Igepal CA-630 
0.5% Na-deoxicholate 
0.1% SDS 
 
co-IP buffer:    20 mM Tris-HCl, pH 8.0 
140 mM NaCl 
1.5 mM MgCl2 
1 mM TCEP 
1% Triton-X-100 
10% glycerine 
 
co-IP washing buffer:   20 mM Tris-HCl 
150 mM NaCl 
0.5% Igepal CA-630 
 
1x HEPES:    50 mM HEPES 
140 mM NaCl 
1.5 mM Na2HPO4 
in aq. dest.; pH 7 
 
1x NEBuffer 2: 10 mM Tris-HCl 
50 mM NaCl 
10 mM MgCl2 
1 mM dithiothreitol 
pH 7.9 
 
10x MOPS buffer:   200 mM MOPS 
50 mM Na-acetate 
10 mM EDTA 
pH 7.0 (NaOH) 
 
2x sample buffer:   95% formamide 
0.02% SDS 
0.025% bromphenol blue 
0.025% xylene cyanol  
0.025% ethidiumbromide 
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0.5 M EDTA 
DNA buffer (6x):  30% glycerine 
1 mM EDTA 
0.25% bromphenol blue 
 
10x PBS:     1.37 M NaCl 
27 mM KCl 
100 mM Na2HPO4 
20 mM NaH2PO4 
in aq. dest.; pH 7.2 
 
1x PBS:     100 ml 10x PBS 
ad 1 l aq. dest. 
 
1x PBST:    1x PBS 
     0.25% Tween 
 
 
X-GAL soultion:   156 μl X-GAL  
100 μl DTT (1M)  
10 ml Z-buffer 
X-GAL:    20 mg/ml X-GAL in dimethyl formamide 
 
Z-buffer:    10.6 g/l Na2HPO4 x 2 H2O 
5.5 g/l NaH2PO4 x H2O 
0.75 g/l KCl 
0.25 g/l MgSO4 x 7 H2O 
2.5 RNA and DNA Gel Composition 
RNA gel:     0.6 g agarose 
37 ml aq. dest. 
5 ml 10x MOPS buffer 
 
DNA gel:    10 mM EDTA 
pH 7.0 (NaOH) 
     5 µl of 1% EtBr on 100 ml  
2.6 Commercial Assay Systems 
(i) Dual-Luciferase Reporter Assay System (Promega Corporation, Madison, Wisconsin, 
USA). (Cat. no. E1960) 
(ii) SuperSignal West Pico Chemiluminscent Substrate (Pierce Biotechnology Inc., Rockford, 
Illinois, USA). 
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(Cat. no. 34079) 
2.7 DNA Marker 
1 kb DNA ladder:   (NEB, Cat. no. N3232) 
100 bp DNA ladder:   (NEB, Cat. no. N3231) 
2.8 Bacteria 
2.8.1 Bacteria Strains 
DH10B     F` mcrA Δ-(mrr hsd RMS-mcr BC) ϕ80dlacZΔM15 ΔlacX74 de 
recA1 araD139 Δ(ara leu)7697 galU galK λ- rpsL endA1 nupG 
(Invitrogen) 
 
XL1-Blue     recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac- F`[proAB 
laclqZΔM15 Tn10 (Tetr) (Stratagene) 
2.8.2 Media for Bacteria 
LB medium:   10 g NaCl 
10 g bactotryptone 
5 g yeast extract 
ad 1 l aq. dest. 
autoclave 
 
LB agar plates:   1 l LB medium 
10-15 g agar (BD Biosciences) 
autoclave 
 
LB selective medium:   1 l LB agar 
LB ampicillin 100 μg/ml ampicillin 
LB kanamycin 100 μg/ml kanamycin 
stock solutions: 100 mg/ml in 70% EtOH 
 
S.O.C. medium:    0.5% w/v yeast extract 
2% w/v tryptone 
2.5 mM KCl 
10 mM NaCl 
10 mM MgCl2 
10 mM MgSO4 20 mM D-(+)-glucose
 
Materials              17 
 
2.9 Yeast 
2.9.1 Yeast Strains 
L40ccU MATa MATa his 3Δ200 trp1-901 leu 2-3,112 LYS 2 :: (lex Aop)4--
HIS3 ura3:: (lex Aop)8 -lacZ ADE 2 :: (lexAop)8-URA3 GAL4 
gal 80 can 1 cyh 2 [39] 
 
L40cc MATα MATα his3Δ200 trp1-910 leu2-3,112 ade2 LYS2::(lexAop)4-
HIS3URA3::(lexAop)8-lacZ GAL4 gal80 can1 cyh [39] 
2.9.2 Media for Yeast 
YPD medium:   10 g/l bacto yeast extract 
20 g/l bacto peptone 
20 g/l glucose 
 
 
SD medium:   6.7 g/l yeast nitrogen base 
20 g/l glucose 
10 ml 100x aa (amino acid) per l 
 
NBG medium:   6.7 g/l yeast nitrogen base 
20 g/l glucose 
0.5 M betain  
10 ml 100x aa per l 
 
GAL medium:   6.7 g/l yeast nitrogen base 
20 g/l galactose 
10 ml 100x aa per l 
2.9.3 Amino Acids and Nucleobases for Yeast Media 
Amino acids were obtained from Sigma-Aldrich, Germany (amino acid kit, Cat. no. LAA21). 
Adenine and uracil were obtained from Sigma-Aldrich, Germany (Cat. no. A2786-100G and 
U1128-25G).  
Adenine (100x)   20 mg/l final concentration   
Histidine (100x)   20 mg/l final concentration   
Leucine (100x)   20 mg/l final concentration   
Tryptophan (100x)  20 mg/l final concentration 
Uracil (100x)    20 mg/l final concentration    
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2.9.4 Yeast Transformation Reagents 
Mix I:    0.1M LiAc 
1 M sorbitol 
0.5x TE 
 
Mix II:    0.1 M LiAc 
2 ml 60% PEG 3350 
1x TE 
2.10 Human Cell Lines 
2.10.1 HEK293 Cells  
HEK293 cells were used for ectopic expression of recombinant proteins. 
Organism  homo sapiens (human)  
Tissue  kidney; transformed with adenovirus 5 DNA  
Comments  the cells express the transforming gene of adenovirus 5  
Growth properties  adherent  
Morphology  epithelial  
Propagation  DMEM Medium, 10% v/v FBS 
2.10.2 HEK293T Cells 
HEK293T cells were used for lentivirus production. 
Organism  homo sapiens (human)  
Tissue  kidney; transformed with SV40 adenovirus DNA 
Comments  the cells express the transforming gene of the large T antigen 
from SV40 that inactivates pRb 
Growth properties  adherent  
Morphology  epithelial  
Propagation  DMEM Medium, 10% v/v FBS 
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2.10.3 U2OS Cells 
U2OS cells were used for dynamic circadian oscillations recordings, ectopic expression of 
recombinant proteins and detection of clock genes via q-PCR and Western blot analysis.  
Organism  homo sapiens (human)  
Tissue  bone tissue, osteosarcoma cell line  
Comments  Circadian oscillating cell line [22, 35], cells express wild type 
p53 and Rb, but lack p16  
Reporter Bmal1-promoter luciferase fragment 
Growth properties  adherent, contact inhibited growth 
Morphology  epithelial  
Propagation  DMEM Medium, 10% v/v FBS 
2.10.4 Cell Culture and Reporter Media  
CM (complete medium):  500 ml DMEM  
50 ml FBS  
5 ml penicillin/streptomycin 100x  
14 ml 1M HEPES 
 
CM (without antibiotics):  45 ml DMEM  
5 ml FBS  
Reporter medium: 500 ml High Glucose DMEM, phenolred free  
50 ml FBS   
5 ml penicillin/streptomycin, 100x   
5 ml D-luciferin in DMEM, 25 mM   
500 μl puromycin, 10 mg/ml or 
500 µl blasticidin, 10 mg/ml  
 
FBS (fetal bovine serum) (Gibco, Cat. no. 10106-169) 
 
Penicillin/streptomycin:  10.000 U/10.000 μg/ml, (Biochrom AG) 
Final concentration: 100 μg/ml 
 
Blasticidin:    5 mg/ml in 1x PBS (Invitrogen, Cat. no. R210-01) 
Final concentration: 5-10 μg/ml 
 
 
Hygromycin B:    50 mg/ml (Invitrogen, Cat. no. R220-05) 
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Final concentration: 50-100 μg/ml 
 
Kryomedia:    90% FBS 
10% DMSO 
 
Dexamethasone:    1 mM in EtOH (Sigma-Aldrich, Cat. no. D4902) 
Final concentration: 1 μM 
 
Luciferin (firefly):  0.1 mM in CM (P.J.K., Cat. no. 260150) 
Final concentration: 1 μM 
 
Cycloheximide (CHX):  100 mg/ml in DMSO (Sigma-Aldrich, Cat. no. C4859) 
Final concentration: 0.2-2 μg/ml 
2.11 Protein Extraction 
Phosphatase-Inhibitor-Cocktail I 100x:   (Sigma-Aldrich, Cat. no. P-2850) 
Phosphatase-Inhibitor-Cocktail II 100x:   (Sigma-Aldrich, Cat. no. P-5726) 
Protease-Inhibitor-Cocktail 100x:   (Sigma-Aldrich, Cat. no. P-8340) 
2.12 BCA-Test for the Determination of Protein Concentration 
Reagent A:    2% (w/v) Na2CO3 x H2O 
1% (w/v) BCA-Na2 
0.95% (w/v) NaHCO3 
0.4% (w/v) NaOH 
0.16% (w/v) Na2 tartrate 
ad 1 l aq. dest.; pH 11.25 
 
Reagent B:    4% (w/v) CuSO4 x 5 H2O 
2.13 SDS Gelelectrophoresis 
NuPAGE LDS Sample Buffer (4x):       (Invitrogen, Cat. no. NP0007) 
NuPAGE 4-12% Bis-Tris Gel 1.0 mm, 10 well:    (Invitrogen, Cat. no. NP0321PK2) 
NuPAGE 4-12% Bis-Tris Gel 1.5 mm, 10 well:   (Invitrogen, Cat. no. NP0335PK2) 
NuPAGE MES SDS Running Buffer (20x):     (Invitrogen, Cat. no. NP0002) 
MagicMark XP:          (Invitrogen, Cat. Nr. LC5602) 
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Laemmli buffer (6x):   0.1 ml 20% (w/v) SDS 
2 ml 14 M 2-mercaptoethanol 
1 ml glycerine 
10 mg bromphenol blue 
ad 5 ml aq. dest. 
 
10x SDS-PAGE buffer: 0.25M Tris-base 
1.92 M glycine 
1% (w/v) SDS 
pH 8.5 
 
1x SDS-PAGE buffer:   100 ml 10x SDS-PAGE buffer 
ad 1 l aq. dest. 
 
Buffer SDS-PAGE:   0.5 M Tris-HCl 
pH 6.8 
 
Seperation buffer:   1.5 M Tris-base 
     pH 8.8  
2.14 Protein Blotting 
NuPAGE Transfer Buffer (20x): (Invitrogen, Cat. No NP0006-1) 
 
Transfer buffer:    100 ml 10x SDS-PAGE buffer 
20% (v/v) methanol 
ad 1 l aq. dest. 
10x TBS: 1.37 M NaCl 
100 mM Tris-Base 
pH 7.3 
 
1x TBST:      100 ml 10x TBS 
0.05% (v/v) Tween 20 
ad 1 l aq. dest. 
 
Blocking solution:    1x TBST 
5% (m/v) dry milk (BD, Cat. no. 232100) 
 
Detection:      SuperSignal West Pico Chemiluminscent Substrate 
(Pierce, Cat. Nr. 34080) 
 
Membrane:     Nitrocellulose membrane Protan BA85, pore size 0.45 μm 
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(Schleicher and Schuell, Cat. no. 10401196) 
 
Blotting paper:    Whatman Gel Blotting Paper 
(Schleicher and Schuell, Cat. no. 10426982) 
2.15 Agarose Gelelectrophoresis 
50x TAE:     2 M Tris base 
50 mM EDTA 
1 M 100% asparic acid 
pH 8.5 
 
1x TAE:     20 ml 50x TAE 
ad 1 l aq. dest. 
2.16 Animals 
2.16.1 Mouse Strains 
C57black6 (The Jackson Laboratory, Bar Harbor, Maine, USA) strain mice were sacrefied for 
liver extraction. 
2.16.2 Entrainment of Mice 
Male C57black6 mice were entrained to a 12 hrs light dark regime. Locomotor activity was 
monitored by the CLOCKLAB ANALYSIS software (Actimetrix). Mice were sacrefied in 
free run conditions (complete darkness) at the indicated timepoints in constant darkness via 
cervical dislocation. Liver dissection was performed on ice.  
2.17 Plasmids 
Constructs/cell lines have either been generated during my PhD work by me (TW) or were 
already available from Prof. Kramer’s or Prof. Wanker’s group or were purchased at 
Imagenes.  
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2.17.1 ENTRY Constructs 
Symbol Clocne ID Obtained from 
hNONO RZPDo834C104D/RZPD [41] 
hWDR5 IOH4895/RZPD [41] 
hDEC1 CCSB_14984/MGC [41] 
hNPAS2 IOH29403/RZPD [41] 
hNR1D1       ORF_SEQ_3F10 [41] 
hNR1D2      ORF_SEQ_6C06/1-22 [41] 
hRORA CCSB_4928/MGC [41] 
hRORB IOH39668/RZPD Imagenes 
hRORC CCSB_8508/MGC Imagenes 
hNFIL3 RZPDo839B0796/RZPD Imagenes 
hEZH2 CCSB_143/MGC [41] 
hRASD1 CCSB_1134/MGC [41] 
hCSNK2A1   RZPDo839B0979/RZPD [41] 
hCSNK2A2 IOH6369/RZPD [41] 
hCSNK2B   RZPDo834F0628D/SMP [41] 
hPRKCA IOH29644/SMP [41] 
hPRKACA IOH26286/SMP [41] 
hPPP1CA CCSB_3788/MGC [41] 
hPPP1CB CCSB_4085/MGC [41] 
hPPP1CC CCSB_7076/MGC [41] 
hPPP2CA  RZPDo834A1014D/RZPD [41] 
hPPP2CB ORF SEQ 1H11 [41] 
hPPP2R1A RZPDo839E0974/RZPD [41] 
hPPP2R1B RZPDo839F0390/RZPD [41] 
hPPP2R5D IOH43173/IM/imaGenes [41] 
hPPP2R5E   IOH29856/imaGenes [41] 
hFBXL3 CCSB_14644/MGC [41] 
2.17.2 Generated Constructs and Cell Lines 
2.17.2.1 HEK293 Cells Expressing Luciferase Fusions 
HEK293 CLOCK-luciferase (pLenti6 backbone, Invitrogen), TW 
HEK293 BMAL1-luciferase (pLenti6 backbone, Invitrogen), TW 
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2.17.2.2 Prey and Bait Constructs 
No. Gene Prey config. (pACT4-DM) Bait config. (pBTM116-D9) 
1 PER1 TW TW 
2 PER2 TW TW 
3 PER3 TW TW 
4 CRY1 TW TW 
5 CRY2 TW TW 
6 NONO TW TW 
7 WDR5 TW TW 
8 TIMELESS TW TW 
9 CIPC TW TW 
10 DEC1 TW TW 
11 DEC2 TW TW 
12 CLOCK TW TW 
13 NPAS2 TW TW 
14 BMAL1 TW TW 
15 BMAL2 TW TW 
16 NR1D1 TW TW 
17 NR1D2 TW TW 
18 RORA TW TW 
19 RORB TW TW 
20 RORC TW TW 
21 DBP TW TW 
22 NFIL3 TW TW 
23 EZH2 TW TW 
24 RASD1 TW TW 
25 CSNK1D TW TW 
26 CSNK1E TW TW 
27 GSK3B TW TW 
28 CSNK2A1 TW TW 
29 CSNK2A2 TW TW 
30 CSNK2B TW TW 
31 PRKACA TW TW 
32 PRKCA TW TW 
33 PPP1CA TW TW 
34 PPP1CB TW TW 
35 PPP1CC TW TW 
36 PPP2CA TW TW 
37 PPP2CB TW TW 
38 PPP2R1A TW TW 
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39 PPP2R1B TW TW 
40 PPP2R5D TW TW 
41 PPP2R5E TW TW 
42 PPP5C TW TW 
43 BTRC TW TW 
44 FBXW11 TW TW 
45 FBXL3 TW TW 
46 FBXL15 TW TW 
2.17.2.3 pLenti6, MYC and FLAG Constructs 
No. Gene pLenti6 pMYC-CMV-D12 pFLAG-CMC-D11 
1 PER1 Prof. Kramer TW Prof. Kramer 
2 PER2 Prof. Kramer TW Prof. Kramer 
3 PER3 TW TW TW 
4 CRY1 Prof. Kramer TW Prof. Kramer 
5 CRY2 Prof. Kramer TW Prof. Kramer 
6 NONO Prof. Kramer TW TW 
7 WDR5 Prof. Kramer TW TW 
8 TIMELESS Prof. Kramer TW TW 
9 CIPC Prof. Kramer TW TW 
10 DEC1 TW TW TW 
11 DEC2 TW TW TW 
12 CLOCK Prof. Kramer TW Prof. Kramer 
13 NPAS2 TW TW TW 
14 BMAL1 Prof. Kramer TW Prof. Kramer 
15 BMAL2 TW TW TW 
16 NR1D1 TW TW TW 
17 NR1D2 TW TW TW 
18 RORA TW TW TW 
19 RORB TW TW TW 
20 RORC TW TW TW 
21 DBP TW TW TW 
22 NFIL3 TW TW TW 
23 EZH2 TW TW TW 
24 RASD1 TW TW TW 
25 CSNK1D Prof. Kramer TW TW 
26 CSNK1E Prof. Kramer TW TW 
27 GSK3B Prof. Kramer TW TW 
28 CSNK2A1 Prof. Kramer TW TW 
29 CSNK2A2 Prof. Kramer TW TW 
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30 CSNK2B TW TW TW 
31 PRKACA TW TW TW 
32 PRKCA TW TW TW 
33 PPP1CA TW TW TW 
34 PPP1CB TW TW TW 
35 PPP1CC TW TW TW 
36 PPP2CA Prof. Kramer TW TW 
37 PPP2CB Prof. Kramer TW TW 
38 PPP2R1A Prof. Kramer TW TW 
39 PPP2R1B Prof. Kramer TW TW 
40 PPP2R5D Prof. Kramer TW TW 
41 PPP2R5E Prof. Kramer TW TW 
42 PPP5C TW TW TW 
43 BTRC TW TW TW 
44 FBXW11 TW TW TW 
45 FBXL3 TW TW TW 
46 FBXL15 TW TW TW 
2.17.2.4 Reporter Cell Lines 
No. Expressed gene (pLenti6) U2OS Bmal1-promoter luciferase reporter cells (pLenti6) 
1 PER1 TW 
2 PER2 TW 
3 PER3 TW 
4 CRY1 TW 
5 CRY2 TW 
6 NONO TW 
7 WDR5 TW 
8 TIMELESS TW 
9 CIPC TW 
10 DEC1 TW 
11 DEC2 TW 
12 CLOCK TW 
13 NPAS2 TW 
14 BMAL1 TW 
15 BMAL2 TW 
16 NR1D1 TW 
17 NR1D2 TW 
18 RORA TW 
19 RORB TW 
20 RORC TW 
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21 DBP TW 
22 NFIL3 TW 
23 EZH2 TW 
24 RASD1 TW 
25 CSNK1D TW 
26 CSNK1E TW 
27 GSK3B TW 
28 CSNK2A1 TW 
29 CSNK2A2 TW 
30 CSNK2B TW 
31 PRKACA TW 
32 PRKCA TW 
33 PPP1CA TW 
34 PPP1CB TW 
35 PPP1CC TW 
36 PPP2CA TW 
37 PPP2CB TW 
38 PPP2R1A TW 
39 PPP2R1B TW 
40 PPP2R5D TW 
41 PPP2R5E TW 
42 PPP5C TW 
43 BTRC TW 
44 FBXW11 TW 
45 FBXL3 TW 
46 FBXL15 TW 
2.18 RNAi Constructs 
RNAi constructs were obtained from Open Biosystems. Lists with the used constructs can be 
found in the Appenidix section. 
2.19 Oligonucleotides 
2.19.1 Primer for TOPO Cloning 
Symbol Primer pairs (FW: forward, RV: reverse) 
mPER1 
 
FW: CAC CAT GAG TGG TCC CCT AGA AGG 
RV: CTA GCT GGT GCT GTT TTC TTC 
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mPER2 
 
FW: CAC CAT GAA TGG ATA CGT GGA CTT CTC 
RV: TTA CGT CTG GGC CTC TAT CC 
mPER3 
          
FW: CAC CAT GGA TCC CTG TGG AGA CCC 
RV: TCA ACT GGT GTC TTC TGC TGG 
mCRY1 
 
FW: CAC CAT GGG GGT GAA CGC CGT GC 
RV: TCA GTT ACT GCT CTG CCG CTG 
mCRY2 FW: CAC CAT GGC GGC GGC TGC TGT 
RV: TCA GGA GTC CTT GCT TGC TG 
mTIM 
 
FW: CAC CAT GGA CTT GTA CAT GAT GAA CTG 
RV: TCA GTC ATC CTC ATC CTC AAT 
mCIPC 
  
FW: CAC CAT GGA GAG GAA AAT CCC ATC CA 
RV: CTA TAC GTC TGG GTG ATC AGA C 
hDEC2 
 
FW: CAC CAT GGA CGA AGG AAT TCC TCA 
RV: TCA GGG AGC TTC CTT TCC TG 
mCLOCK FW: CAC CAT GGT GTT TAC CGT AAG CTG TA 
RV: CTA CTG TGG CTG GAC CTT GG 
mBMAL1 
 
FW: CAC CAT GGC GGA CCA GAG AAT GGA 
RV: CTA CAG CGG CCA TGG CAA G 
hBMAL2 
 
FW: CAC CAT GGC GGC GGA AGA GGA GG 
RV: CTA GAG GGT CCA CTG GAT GT  
hDBP FW: CAC CAT GGC GCG GCC TGT GAG C 
RV: TCA CAG GGC CCC GTG CTG 
mCSNK1E FW: CAC CAT GGA GTT GCG TGT GGG AAA 
RV: TCA TTT CCC AAG ATG GTC AAA TG 
hCSNK1D FW: CAC CAT GGA GCT GAG GGT CGG GA 
RV: TCA TCG GTG CAC GAC AGA CTG 
mGSK3B FW: CAC CAT GTC GGG GCG ACC GAG AAC C 
RV: TCA GGT GGA GTT GGA AGCTGA 
rPPP5C         FW: CAC CAT GGC GAT GGC GGA GGG C 
RV: TCA CAT CAT TCC TAG CTG CAG 
mBTRC FW: CAC CAT GGA CCC GGC AGA GGC GGT G 
RV: TTA TCT GGA GAT GTA GGT GTA TGT CC 
mFBXW11 
 
FW: CAC CAT GGA CCC GGC AGA GGC GGT G 
RV: TTA TCT GGA GAT GTA GGT GTA TGT CC 
hFBXL15 FW: CAC CAT GGA GCA ACC GAT GGA GC 
RV: TCA GAC CTG CAG GTT GAC AA 
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2.19.2 Primer for q-PCR 
No. Gene Gene ID Cat. no. Supplier 
1 hGAPDH 2597  QT01192646 Qiagen 
2 hPer1 5187  QT00069265 Qiagen 
3 hPer2 8864  QT00011207 Qiagen 
4 hNr1d1 9572  QT00000413 Qiagen 
5 hDbp 1628  QT00055755 Qiagen 
6 hPPP1CA 5499  QT00031654 Qiagen 
2.20 Antibodies 
2.20.1.1 Primary Antibodies 
Anti-MYC    (Novous Biologicals, Cat. no. NB600-335) 
Anti-FLAG   (Sigma-Aldrich, Cat. no. F3165) 
Anti-BMAL1   (Michael Brunner laboratory [29]) 
Anti-PPP1CA   (Santa Cruz Biotechnology, Cat. no. sc-7482) 
Anti-PPP1R15B   (Novous, Cat. no. NBP1-06588) 
Ideotypic IgG   (Acris, Cat. no. PPP500P) 
Anti-β-actin   (Sigma-Aldrich, Cat. no. A-5441) 
2.20.1.2 Secondary Antibodies 
Donkey anti-rabbit-HRP  (Santa Cruz, Cat. no. sc-2317) 
Goat anti-rabbit-HRP   (Santa Cruz, Cat. no. sc-2030) 
Goat anti-mouse-HRP  (Santa Cruz, Cat. no. sc-2005) 
Donkey anti-mouse-HRP  (Santa Cruz, Cat. no. sc-2314) 
Donkey anti-goat-HRP  (Santa Cruz, Cat. no. sc-2020) 
2.21 Kits 
Bradford Proteinassay Kit   (BioRad, Cat. no. 500-0002) 
CalPhos-Kit     (BD-Biosciences, Cat. no. 631312) 
FuGene 6     (Roche, Cat. no. 11815091001) 
MinElute PCR-Purification Kit  (Qiagen, Cat. no. 28004) 
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Lipofectamin 2000    (Invitrogen, Cat. no. 11668-019) 
TOPO Cloning Kit   (Invitrogen, Cat. no. K450001) 
QIAprep Spin Midiprep Kit   (Qiagen, Cat. no. 12145) 
QIAprep Spin Miniprep Kit   (Qiagen, Cat. no. 27104) 
QIAprep Plasmid Maxi Kit   (Qiagen, Cat. no. 12163) 
QIAquick PCR Purification Kit  (Qiagen, Cat. no. 28104) 
QIAquick Gel Extraction Kit  (Qiagen, Cat. no. 28704) 
RNeasy Purification Kit  (Qiagen, Cat. no. 74106) 
RNase-Free DNase Set   (Quiagen, Cat. no. 79254) 
2.22 Databases 
BIND http://binddb.org/ 
BIOGRID http://thebiogrid.org/ 
Circadian BIOGPS http://biogps.org/circadian/ 
DIP www. dip.doe-mbi.ucla.edu/ 
Expasy www.expasy.org 
HD Research Crossroads http://www.hdresearchcrossroads.org/ 
HPRD www.hprd.org/ 
INTACT: www.ebi.ac.uk/intact/ 
Ncbi www.ncbi.nlm.nih.gov/ 
Cancer Gene Census www.sanger.ac.uk/genetics/CGP/Census 
UNIHI  www.UniHI/pages/unihiSearch 
2.23 Software 
Bioconductor: www.bioconductor.org/ 
Chronostar: In house generated software for evaluation of dynamic oscillation 
recordings (Dr. Stephan Lorenzen, Dr. Bert Maier) 
CLOCKLAB:   Actimetrix 
ClusterOne   www.paccanarolab.org/cluster-one 
Cytoscape 2.8.1:  www.cytoscape.org/ 
ImageJ 1.44p  National Institutes of Health  
LumiCyle analysis: Actimetrix 
Matlab 7.0:   Mathworks 
MCODE   http://baderlab.org/Software/MCODE 
MS Office:   Microsoft Word, Excel and Powerpoint 
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3 METHODS 
3.1 RNA and DNA Techniques 
3.1.1 RNA Isolation and Quantification 
The template mRNA for RT-PCR was purified using the RNeasy Mini Kit from Quiagen 
according to the user’s manual. In this system, a specialized high-salt buffer allows up to 100 
μg of RNA longer than 200 bases to bind to the RNeasy silica membrane with help of speed 
microspin technology. In addition, an on column DNA digestion was performed using the 
RNase-Free DNase Set (Quiagen). RNA quantification was performrd measuring the 
absorbtion at 260 nm with the NANODrop (Roche) device. 
3.1.2 Reverse Transcription  
RT-PCR is a laboratory technique for amplifying a defined piece of ribonucleic acid (RNA) 
molecule. The RNA strand is first reverse transcribed into its DNA complement or cDNA 
(complementary DNA), followed by amplification of the resulting DNA using polymerase 
chain reaction (PCR). In the first step of RT-PCR, named the first strand reaction, the cDNA 
is made from mRNA template using dNTPs and RNA-dependent DNA polymerase (reverse 
transcriptase) through the process of reverse transcription. The above components are 
combined with designed DNA primers in a reverse transcriptase buffer at 37°C. After the 
reverse transcription reaction is finished, and the cDNA has been generated from the mRNA, 
the standard PCR, termed the second reaction can be initiated.  
Reagents  1 reaction in μl  
5x buffer  10 
dNTP´s (each 10 mM) 1 
RNase inhibitor   (40 U/μl) 0,5 
0.1 M DTT  5 
pentadecamers    (50 μM) 5 
Superscript pol.   (200 U/μl) 0.25 
RNA (2 μg)  X 
RNase free H2O  Y 
Σ final volume µl 50 
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Thermocyle program for second reaction: 
Time Temperature 
50 min 37° C 
15 min 70° C 
∞ 4°C 
 
3.1.3 DNA Purification 
Depending on the amount of plasmid DNA needed, the desired vector construct was 
amplified. Bacteria were cultured in 4, 50 or 200 ml of LB growth medium plus ampicillin or 
kanamycin at 37°C with agitation (200 rpm) overnight. Qiagen mini-, midi- or maxi-kit was 
used to purify the vector DNA. The concentration of the DNA solution was measured at 260 
nm. Quality of DNA was also assumed by running 0.5 μg of plasmid on an agarose gel after 
enzymatic digestion. 
3.1.4 Agarose Gelelectrophoresis 
Agarose gels were prepared by dissolving 0.6 g of agarose in 60 ml of 1x TAE buffer for a 
1% w/v gel. For a 2% gel, double the amount of agarose was used. Once the agarose solution 
cooled to approximately 50°C, 1 μl of ethidium bromide (EtBr; 10 mg/ml) was added. The 
DNA samples were diluted in 6x loading buffer and loaded onto the gel. 10 μl of 1 kb or 100 
bp DNA ladder was loaded and used as a size standard. Electrophoresis was run at 130 V for 
approximately 15-30 min, depending on the size of the expected products. The separated 
DNA was visible under ultraviolet (UV) light due to the DNA intercalation property of EtBr. 
3.1.5 Enzymatic Digeston 
0.5 µg of DNA were incubated with 1x NEBuffer 2 supplemented with 100 μg/ml bovine 
serum albumin (BSA) at 37°C for at leats 1 h. 10 µl of sample were mixed with 2 µl of 6x 
DNA loding buffer and agarose gels were run as described above. 
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3.1.6 PCR 
PCR is a scientific technique in molecular biology to amplify a single or a few copies of a 
piece of DNA generating copies of a particular DNA sequence.The method relies on thermal 
cycling, consisting of cycles of repeated heating and cooling of the reaction for DNA melting 
and enzymatic replication of the DNA. Primers are short DNA fragments containing 
sequences complementary to the target gene and enable selective and repeated amplification. 
Topo cloning of ENTR vectors was performed using theTOPO Cloning Kit  (Invitrogen, Cat. 
no. K450001) according to the manufacturer’s manual. 
PCR reaction for amplification of gene of interest. 
Reagents   1 reaction in μl 
DNA template   10-100 ng 
10x PCR buffer   5 μl 
50 mM dNTPs  0.5 μl 
Primers    100-200 ng each 
ad H2O    49 μl 
Taq Polymerase   (1 unit/μl) 1 μl 
Σ final volume   50 μl 
 
PCR program: 
Step     Time  Temperature Cycles 
Initial denaturation  2 min  94°C   1x 
Denaturation   1 min  94°C   1x  
Annealing    1 min  55°C   25x 
Extension    1 min  72°C   1x 
Final extension   7 min  72°C   1x 
 
TOPO reaction:  
Reagents    1 reaction in μl 
PCR product   0.5-4 μl 
Salt solution   1 μl 
ad. H2O    5 μl 
TOPO vector   1 μl 
Σ final volume  7.5 μl 
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3.1.7 Quantitative PCR 
Real-time PCR, also called quantitative real-time PCR (q-PCR/qRT-PCR) is a laboratory 
technique based on PCR, which is used to amplify and simultaneously quantify a targeted 
DNA molecule. For one or more specific sequences in a DNA sample, Real-Time PCR 
enables both detection and quantification. The quantity can be either an absolute number of 
copies or a relative amount when normalized to DNA input or additional normalizing genes. 8 
µl of cDNA template, 2 µl of specific primer mixture and 10 µl of ready-to-use mastermix 
(Fermantas) were placed into a 96-well plate. 96-well plates were sealed and centrifuged 
before starting the q-PCR reaction using the ABI 7000 q-PCR cycler. 
Reagents     1 reaction in μl 
20x universal mastermix   10 
Primer/probe mix     2 
cDNA (1:10 dilution)     8 
Σ volume      20 
 
Cycler program:      2 min 50°C 
10 min 95°C 
15 sec 95°C 
1 min 60°C 40x 
       ∞ 8°C 
3.1.7.1 Quantification and Evaluation 
The quantification of the mRNA transcripts was done using the 2-ΔΔCt- method (see also [22]). 
(i)  Means of gene Ct triplicates were generated. 
(ii)  Normalization to reference control (Gapdh). 
(ii)  Ct target gene - Ct Gapdh = ΔCt sample  
(iv)  Normalization to a calibrator 
(v)  ΔCt sample - ΔCt calibrator = ΔΔCt 
(vi)  Calculation with 2-ΔΔCt 
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3.2 Bacterial Transformation 
Competent cells were slowly defrosted for 15 min on ice. 1-5 μl of ligation mixture were 
added to 25 μl of bacterial competent cells (Invitrogen, Top10 super competent cells) 
followed by an incubation period on ice of 20 min. The transformation mixture was then 
incubated for 90 sec at 42°C and immediately chilled on ice for 2 min. 250 μl of S.O.C 
(Invitrogen) medium were added to the mixture and incubated for 30 min with agitation at 
37°C. The mixture was then centrifuged for 1 min (5,000 x g). The bacterial pellet was 
resuspended in 50 μl of the supernatant and plated on LB medium plates containing 100 
μg/ml ampicillin or kanamycin. The bacteria were grown at 37°C over night.  
3.3 Yeast Transformation 
Yeast strains were grown in 2 ml YPD medium overnight. After the addition of 28 ml YPD 
medium, cells were grown to reach the optic desity (OD600) of 0.6-0.8. Cells were 
centrifuged at 3,000 x g for 5 min. Pellets were washed with 10 ml 1x TE and resuspendend 
in Mix I followed by incubation for 10 min at RT. 40 µl of yeast cells of each transformation 
condition were mixed with 0.5 µg of DNA, 5 µg fish sperm DNA and 320 µl of Mix II and 
incubated for 30 min at 30°C. Heat shock was performed after the addition of 30 µl of DMSO 
for 7 min at 42°C. Cells were plated on selective medium for 4 to 6 days. 
3.4 Protein Techniques 
3.4.1 Cell Culture 
Human cell lines were maintained at 37ºC in humidified atmosphere containing 5% CO2 
unless otherwise stated. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin and 0.25 μg/ml 
streptomycin. Monolayer cells were split 1:10 and 1:20 at 70-80% confluence. To dislodge 
the cells, cell medium was removed from tissue culture dish, cells were rinsed once with 1x 
PBS and incubated in Trypsin-EDTA solution (Gibco) for 2-4 min at RT. Cells were then 
suspended in complete DMEM and split into 10 cm dishes.  
Subculturing procedures were carried out in a laminar flow hood in a sterile environment 
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using medium and reagents that were all pre-warmed to 37ºC. 
3.4.2 Whole Cell Protein Extraction 
Mammalian or mouse cells were washed twice with ice-cold 1x PBS and extracted with RIPA 
or co-IP buffer. Total cell extracts were incubated on ice for 30 min and then centrifuged at 
13,000 x g for 15 min at 4ºC to pellet the insoluble cell debris. The supernatant fraction was 
then removed and used for cellular protein analysis. 
3.4.3 Transient Transfection 
Cells were seeded at 1.2 × 106/60-mm dishes at least 12 hrs prior to transfection. For other 
well sizes, the cell number was adjusted proportionally. Transient transfection was performed 
with 1-5 μg of total DNA using Lipofectamine 2000 reagent (Invitrogen) or FuGene 6 
(Roche) according to the manufacturer’s recommendations. For each transfection, DNA and 
3x the amount of transfection reagent were separately diluted in 100 μl of Opti-MEM I 
Reduced Serum Medium or serum free medium (Gibco). Mixtures were incubated for 10-45 
min at RT, combined and then left at RT for the next 30 min to allow the formation of DNA-
liposome complexes. DNA-liposome complex solution was overlaid onto the cells. Following 
incubation, the medium was replaced with complete DMEM and transfected cells were grown 
for the next 24-48 hrs. 
3.4.4 Protein Quantification 
The BCA Assay is based on the reduction of Cu2+
 
to Cu1+
 
by protein in an alkaline medium 
and the highly sensitive and selective colorimetric detection of the cuprous cation using 
bicinchoninic acid (BCA).  
For the determination of the protein concentrations, BCA Protein Assay Reagent A and BCA 
Protein Assay Reagent B (Pierce) were mixed in the proportion 50:1. 10 μl of BSA standards 
(0.1 μg/μl, 0.5 μg/μl, 1 μg/μl, 2 μg/μl, 6 μg/μl) and protein samples were added to 500 μl BCA 
(A + B) solution following 30 min incubation at 37°C. 200 μl of each sample were placed into 
a 96-well plate and the protein concentration was appointed using a plate reader device. 
Samples were diluted to a 1x concentration with the NUPAGE SDS Sample Buffer (4x) 
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(Invitrogen) containing 0.8% 2-ß mercaptoethanol (Sigma) and boiled for 5-10 min. 
3.5 High-Throughput Interaction Mapping 
3.5.1 Selection of Candidates for the Y2H High-Throughput Interaction Mapping  
For the generation of the circadian protein-protein interaction network, all currently described 
circadian as well as assumed components in mammals were considered at the start of the 
study (July 2007). Furthermore, suggested candidates based on gene homology and orthology 
from other species (Drosophila, Neurospora) were included. E.g. to complete the set of well- 
established kinases within the molecular oscillator like CSNK1E/D and GSK3Β [1], recent 
studies indicated the involvement of the mammalian PRKCΑ [50] and PRKACΑ described in 
the Neurospora system [51] to be important to regulate circadian rhythms. In addition, based 
on at this time unpublished findings of [22] CSNK2 subunits as well as FBXL3 [21, 22, 35, 
52] were also considered for systematic interaction mapping. Fbxl15, the mammalian 
homolog of Drosophila Jetlag [53] and the long isoform of mammalian TIMELESS (TIM) 
[54] were also selected as potential candidates. PPP2 catalytic subunits and the mammalian 
regulatory subunits closely related to Drosophila Widerborst were as well included for high-
throughput interaction experiments (for list of candidates see below). 
3.5.2 Generation of the Y2H Matrix 
18 circadian clock genes were amplified via PCR and TOPO cloning (Invitrogen) was 
performed according to the manufacturer’s protocol to generate a GatewayTM compatible 
entry clone collection. Primer pairs and source of additional 29 entry constructs are shown in 
the Materials section. All 46 open reading frames (ORFs) were sub-cloned into bait 
(pBTM116-D9) and prey destination vectors (pACT4-DM), respectively [39, 41]. DNA 
quality was controlled by digestion in the attR1/attR2 sites of yeast destination vectors and 
gene identity of ORFs was ensured by sequencing. 
3.5.3 Automated Y2H Screening 
The L40ccαMATα yeast strain was independently transformed with prey plasmids encoding 
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the Gal4 transcription activation domain (N-terminal fusions) while the bait plasmids 
containing the LexA DNA binding domain hybrids (N-terminal fusions) were introduced into 
the L40ccU MATa strain, respectively. All constructs were tested for auto-activation of the 
three reporters (his3, ura3 and lacZ) by co-transformation of baits or preys with constructs 
harboring only the transcription activation or DNA binding domain in four independent 
repetitions in 96 wells. 13% (6 baits) of the constructs have strongly activated the reporters by 
themselves and were excluded from the Y2H matrix screen. For each of the six independent 
interaction matings, 50 µl of the liquid cultures of the MATa yeast strain were placed into 
384-micro titer plates by a pipetting robot (Biomek FX) while the prey colonies were stirred 
from solid selective medium into the liquid cultures using a spotting robot (KBiosystems). 
The yeast mixtures were then spotted onto YPD (yeast complete medium) agar plates and 
incubated for at least three days at 30°C. After the mating procedure, colonies were 
automatically transferred into 348 wells containing SDII liquid (-Leu, -Trp) selective medium 
and transferred to SDII agar for selection of diploid yeast followed by incubation at 30°C for 
at least two days. Diploid yeasts were again stirred into liquid and subsequently spotted on 
solid selective SDIV agar plates (-Leu, -Trp, -Ura, -His) as well as nylon membranes placed 
on SDIV agar plates. After 6 days at 30°C, β-Galactosidase assays were performed with the 
colonies that grew on membrane. Digital images were taken. Growth and β-Galactosidase 
activity was analyzed using the Visual Grid (GPC Biotech) software [39, 41]. Because of a 
very low mating efficiency of mPER2 (prey configuration) and mCRY2 (bait configuration) 
matings with yeast expressing all 45 components were individually performed for these two 
candidates in 96-well format in six independent experiments. In case that interaction of two 
components occurred in both the bait and prey configuration the conformation with the 
highest interaction score was selected for representation. Yeast strains expressing BHLHB2 
(= DEC1) could not successfully mate with strains expressing BTRC, FBXW11, NPAS2 and 
PRKCA. In addition, yeast strains expressing PRKCA were not mating with BHLHB2 or 
PPP2R1B expressing strains. 
3.5.4 X-GAL Assay 
Yeast colonies were grown on membranes (MicronSeparations Inc.) placed on solid SDII or 
SDIV medium for 3-6 days at 30°C. Membranes harboring colonies were shock-frosted with 
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liquid niriogen for 5 min and defrosted at RT. This procedure was repeted for 2-4 times. 
Membranes were placed on 3 MM Whatman paper in a dish and incubated for 2-6 hrs with 
the X-GAL solution. If lacZ was expressed in the yeast cells blue stainig of the colonies 
demonstrated β-Galactosidase activity. Within this process the clear 5-brom-4-chlor-3-
indolyl-β-D-galactoside of β-Galactosidase is cleaved into the blue 5-brom-4-chlor-indigo. 
3.5.5 Cryoconservation of Yeast Cells 
Yeast cells were grown in NBG medium overnight and frozen at -80°C.  
3.5.6 Scoring of Interactions Detected in Yeast 
Interactions were scored based on their reproduction rate in six independent repetitions. The 
ratio of positive colony growth on SDIV or positive colonies for β-Galactosidase activity and 
the corresponding mating controls on SDII medium was calculated and represented in percent. 
For example, Clock and Bmal1 were six times positive for interaction on SDIV medium 
underlying six successful matings for diploid yeast on SDII (6 x SDIV positive/6 x SDII 
positive x 100 = 100% - all of tested interactions have been detected). The analogs calculation 
was performed for β-Galactosidase activity. Values > 50% were scored with 2 points, values 
between 25% and 50% were scored with one point and values < 25% were scored with 0 
points. Final score is represented by the sum of score points for SDIV growth selection and β-
Galactosidase activity. 90 interactions have received 4 points and were classified as high 
score, 41 interactions with 3 or 2 points were defined as medium score and 19 interactions 
have received 1 point and were therefore categorized as low score. PER3, TIMELESS, 
NR1D1, PRKCA, PPP5C, BTRC and FBXL3 showed no interactions in yeast cells. 
3.6 Validation of New CLOCK and BMAL1 Interactions in Mammalian Cells 
3.6.1 Co-Immunoprecipitation (Co-IP) Experiments in HEK293 Cells 
Immunoprecipitation (IP) is a technique of precipitating an antigen out of solution using an 
antibody specific to that antigen. This process can be used to identify protein complexes 
present in cell extracts (co-IP), by targeting a protein believed to be in the complex. The 
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complexes are brought out of solution by antibody-binding proteins isolated initially from 
bacteria, such as Protein A and Protein G. These can also be coupled to sepharose beads that 
can easily be isolated out of solution e.g. by centrifugation. After washing, the precipitate can 
be analyzed using mass spectrometry, western blotting, or enzymatic activity measurements.  
HEK293 cells were lentivirally transduced with constructs expressing Clock or Bmal1 
luciferase fusion proteins in the pLenti6 backbone (Invitrogen). Cells stably expressing 
luciferase fusions were transiently transfected with N-terminal MYC-tagged components (pc-
myc-CMV-D12) using FuGene 6 (Roche) or Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s protocol. 48 hrs after transfection cells were harvested in co-IP buffer 
containing a protease inhibitor cocktail (P-8340, Sigma-Aldrich). Lysates with one million 
luciferase counts were subjected for co-IP experiments. Input counts of 5 µl lysate were 
detected with the Beta Scout (PerkinElmer) device using 25 µl of LARI (Promega) as a 
substrate containing reagent for 10 sec. Pull-downs were performed with 2 µg of an anti-
MYC (NB600-335, Novous Biologicals) or an isoform specific ideotypic (PPP500P, Acris 
Antibodies) antibody with G PLUS-agarose beads (Santa Cruz Biotechnology) via overnight 
incubation at 4°C and constant agitation. Beads were washed three times in 250 µl co-IP 
washing buffer. Luciferase activity of beads pellets was measured as performed for input 
detection. Beta Scout background values were subtracted for all conditions. Validation 
experiments were performed at least twice with comparable results.  
3.6.2 Input Detection of MYC-Tagged Components via Western Blot 
Lysates used for co-IP experiments containing MYC-tagged proteins were denatured in SDS-
loading buffer (Invitrogen) for 10 min at 95°C. Separation was performed by SDS-PAGE 
with 4%-12% Bis-Tris gels (Invitrogen). Proteins were transferred to nitrocellulose membrane 
(0.45 μm) using a tank transfer system (wet transfer). For one gel, one sheet of membrane and 
two sheets of chromatography paper were cut to size of the gel. The gel, membrane, paper and 
two foam pads were equilibrated in the transfer buffer for 5 min, assembled into a stack, and 
placed in the tank blotting gear with membrane side facing the anode. SDS-denaturated 
proteins are negatively charged and move from the gel to the membrane. The transfer was run 
for 60 min at 90 V. The buffer was cooled with an ice block to prevent overheating during the 
transfer. Membranes were incubated with an anti-MYC antibody (NB600-335, Novous 
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Biologicals) according to the manufacturer’s protocol. For standard Western blots, the 
membrane was blocked in PBS(T) with 5% nonfat dry milk for 1 h at RT or overnight at 4°C. 
After washing in PBS(T) (3x 5 min)m, the membrane was placed in the primary antibody 
solution and gently shaken overnight at 4°C. The membrane was then washed in PBS(T) (3x 5 
min) and incubated with the HRP-conjugated secondary antibody (Santa Cruz 
Biotechnologies) for 1 h at RT. After another washing step in PBS(T) (3x 5 min), 
chemiluminescence reaction (see below) was performed with Super SignalWest Pico substrate 
(Pierce). Protein bands were visualized using the ChemoCam (Intas) detection system. 
3.6.3 Enhanced Chemiluminescence Immunodetection  
This method, developed by Amersham, was subsequently used for all antibody detection because 
of the speed of the reaction and the exclusion of radioactivity. ECL is a light emitting, 
nonradioactive method for the detection of immobilised specific antigens with antibodies 
conjugated to horseradish peroxidase (HRP). The system utilises a chemiluminescent reaction in 
that immunoreactive proteins were detected by enhanced chemiluminescence. Equal volumes of 
Super SignalWest Pico substrate solution 1 and 2 (Pierce) were mixed and added to the 
membrane. The reaction was allowed to proceed for 1 min at RT and excess of HRP substrate was 
removed. Chemiluminescence was detected as described above. 
3.7 Genetic Perturbation Studies in Oscillating Cells 
3.7.1 Production of Lentiviruses in Flasks 
HEK293T cells were trypsinized using Trypsin/EDTA (BIOCHROM AG, Cat. no. L2143) for 
~5 min at 37°C from an almost confluent 175 cm2 culture flask (culture time < 6 weeks). 
Cells were seeded in a 175 cm2 or 75 cm2 flask in equal parts in 25 ml or 12.5 ml cell culture 
medium. Next day, cells were transfected with packaging plasmid and lentiviral vector. 
Culture medium was replaced prior tranfection. 17.5 μg or 8.4 μg of lentiviral expression 
plasmid (RNAi or overexpression vectors), 12.5 μg or 6 μg of psPAX and 7.5 μg or 3.6 μg 
pMD2G plasmid were mixed and the volume was adjusted to 1095 μl or 526 μl with the 
supplied H2O (solution A). 155 μl or 74 μl of supplied 2 M Calcium solution (CalPhos-Kit, 
BD-Biosciences, Cat. no. 631312) was added to solution A. Transfection sample was mixed 
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by carefully vortexing solution B (1250 μl or 600 μl of 2x HBS) while adding drop wise 
solution A. Mixtures were incubated for 20 min at RT. 2.5 ml or 1.2 ml of each transfection 
solution were added to almost confluent HEK293T cells growing in one 175 cm2 or 75 cm2 
flask. Cells were incubated overnight at cell culture conditions. Medium was replaced the next 
day and the first supernantant was harvested into a 50 ml tube and stored on ice overnight. 
Flasks were refiled with the equivalent amount of new cell culture medium. 24 hrs later, the 
remaining supernantant was harvested into the corresponding 50 ml tube and tubes were 
spinned at 4,100 x g for 15 min to remove cell debris. Supernatant was passed through a 0.45 
μm filter (SARSTEDT, Cat. no. 83.1826) to remove remaining cell particles and used directly 
for lentiviral transduction of reporter cells or was frozen down to -80°C in working aliquots. 
3.7.2 Production of Lentiviruses in 96-Well Plates 
HEK293T cells (culture time < 9 weeks) in log phase were trypsinized with Trypsin/EDTA 
(BIOCHROM AG, Cat. no. L2143) for ~5 min at 37°C. 30*103 cells were seeded in 100 μl 
medium per well on clear 96-well plates (BD Falcon, Cat. no. 353072). Constructs were prepared 
in 96-well format with ~0.14 μg/μl of DNA in HPLC H2O. Two 15 ml tubes with 2.75 ml 
OptiMEM (GIBCO, Cat. no. 31985) each were prepared. Tube A contained 11 μg psPAX and 6.6 
μg pMD2G plasmid while tube B 55 μl Lipofectamin 2000. Reagents were incubated for 5 min at 
RT. 25 μl of tube A reagent were transferred onto 96-well PCR V-bottom microtiter plate (Costar, 
Cat. no. 3363) using a multichannal pipette. 1 μl of prediluted DNA was transferred anlogous in 
the same 96-well PCR microtiter plate. 96-well plates were sealed with adhesive tape (Roth, Cat. 
no. EN83.1), mixed, and centrifuged with ~400 x g (using max. 2x 4 plates per run) for 1 min. 
Next, 25 μl of tube B were transferred onto the 96-well PCR microtiter plate. Plates were sealed 
with adhesive tape and mixed well followed by centrifugation at ~400 x g. Mixtures were 
incubated for 20-40 min at RT. Transfection mix was then transferred to 96-well microtiter plate 
with HEK293T cells. Next day, supernatant was removed from HEK293T cells with a NUNC 
immuno-washer device (NUNC, Cat. no. 470175) with a 9.5 mm comb depth and medium was 
replaced with 150 μl fresh culture medium. 
3.7.3 Lentiviral Transduction in 96-Well Plates 
U2OS BLH TD1 2K5 reporter cells [22, 35] (culture time < 9 weeks) grown in log phase (one 
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175 cm2 flask) were trypsinized with trypsin/EDTA for ~5 min at 37°C. Reporter cells (20 * 
103/well) were seeded in 50 μl culture medium plus 32 μg/ml protamine-sulfate (final 
concentration 8 μg/ml) in white 96-well plates. Viral particles containing supernantant from 
HEK293T cells (see previous section) were filterd using MultiScreen HTS filter plates 
(Milipore, Cat. no. MSFBN6B50), which were placed on top of a white 96-well culture plate 
(NUNC, Cat. no.136101) by spinning at 3,000 x g for 1 min. Next, GFP expression (in the 
case of GIPZ constructs) of the HEK293T cells was measured with the Infinite F200Pro 
device (TECAN). Next day, supernatant was removed from reporter cell plate using the NUNC 
immuno-washer and replaced with 150 μl fresh culture medium plus puromycin (10 μg/ml) or 
blasticidin (10 μg/ml).  
3.7.4 Dynamic Oscillation Monitoring 
Cells were synchronized by adding 50 μl of dexamethason solution (Sigma-Aldrich, Cat. no. 
D4902, solubilized in EtOH) to reporter cell plate, using a multichannel pipette. After a 15-30 
min incubation time at at 37°C with 5% CO2. The reporter cell plate was washed twice with 
150 μl prewarmed PBS/well (using the immuno-washer). During the second wash with PBS 
on plate, GFP expression of the U2OS cells was measured (for GIPZ constructs) with the 
Infinite F200Pro device (TECAN). Finally, 150 μl of reporter medium per well were added to 
the plate and plates were sealed with Diamont Seal (Abgene, Cat. no. AB-0812) and the 
ALPS 50 device (Abgene) (2x with 165°C for 3 sec). Luminescence recording in TopCount 
luminometer (PerkinElmar) was started.  
3.7.5 RNAi-Mediated Gene Silencing 
Lentiviruses delivering RNAi (pGIPZ) constructs (Open Biosystems, Huntsville AL) were 
produced in HEK293T cells in a 96-well-plate format essentially as described above. Virus 
containing supernatants were filtered using Acro-Prep filterplates (Milipore). U2OS reporter 
cells (with a stably integrated 0.9 kb Bmal1 promoter fragment) [22, 35] were transduced with 
100 μl virus filtrate plus 8 µg/μl protamine sulfate (Sigma, Munich, Germany) in white 96-
well plates (Nunc, Langenselbold, Germany). After one day, medium was exchanged to 
puromycin (10 μg/ml) containing medium. Three days later, cells were synchronized with 
dexamethasone (1 μM) for 30 min. Bioluminescence was recorded for 5 to 7 days in a 
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TopCount luminometer (PerkinElmer) with a stacker unit (sampling rate: ~30 min). RNAi 
data for 88 network neighborhood genes are part of a genome-wide screen (n = 1). RNAi 
experiments for clock core and regulatory components (45 genes; no RNAi construct was 
available for DEC1 in our library) were performed in three independent experiments 
(independent virus productions) with 20 non-silencing pGIPZ constructs per 96-well plate 
serving as controls.  
3.7.6 Overexpression 
U2OS reporter cells were lentivirally transduced with 46 ORFs in pLenti6 backbone 
(Invitrogen). After ten days of positive selection with blasticidine (10 µg/ml) (Invitrogen), 
bioluminescence was recorded as described above. PRKACA overexpression caused cell 
lethality. Experiments were independently performed three times. Cells expressing GFP 
(pLenti6) (n = 10 per plate) were considered as controls. 
3.7.7 Data Analysis and Phenotypic Score 
Network neighborhood (88 genes): period values were determined using an in-house 
programmed software (Chronostar), which basically performs a detrending by division of 
individuals data 24-hrs-running average and gives parameter estimations by fitting of a cosine 
wave function: y=a*exp(b*t)*cos(2 *pi * t * 24/c + d) where a = amplitude, b = damping, c = 
period and d = phase. The reliability of fitted parameters was determined by the correlation 
coefficient (cc). This software allows batch-processing of large quantities of circadian 
bioluminescence datasets. Curve fits with cc-values < 0.86 where considered as not reliable 
and marked for visual inspection. Those datasets which could not be described properly by 
above cosine function where excluded from further analysis. Datasets with cc < 0.86 and an 
arrhythmic characteristic where labeled as arrhythmic. Individual period values where 
normalized on global period effects of lentiviral load as determined by GFP fluorescence 
(Infinite F200pro, Tecan, Austria) of U2OS cells right before bioluminescence recording, as 
well as on optimized plate mean value (arbitrarily set to 24 hrs). This optimized mean value 
was determined by an iterative process, where extreme values (more than two standard 
deviations away from the respective actual mean) were excluded. We considered only those 
values as altered phenotypes, which deviated at least 0.5 hrs from an optimized mean value of 
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the respective plate. We evaluated 88 genes from circadian network neighborhood. For 82 
genes, we found at least one targeting construct in our pGIPZ library (this was not the case for 
the genes: CEBPA, DDIT3, EP300, HSP90AA1, NOS1 and PXN). Genes from the network 
neighborhood, which showed at least two RNAi constructs with similar period phenotype, i.e. 
extreme period changes in the same direction or one period phenotype plus one arrhythmic 
phenotype, where considered as neighborhood hits. 
Clock core and regulatory components (46 genes): data were analyzed as described above. 
Period differences to control values (mean of 20 non-silencing controls/plate for knockdowns; 
mean of 10 GFP expressing controls/plate for overexpression) within individual plates of 
> 0.5 hrs were considered as altered phenotypes. Amplitude and damping values that were 
more than 2.5 standard deviations different from the mean of the controls were considered as 
significant. Time series with a bad fit to a cosine function, i.e. a cc < 0.8 for knockdowns and 
cc < 0.9 for overexpression were classified as arrhythmic. Arrhythmic phenotypes were 
confirmed or rejected by visual inspection of the corresponding raw data.  
Phenotypic score: Oscillations classified as arrhythmic based on bad fit to a cosine function 
(see above) were scored with 4 points. Period between 0.5 hrs and 1 h different from controls, 
between 1 h and 2 hrs, and more than 2 hrs were scored with 1, 2 or 3 points, respectively. 
Low amplitude and high damping were scored with 1 point and not assigned if a phenotype 
was already classified as arrhythmic. Phenotypic scores represent the sum of points from 
knockdown and overexpression experiments for an individual component in all categories. 
3.8 Dual-Luciferase Reporter Assay System 
In the Dual-Luciferase Reporter Assay System (DLR) from Promega, the activities of the firefly 
and Renilla luciferases are measured sequentially from a single sample. The firefly luciferase 
reporter is measured first by adding LAR II reagent to generate a "glow-type" luminescent signal. 
After quantifying the firefly luminescence, this reaction is quenched and the Renilla luciferase 
reaction is initiated by adding Stop and Glo reagent to the same tube. The Stop and Glow reagent 
also produces a "glow-type" signal from the Renilla luciferase, which decays slowly over the 
course of the measurement. This assay sytem was used for the co-transactivation experiments and 
BMLA1-luc and CLOCK-luc stability measurements (see below). 
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3.9 CLOCK/BMAL1 Co-Transactivation Assay 
An artificial 6 E-box luciferase reporter (pGL3, Promega), Clock/Bmal1 (pDEST26, 
Invitrogen) and individually all discovered CLOCK and BMAL1 interactors and their 
paraloges (pLenti6, Invitrogen) that have been found by high-throughput interaction mapping 
in yeast were transiently transfected with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol in HEK293 cells. CLOCK/BMAL1 co-transactivation assays were 
performed as previously described [19, 55]. Normalization was performed to Renilla-
luciferase signals in lysates. Equal DNA amounts in transfections were ensured by the 
addition of lacZ DNA in the corresponding backbone. Signal detection was performed with 
the Dual-Luciferase Reporter Assay (Promega) in the Orion II Luminometer plate reader 
(Berthold Detection Systems). Experiments with all candidates were independently performed 
three times. A fourth repetition was only performed with candidates that showed consistent 
results in the previous repetitions (n = 3). Regulatory and scaffolding subunits were co-
transfected with their corresponding catalytic subunits to simulate functional holoenzymes. 
Overexpression of candidates had no effect on the reporter alone.  
3.10 Co-IP with Endogenous Components from Mouse Liver 
Animals were sacrificed at circadian time points (CT) CT12 or CT0 for liver preparation. 
Lysates were generated and co-IPs were performed as described for Y2H validation. Co-IPs 
and Western blot analysis were performed with an anti-BMAL1 antiboby (kindly donated by 
the M. Brunner laboratory; specificity was intensively characterized using Bmal1 knock out 
mouse tissue [29] or an anti-PPP1Cα antibody (sc-7482, Santa Cruz Biotechnology)). 
Controls were performed with the following ideotypic antibodies (sc-3878, sc-2037 Santa 
Cruz Biotechnology). 100 µg of total lysate were loaded as input controls. 500 µg of protein 
were subjected for immunoprecipitation experiments. 
3.11 BMAL1 and CLOCK Stability Measurements 
3.11.1 Protein Stability Measurement of BMAL1-and CLOCK-Luciferase Hybrids 
HEK293 cells stably expressing BMLA1 or CLOCK luciferase fusions (as generated for 
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interaction validation experiments) were lentivirally transduced with pLenti6 PPP1CA or 
tGFP DNA in 24-well format. 48 hrs after transfection, luciferase activity in lysates was 
detected as described for the co-transactivation assays.  
3.11.2 Endogenous BMAL1 Levels in the Presence of PPP1CA 
Steady-state: U2OS Bmal1-promoter luciferase reporter cells stably expressing PPP1CΑ or 
GFP (pLenti 6, Invitrogen) were harvested in RIPA buffer containing protease inhibitor 
cocktail (P-8340, Sigma-Aldrich). 30 µg of total lysate were loaded for Western blot analysis 
as performed in 2.1 using the anti-BMAL1 antibody from M. Brunner’s laboratory. 
Membranes were probed with an anti-Actin IgG (A-5441, Sigma-Aldrich) as loading controls. 
Quantification was performed with ImageJ 1.44p software (National Institutes of Health).  
Cyclohexamide (CHX) time series: U2OS cells – as described above – were treated with CHX 
(C4859, Sigma-Aldrich) using a 0.71 mM final concentration. Cells were harvested at the 
following selected time points: 3 hrs, 4 hrs, 5 hrs and 6 hrs. Western blotting and incubation 
with antibodies were performed as described above. 
3.12 Network Visualization 
Network was depicted using the Cytoscape 2.8.1 software as available at 
www.cytoscape.org/. 
3.13 Bioinformatics Analysis 
Bioinformatics analyses were conceptionally designed by me and performed by Dr. Matthias 
Futschik and Dr. Ravi Kalthur (Universtiy of Algarve, Faro, Portugal). I have performed 
network topology analysis (network properties and cluster analysis using Cytoscape 2.8.1 
sofware) as well as KEEG pathway analysis. I and Dr. Matthias Futschik have written the 
following Methods section.  
3.13.1 Construction of Protein-Protein Interaction Networks form UNIHI 
For network analyses, proteins were indexed by corresponding human Entrez Gene IDs. For a 
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proteome-wide interaction network, data curated in the original databases HPRD (binary 
interactions only), DIP, BIND, BIOGRID and INTACT as stored in the UNIHI4 version were 
integrated [56]. This generated a global network of 9,982 proteins and 45,775 interactions. 
The network was used to identify additional interactions between the proteins in the circadian 
network (PPIs among 46 components (clock core and regulatory components)) as well as to 
assess the molecular context of the circadian network. First, the global protein networks were 
examined for overlap (common proteins and interactions) with the circadian PPI network. 
Identified additional interactions between the 46 components were added to enlarge the 
circadian PPI network. Furthermore, we included proteins interactions based on a literature 
review that we conducted. 
3.13.2 Determination of Periodic Expression 
To identify periodic expression patterns, the data set by [27] measuring gene expression in 
mouse liver was utilized. The microarray dataset includes consecutive sampling over 48 hrs 
(with intervals of 1 h) for 45,101 probe sets. These probe sets correspond to 21,308 unique 
mouse Entrez Gene identifiers. For derivation of probe set intensities, the RMA method as 
implemented in the Bioconductor affy package was utilized.  
To evaluate the periodicity, the expression vectors mRNA profiles were standardized and 
subsequently corresponding Fourier scores for a periodicity of 24 hrs were calculated. The 
Fourier score is defined as  
 
F[x] =  
 
where x is the standardized expression vector (mean(x) = 0; sd(x) = 1) for the gene, T is the 
period (in our case 24 hrs), and xi is the measured expression at time point ti. Statistical 
significance (i.e. false discovery rate (FDR)) was derived through comparison using randomly 
permutated time series [57]. The expression analysis was performed using the Bioconductor 
cycle package. 
( ) ( )2ii2ii  x/T) t  (sin(2 x/T) t  (cos(2 ∑∑ ⋅⋅⋅+⋅⋅⋅ ii ππ
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3.13.3 Interactions and Expression of Regulatory Proteins 
To compare the number of interactions of regulatory and non-regulatory proteins in the 
human interactome, we first calculated the number of interactions for each protein in the 
global protein-protein interaction networks derived from UNIHI database. For the 
classification of regulatory proteins, we utilized gene annotation from the GO database. 
Proteins whose corresponding genes were associated with the GO category `Regulation of 
biological process´ (GO:0050789) were assigned as regulatory proteins (n = 4,635). The 
remaining proteins were classified as non-regulatory (n = 5,347). Subsequently, the numbers 
of interactions of proteins in both groups were compared. We observed that regulatory 
proteins tend to have more interactions than non-regulatory proteins. The mean number of 
interactions for regulatory proteins was 12.74, whereas non-regulatory proteins have in 
average only 5.64 interactions. Statistical testing demonstrated that this difference is highly 
significant (Wilcoxon test: p < 10-15). 
We also examined the relationship between periodic expression and number of interactions. 
First, we calculated the number of interactions for human proteins for which the mouse 
ortholog is showing significant periodic expression (FDR < 0.01; n = 2,468). The average 
number was 11.31 interactions compared to 8.81 for proteins with a mouse orthologs that are 
not periodically expressed (n = 5,011). The difference is statistically highly significant 
(Wilcoxon Rank test; p < 10-10) indicating that proteins with periodic expression tend to have 
more interactions compared to constitutively expressed proteins. Secondly, we examined 
whether the reverse is valid i.e. interaction-rich proteins tend to be periodically expressed. To 
this end, we classified proteins with more than 50 interactions as interaction-rich (n = 762), 
and compared their periodic expression with proteins that have less than 5 interaction (n = 
6,654). Notably, almost 42% of the interaction-rich proteins were periodically expressed 
compared to only 29% for interaction poor. Statistical evaluation of the difference by Chi-
squared test indicated a high significance (p < 10-5). 
3.13.4 Identification of Dynamic/Rhythmic Protein-Protein Interactions 
To obtain an approximation of the dynamics of PPI in the network, we assumed that the 
abundance AC of the complex C formed by two interacting proteins P1,2 through a PPI is 
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proportional to the expression E of P1,2. Thus, the abundance AC(t) over time can be 
approximated by the product of expression vectors mRNA profiles EP1(t) * EP2(t) which was 
then associated with the corresponding PPI between P1 and P2. As proxy for the expression, 
the transcript levels over time were utilized, thus 
 
PPI12 ~ AC(t)  ≈ c * AP1 (t)* AP2(t) → AC(t) ≈  EP1 (t)* EP2(t). 
 
The statistical significance of the product of expression vectors mRNA profiles was 
calculated in the same manner as for simple expression vectors (i.e. using the Fourier-score 
and permutated time series as background model) after standardization (i.e. mean(EP1 * EP2) = 
0; sd(EP1 * EP2) = 1). Additionally, a phase was assigned to a periodic interaction through 
shifting a cosine (with periodicity 24 hrs) along the time axis and measuring the overlap of the 
expression levels with the cosine curve. PER1-3 mRNA profiles were shifted + six hrs (see 
[20]). The time shift leading to a maximum overlap was considered as the phase α of the PPI 
and ranges from 0 to 24 hrs.  
3.13.5 Dynamic Interactions between Biological Processes in the Circadian Protein-
Protein Interaction Network 
To examine the dynamic coupling between biological processes in the circadian network, we 
first selected the processes, which were examined in the analysis. Biological processes (BP) 
and their associated genes (or respectively proteins) were given by the annotation in Gene 
Ontology (GO, www.geneontology.org). Here, we chose processes, for which associated 
proteins were overrepresented in the circadian network. For calculation of statistical 
significance of enrichment, hypergeometric test (which is equivalent to Fisher´s exact test) 
with subsequent Benjamini-Hochberg for multiple testing was utilized. A FDR cut-off of 0.25 
for significance was set.   
A well-known difficulty in the interpretation of enrichment analysis for GO categories is 
occurrence of highly overlapping terms. This is caused by the hierarchical structure of GO: 
significance of enrichment in children terms frequently result in significance of their parent 
terms (e.g. significance in proteins linked to the term `Intracellular signal transduction´ 
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contribute to the statistical enrichment of proteins in the term `Signal transduction´). To 
reduce the set of significant terms to a smaller and less redundant set of terms, we used 
following filtering procedure: Categories were excluded if the majority of included genes (i.e. 
more than 50%) had been associated with a single category having less genes. This procedure 
generally led a reduced set of more specific categories facilitating inspection of results. 
Applied to the 134 genes included in circadian network and the full set of categories for 
biological processes derived from GO through the Bioconductor GO package, 16 significant 
categories with a minimum size of 10 associated genes were derived. 
Next, we counted the number of interactions between proteins for all possible pairs of 
processes. Also, the number of dynamic interactions (with a significance of periodicity of  
FDR < 10-5) was counted. Using the calculated numbers, we tested whether dynamic 
interactions were over-represented in the total set of interactions between a pair of categories 
using Fisher’s exact test with subsequent Benjamini-Hochberg adjustment for multiple 
testing. A network of biological processes was then constructed based on the significance for 
the enrichment in dynamic interactions between categories. 
For the reduced set of GO categories, setting a threshold for significance of FDR < 0.1 
resulted in a network with 12 links between 11 processes. The central position is constituted 
by the BP category `Circadian rhythm´ which is linked to the 10 other categories by dynamic 
interactions.  
3.13.6 KEGG Pathway Analysis of Components of the Network Neighborhood 
The circadian network neighborhood was examined for enriched KEGG (Kyoto Encyclopedia 
of Genes and Genomes) pathways. To this end, the 88 proteins in the neighborhood were 
annotated with pathway information derived from KEGG through the Bioconductor KEGG 
package. The significance for enrichment was calculated using the hypergeometric test, which 
is equivalent to the Fisher’s exact test. Pathways with less than 5 associated proteins from the 
network neighborhood were excluded. For multiple testing, an adjustment by the Benjamini-
Hochberg method was conducted and FDR were derived. A threshold of FDR < 0.25 was 
applied.  
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3.13.7 Overlap with Reference Gene Sets 
Significance was calculated using the hypergeometric test with the complete lists of genes 
included in the global network as reference set. 
The overlap with the Cancer Gene Census (www.sanger.ac.uk/genetics/CGP/Census) of 427 
genes is:  
− for the clock core and regulatory components (46 proteins): EZH2, NONO, PER1; three 
genes; p = 0.10 
− for the full extended network (134 proteins): AKT1, ATF1, CEBPA, CREBBP, DDIT3, 
EP300, EZH2, HLF, HSP90AA1, MEN1, MLL, MYC, NCOA1, NCOA2, NONO, 
PER1, PML, RARA, SFPQ, SUZ12; 20 genes, p = 2.8 * 10-8  
− for the neighborhood only (88 proteins): AKT1, ATF1, CEBPA, CREBBP, DDIT3, 
EP300, HLF, HSP90AA1, MEN, MLL, MYC, NCOA1, NCOA2, PML, RARA, SFPQ, 
SUZ12; 17 genes; p = 3.8 * 10-9  
The overlap with the HD Research Crossroads (www.hdresearchcrossroads.org) gene list of 
692 HD-relevant genes is: 
− for the clock core and regulatory components (46 proteins): CSNK2A1, CSNK2B, 
GSK3B, NR1D1, PPP1CA, PRKACA, PRKCA, RORB; eight genes; p = 0.0012 
− for the full extended network (134 proteins): for the full extended network (134 proteins): 
AKT1, AR, CREBBP, CSNK2A1, CSNK2B, GANI1, GNB1, GSK3B, HDAC1, 
HDAC2, HSP90AA1, NCOR1, NOS1, NPAS4, NR1D1, POLR2A, PPP1CA, PRKACA,  
PRKCA, RORB, RXRA, SP1, UBE2I; 23 genes; p = 1.6 * 10-6 
− for the neighborhood only (88 proteins): AKT1, AR, CREBBP, GANI1, GNB1, HDAC1, 
HDAC2, HSP90AA1, NCOR1, NOS1, NPAS4, POLR2A, RXRA, SP1, UBE2I; 15 
genes; p = 7.2 * 10-5  
3.13.8 Identification of Structural Modules 
In order to identify dense local sub-networks (i.e. structural modules), two algorithms were 
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used: 1. The MCODE algorithm (http://baderlab.org/Software/MCODE) and 2. The 
ClusterOne algorithm (www.paccanarolab.org/cluster-one). For both algorithms, their Cyto-
scape implementation was utilized. The two methods are similar in their general procedure, 
i.e. to detect first dense local networks and them to expand them.  
Significance of periodicity of interaction is represented by edge color with red representing 
highly significant (FDR < 10-5) and yellow/white representing low significance of periodic 
expression. Similarly, edge width represents also the significance of periodicity of interaction 
with larger width representing higher significance. Yellow circles highlight rhythmic RNA 
profiles; circle width corresponds to significance of periodic expression. Calculation of 
significance of functional enrichment was based on Fisher’s exact test with Benjamini-
Hochberg adjustment using the annotation provided by the GO Bioconductor package.  
3.13.8.1 MCODE Modules 
To identify structural modules using the MCODE algorithm, the node score cutoff parameter 
was set to 0.05. For other parameter, the default values (Version 1.32) were used. This 
parameter setting led to small structural modules facilitating their inspection. In total, nine 
clusters were identified, five of which were simple triangles and disregarded in the subsequent 
analysis. The top four modules are as follows: 
1. Module  
This module obtained rank 1 and a score of 3. The score produced by MCODE is the average 
number of distinct interactions per protein. It includes seven proteins and 21 interactions. Five 
proteins are significantly (FDR < 0.01) periodically expressed. The GO terms `Histone 
methyltransferase complex´ (FDR < 10-11; five genes: ASH2L, HCFC1, MEN1, MLL, 
RBBP5) and `Transcription from RNA polymerase II promoter´ (FDR = 0.0008; five genes: 
ASH2L, HCFC1, HCFC2, MEN1, MLL) are significantly enriched.  
2. Module  
This module obtained rank 2 and a score of 2. It includes five proteins and ten interactions. 
The GO term `Transcription from RNA polymerase II promoter´ (FDR= 0.004; four genes: 
CEBPG, DDIT3, HLF, TEF) as well as the Pfam family `Basic region leucine zipper´ (FDR < 
10-10); four genes: CEBPG, DDIT3, HLF, TEF) are significantly enriched. 
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3. Module 
This module obtained rank 3 and a score of 1.8. It includes five proteins and nine interactions. 
The GO terms `Transcription coactivator activity´ (FDR = 0.0016; three genes: KAT2B, 
NCOA1, NCOA2) and `Positive regulation of transcription from RNA polymerase II 
promoter´ (FDR = 0.0004; four genes: AR, HIF1A, NCOA1, NCOA2) are significantly 
enriched.  
4. Module  
This module obtained rank 4 and a score of 1.5. It includes eight proteins and twelve 
interactions. The GO terms `Chromatin modification´ (FDR < 10-4; five genes: CHD4, EED, 
EP300, HDAC1, HDAC2), `Transcription factor binding´ (FDR < 10-4; six genes: AHR, 
CHD4, EP300, HDAC, HDAC2, NCOR2), `Negative regulation of transcription´ (FDR < 
10-3; four genes: EED, HDAC2, NCOR2, UBE2I) are significantly enriched.  
3.13.8.2 ClusterOne modules 
Besides MCODE, we used the ClusterOne Cytoscape plugin to detect structural modules. For 
the detected modules, the density, quality and p-value of the modules are reported. Density of 
a structural module is defined by the number of observed interactions within the module 
divided by the maximum number of possible interactions. The quality of a module is the 
number of internal interactions divided by the sum of internal interactions and interactions 
with proteins outside the module. The p-value is based on a one-sided Mann-Whitney U test 
distinguishing internal interactions and interactions with proteins outside the module. More 
details are available at http://www.cs.rhul.ac.uk/home/tamas/assets/files/cl1/cl1-cytoscape-
0.92.html. 
1. Module 
This module has ten proteins connected by 24 interactions. It obtained a density of 0.54, a 
quality of 0.57 and a p-value of 0.003 by the ClusterOne algorithm. The GO terms `Rhythmic 
process´ (FDR < 10-4; four genes: DBP, HLF, NFIL3, TEF) and `RNA polymerase II 
transcription factor activity´ (FDR < 10-3; four genes: BATF, CEBPA, DBP, TEF) as well as 
the Pfam family `Basic region leucine zipper´ FDR < 10-18; seven genes: CEBPA, CEBPG, 
DBP, DDIT3, HLF, NFIL3, TEF) were significantly enriched.  
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2.  Module 
This module has nine proteins connected by 20 interactions. It obtained a density of 0.56, 
quality of 0.58 and a p-value of 0.004 by the ClusterOne algorithm. The GO terms 
`Transcription from RNA polymerase II promote´ (FDR = 0.00013, six genes: CEBPG, 
DDIT3, DR1, HLF, NFIL3, TEF), `Transcription corepressor activity´ (FDR < 10-3; three 
genes: DDIT3, DR1, NFIL3) as well as the Pfam family `Basic region leucine zipper´ (FDR < 
10-11; five genes CEBPG, DDIT3, HLF, NFIL3, TEF) are significantly enriched.  
3. Module 
This module has 18 proteins connected by 77 interactions. It obtained a density of 0.50, 
quality of 0.42 and a p-value of 0.01 by the ClusterOne algorithm. The KEGG pathways 
`Circadian rhythm – mammal´ (FDR < 10-7; five genes: BHLHE40, BHLHE41, CRY1, 
CSNK1E, CLOCK) and `Wnt signaling pathway´ (FDR < 10-5; seven genes; CSNK1E, 
CSNK2B, PPP2CA, PPP2R1A, PPP2R1B, PPP2R5D, PPP2R5E) as well as the GO term 
`Protein phosphatase type 2A complex´ (FDR < 10-5; four genes: PPP2CA, PPP2R1A, 
PPP2R5D, PPP2R5E) are significantly enriched.  
4. Module 
This module has nine proteins connected by 21 interactions. It obtained a density of 0.58, 
quality of 0.53 and a p-value of 0.015 by the ClusterOne algorithm. The GO terms `Response 
to DNA damage stimulus´ (FDR = 0.0017; four genes; CUL4B, CUL4A, DDB1, DTL) and 
`Nucleotide excision repair´ (FDR < 10-5; 3 genes; CUL4B, CUL4A, DDB1) as well as the 
Pfam family `WD domain, G-beta repeat´ (FDR < 10-6; five genes: DTL, GRWD1, RBBP5, 
SNRNP40, WDR5) are significantly enriched.  
5. Module 
This module has 17 proteins connected by 68 interactions. It obtained a density of 0.50, 
quality of 0.407 and a p-value of 0.015 by the ClusterOne algorithm. The GO terms `Histone 
acetyltransferase activity´ (FDR < 10-8; five genes: CREBBP, EP300, KAT2B, NCOA3, 
NCOA1), `Positive regulation of transcription from RNA polymerase II promoter´ (FDR < 
10-8; nine genes: AR, EP300, HDAC1, HIF1A, MYOD1, NCOA1, NCOA2, RXRA, SP1) as 
well as the KEGG pathways `Notch signaling pathway´ (FDR < 10-5; five genes; CREBBP, 
EP300, HDAC1, KAT2B, NCOR2), `Pathways in cancers´ (FDR < 10-4; eight genes: AR, 
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CREBBP, EP300, HDAC1, HIF1A, PML, RXRA, STAT3) and `Huntington's disease´ (FDR 
< 10-3; five genes: CREBBP, EP300, HDAC1, POLR2A, SP1) are significantly enriched. 
6. Module 
This module has 18 proteins connected by 78 interactions. It obtained a density of 0.51, 
quality of 0.43 and a p-value of 0.02 by the ClusterOne algorithm. The KEGG pathways 
`Circadian rhythm – mammal´ (FDR < 10-10; six genes: BHLHB2 (= DEC1), BHLHB3 (= 
DEC2), CLOCK, CRY1, CSNK1E, PER2) and `Wnt signaling pathway´ (FDR < 10-4; six 
genes: CSNK1E, CSNK2B, FBXW11, PPP2R1B, PPP2R5D, PPP2R5E) are significantly 
enriched.  
7. Module  
This module has 18 proteins connected by 77 interactions. It obtained a density of 0.50, 
quality of 0.41 and a p-value of 0.025 by the ClusterOne algorithm. The KEGG pathways 
`Circadian rhythm – mammal´ (FDR < 10-21; ten genes: BHLHB2, BHLHB3, CLOCK, 
CRY1, CRY2, CSNK1D, CSNK1E, PER1, PER2, PER3) and `Wnt signaling pathway´ (FDR 
< 10-4; six genes CSNK1E, CSNK2B, FBXW11, PPP2R1B, PPP2R5D, PPP2R5E) are 
significantly enriched.  
3.14 Dynamic Interactome 
To examine circadian coupling between processes on a systems-wide level, all PPIs of the 
compiled human interactome (n = 45,775) were assessed for dynamic behavior. Human 
proteins were mapped to their orthologs in mouse. As previously for the circadian network, 
the periodicity of interactions was based on the expression data for mouse liver over the time 
span of 48 hrs. In total, the dynamic behavior of 30,413 interactions could be determined. For 
the remaining interactions, either corresponding gene expression data was not available or the 
mouse orthologs could not been found. 
For the determination of significance in periodic expression, the described Fourier-
based approach with random permutations as background model was used. A threshold of 
FDR < 10-5 was set. This resulted in the identification of 2,788 significantly dynamic 
interactions. The full lists of interactions containing the human proteins and their mouse 
orthologs, corresponding gene symbols, significance of periodic expression and offset of 
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individual interactions partners as well as of the interaction can be found in the Appendix 
section. 
For evaluation, which biological processes are connected in a dynamical manner, we 
performed an enrichment analysis for the 1,979 proteins with dynamic interactions. The 
analysis was based on their GO slim annotation. To obtain non-redundant set of categories for 
biological processes, the previously described filtering procedure was used, i.e. categories are 
excluded if the majority of included genes are associated with a single category having less 
genes. We obtained 27 biological processes with a significant enrichment of FDR < 0.25. 
Next, we mapped the dynamic interactions to the corresponding biological processes. As 
before, the significance of over-representation of dynamical interactions between categories 
was calculated. Connections, which were significantly dynamical enriched, were displayed as 
network. Transcription and signal transduction were detected to be central hubs in the 
network of processes coupled by dynamic interactions. In contrast, processes like `Cellular 
homeostasis´ and `Lipid metabolism´ tended to be linked to other processes via static 
interactions. 
As an alternative approach to examine, which biological processes tend to be linked by 
the dynamic interactions, we compared the wiring of the observed interaction network with 
randomized versions of it. For randomization, the degree distribution of each protein was 
conserved. To this end, the interaction between protein pairs were randomly switched, i.e. 
interactions between protein pairs A-B and C-D were changed to A-C and B-D. Every 
interaction was repeatedly switched in average 100 times. For the randomized networks, the 
number of dynamic interactions between the biological processes were counted and compared 
with the observed network. Altogether, 1,000 randomized networks were independently 
generated. We found that for 26 pairs of biological processes, the numbers of dynamic 
interactions were higher than in any of the randomized network. This number of pairs 
increased if we relax the requirement. We obtained 52 pairs if we required that the number of 
dynamic interactions between processes should not be higher in ten out of the 1,000. 
Data regarding the dynamic interactome analysis will be available as online supporting 
material of my publication (Wallach T, Schellenberg K, Maier B, Kalathur R, Porras P, 
Wanker EE, Futschik M, Kramer A. Dynamic Circadian Protein-Protein Interaction Networks 
Reveal Temporal Organization of Cellular Functions. In preparation). 
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4 RESULTS 
4.1 Large-Scale Y2H Interaction Analysis with Circadian Clock Components 
To systematically map the PPIs within the circadian clock regulatory network, I performed a 
matrix-based Y2H screen in yeast with 46 known or assumed clock or clock-associated 
components. In this screen, each potential interaction was tested individually in six replicas 
minimizing the risk of false negatives (see Figure 8 A, B; Figure 9 A) [39, 41]. After 
excluding transcriptionally autoactive components, I have performed 11,040 individual Y2H 
experiments monitoring growth on selective medium and β-galactosidase activity as readouts 
for interaction (Figure 8 C and Figure 9 A to C). 
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Figure 8. The Yeast-Two-Hybrid (Y2H) Approach.  
(A) Principle of the Y2H screen. Y2H is a genetic approach where two interacting proteins can reconstruct a 
functional transcription factor, which leads to the activation of several reporter genes (ura, his: growth selection 
on minimal medium; lacZ: β-Galactosidase activity). One interactor – X – is fused to a DNA binding domain 
(DBD: LEXA; bait configuration), while the other – Y – to a transcription activation domain (AD: GAL4; prey 
configuration). Both hybrids are transformed into different yeast strains (MATa or MATα). Interaction of X and 
Y is detected after mating via activation of reporter genes. 
(B) Left: Matrix-based Y2H screening. Defined bait and prey fusions allow performing several repetitions of an 
interaction screen. Matrix position reveals positive interaction pairs without the necessity of sequence 
identification. Right: Library-based Y2H screening. Bait is presented to prey library containing redundant 
sequences. Growth competition and sequencing are required for the identification of interactors. 
(C) Auto-activation test for 46 circadian clock components. Left: Yeast strains containing preys were mated with 
a yeast strain expressing the DBD only. Results are shown for four independent mating experiments. NPAS2 
(position D2) showed weak auto-activating properties (weak growth on selective medium, no lacZ expression) 
and was included for high-throughput interaction mapping. Right: Auto-activation test for baits. Yeast containing 
baits were mated with a yeast strain expressing the AD only. PER2 (A2), BMAL1 (A5), NR1D1 (B5), NR1D2 
(B6), RORB (C3) and PPP2CA (G1) showed strong auto-activation of all reporters leading to exclusion of these 
components in the bait configuration from further interaction experiments. 
 
Based on the reproducibility, the putative interactions were sorted into sets with high, medium 
and low confidence (Figure 9 B and C). Thereby, 150 interacting protein pairs that occurred at 
least in two independent experiments were identified, of which I rated 90 as high-score, 41 as 
medium score and 19 as low-score interactions (Figure 9) (for details on scoring see Methods 
section). While I could reproduce a large number (41 in total) of previously described 
interactions (e.g., CLOCK-BMAL1, PERs-CRYs, CRYs-BMAL1), 109 PPIs among circadian 
clock proteins were new (see Appendix section). For example, I detected high-score 
interactions between DEC1/2 and CRY1/2, medium-score interactions between CLOCK and 
RORB, CLOCK and the α-catalytic subunit of protein phosphatase 1 (PPP1CA) as well as 
between BMAL1 and WDR5 and low-score interaction between CLOCK and RORC (Figure 
9 B and C, Figure 10 A). 
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Figure 9. Systematic Interaction Mapping between 46 Circadian Clock Proteins and Associated 
Components.  
(A) Flow chart of matrix based high-throughput Y2H interaction screen.  
(B) CLOCK interactors: Mating controls (top left) on selective medium (-Leu, -Trp) demonstrate that yeast cells 
have simultaneously expressed bait and prey fusion proteins. When proteins interact, several reporter genes (top 
middle: his, ura for growth selection, top right: lacZ for β-galactosidase activity assay) are activated. Bottom: 
Detected interactions for CLOCK protein with circle color representing interaction score (see (C)) and position 
of representative colonies. Red lines show CLOCK interactions that were previously discovered in yeast.  
(C) Detected interactions in yeast. Circles represent interactions between two components not differentiating 
between bait and prey configuration, circle color denotes interaction score based on the reproduction rate within 
six independent repetitions.  
(D) Validation of new CLOCK and BMAL1 interactions in mammalian cells. HEK293 cells stably expressing 
CLOCK- or BMAL1-luciferase fusion proteins were transiently transfected with the indicated MYC-tagged 
components. Co-immunoprecipitations were performed with an anti-MYC or an ideotypic antibody as a control. 
Luciferase activity measurements (cps – counts/10 sec) demonstrate the presence of luciferase fusions in the 
immunoprecipitates. MYC-β-galcactosidase fusions served as negative, MYC-BMAL1 and MYC-CRY1 as 
positive controls, respectively. Depicted are representative results of at least two independent experiments with 
similar results. 
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4.2 Validation of CLOCK and BMAL1 Interactors Detected in Yeast 
To test whether the PPIs discovered in yeast also occur in mammalian cells, co-
immunoprecipitation experiments in HEK293 cells were performed.  
As representatives for the novel PPIs, I focused on the interactions of the transcriptional 
activators CLOCK and BMAL1 – central players within the circadian clock gene-regulatory 
network – whose functional modulation by interacting proteins is likely to be highly relevant 
for normal circadian rhythms. Twelve of the 14 (i.e. 85%) novel CLOCK and BMAL1 
interactions found in yeast were validated using co-IP (Figure 9 D and Figure 10 B and D), 
suggesting that a substantial proportion of all interactions identified in yeast are also 
detectable in mammalian cells. 
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Figure 10. Reproduction Rate of Y2H Screen and Validation of CLOCK and BMAL1-Interactions in 
Mammalian Cells.  
(A) 109 interactions that occurred in the matrix-based Y2H screen were so far uncharacterized. 23 interactions 
were previously found in library based Y2H screens and reproduced with our approach, whereas 18 interactions 
were reproduced that were detected previously by other approaches (not in yeast cells).  
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(B) Principle of co-IP experiments. HEK293 cells stably expressing CLOCK or BMAL1 C-terminal luciferase 
fusions were transfected with MYC-tagged interactors. Lysates containing one million luciferase counts were 
subjected to IP experiments. Pull-downs were preformed with an anti-MYC antibody or an ideotypic antibody in 
(beads) controls. After washing, beads pellets were incubated with a luciferin containing reagent and luciferase 
activity was measured (for details see Methods).  
(C) Input detection via Western blot analysis. 25 µg of total lysate were loaded per lane as an input control. 
MYC-fusions were detected with an anti-MYC antibody. The results for the co-IP as performed in Figure 9 D 
are shown. CLOCK and DBP fusions could not be detected in lysates as MYC (*), FLAG or V5-hybrids (not 
shown). Expected protein size (from Expasy database) is shown in brackets.  
(D) NONO and NR1D2 were not detected as direct BMAL1 interactors in yeast. Co-IP experiments as 
performed for validation with BMAL1-LUC and MYC-NONO or MYC-NR1D2 also show no interaction in 
mammalian cells using the validation system. Western blots show input controls as performed in (C).  
4.3 Enrichment, Extension and Topology Analysis of the Circadian PPI Network 
To understand the structure and the organizing principles of the complex web of interactions 
occurring between circadian clock components, we created an interaction network using our 
novel Y2H interaction data together with previously published interactions among these 
components. In addition, we extended this network by adding known interacting proteins 
(direct `neighbors´) of our network components (except regulatory components such as 
kinases, phosphatases and F-box proteins, which are known to be involved in many other 
cellular processes) to get an idea how the circadian PPI network is embedded in the cellular 
interactome (Figure 11). Thereby, a large PPI network with 134 components and 625 PPIs 
was created consisting of a circadian clock core (24 components), regulatory components (22 
components) and the neighborhood (Figure 12).  
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Figure 11. Construction of the Circadian Protein-Protein Interaction Network and Topology Analysis. 
Enrichment and extension of the circadian protein-protein interaction network. The experimentally derived 
network was firstly enriched by adding previously described interactions (Y2H screen false negatives) from 
literature and extended by the direct neighbors of clock core components as stored in the UNIHI database. This 
resulted in the construction of a circadian protein-protein interaction network consisting of 134 proteins and 625 
interactions.  
For this network, a mean shortest path length between any two proteins of 2.8 links was 
calculated, i.e. most proteins are very closely linked to each other indicating a `small world´ 
type of network [58]. Like many other PPI networks [42], the circadian network has `scale-
free´ properties, i.e. it is a network, for which the distribution of the number of interactions 
(`degree´) for each protein follows a power law – many proteins have few and few proteins 
have many interactions. On average each component has 8.4 interaction partners, however, 11 
proteins are highly connected with more than 20 interactions (e.g. CLOCK, BMAL1, PER2, 
CREBBP, DEC1, AR, HDAC1). Network topology analysis, further revealed that the 
circadian network is hierarchically organized, i.e. highly connected components (so-called 
`hubs´) link network regions with less connected components, which themselves tend to form 
clusters (Figure 12).  
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Figure 12.The Circadian Protein-Protein Interaction Network.  
The circadian interaction network integrates different interaction sources and visualizes 134 proteins with 625 
interactions. Proteins are displayed as nodes with the node color indicating the type or role of the corresponding 
protein. Red lines (edges) are interactions discovered by high-throughput interaction mapping in yeast. Green 
lines represent previously described (but not discovered in the Y2H screen), as stored in the UNIHI database 
and/or described in literature (MAN – manually curated). Blue lines show interactions of network extension 
(EXT – stored in UNIHI), i.e. between clock core and regulatory components and neighborhood components. 
Yellow border highlights components with a rhythmic transcript detected in murine liver [27]. Border width 
represents the significance for rhythmic expression. Visualization was performed using Cytoscape 2.8.1 
(www.cytoscape.org). 64 self-self interactions are excluded from graph. Dr. Matthias Futschik performed the 
circadian transcript expression analysis.  
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4.4 Characterization of the Circadian Clock Network Neighborhood 
Proteins in the direct network neighborhood that interact with circadian clock core 
components might be relevant for regulating clock output functions, but could also include yet 
unknown proteins important for modulating the circadian clock machinery; i.e. I have 
hypothesized that they might be clock components themselves. To test the latter possibility, 
the expression of 88 neighborhood genes was systematically downregulated by RNAi in 
human U2OS cells (as a part of a already performed global RNAi mediated screen for new 
clock genes by Maier et al., unpublished data). These cells have been shown to possess robust 
circadian rhythms in cell culture, which were monitored via a stably integrated Bmal1 
promoter-luciferase reporter construct [22, 35]. Together, we identified 21 components of the 
neighborhood that altered circadian period in oscillating human cells by at least 0.5 hrs 
(Figure 13) (for all identified genes also see Appendix section). For example, downregulating 
the cell-cycle kinase CHEK1 (that interacts with TIMELESS and CK2) significantly 
shortened the circadian period by more than 1 h, while downregulating the DNA helicase 
binding protein CHD4 (that interacts with RORC) lengthened it. In addition, knocking down 
the androgen receptor (AR), which interestingly has many interaction partners (including 
CREBBP, GSK3B, HDAC1, NCOR1/2, NONO and UBE2I), also resulted in a shortening of 
the circadian period by almost one hour. Together, the relatively high number of clock 
modulating components in the network neighborhood indicates the presence of yet 
uncharacterized mechanisms in the molecular circadian oscillator.  
 In addition to being novel clock components, proteins in the network neighborhood 
might also connect specific cellular processes to circadian control by means of directly 
interacting with clock components. Such interactions are likely time-of-day dependent, which 
may be accomplished by rhythmic abundance levels of one or both of the interaction partners. 
Therefore, I have hypothesized that the whole network but also the neighborhood alone are 
significantly enriched in components with rhythmic abundance levels. This is indeed the case 
– at least if we consider (due to the lack of protein abundance data) mRNA expression 
profiles of network components in mouse liver tissue – the circadian transcriptome with 
highest available temporal (1 h) resolution [27]. Of the 134 network components, 65 (49%) 
show a significantly rhythmic mRNA expression profile, a highly significant enrichment 
when compared to a random selection of genes from this expression data set (p < 10-6; Chi-
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squared test). This is not surprising since the network as a whole contains many circadian 
oscillator components, which are known to be rhythmically transcribed. However, if we 
analyze the neighborhood separately, we still find a significant enrichment (p < 10-4; Chi-
squared test) in components that are rhythmically transcribed: of the 88 components in the 
neighborhood, 38 (43%) are rhythmically expressed (Figure 12, yellow circles) suggesting 
that PPIs in the circadian clock network might indeed be a means to mediate rhythmic control 
of cellular physiology. The extraction of rhythmic transcripts from liver data and statistics 
were performed by Dr. Matthias Futschik.  
 
 
Figure 13. Network Neighborhood Contains Clock Modulating Components.  
Systematic RNAi-mediated downregulation of network neighborhood genes in dexamethasone-synchronized 
U2OS cells harboring a Bmal1-promoter luciferase reporter. Shown are altered oscillation dynamics (red curves) 
for 16 genes achieved by individual RNAi constructs. For twelve genes, two RNAi constructs resulted in similar 
phenotypes, for nine genes, only one construct was available in our laboratory library. Black curves are controls 
representing the mean values of at least 80 irrelevant constructs. Period deviations from controls are shown. 
I have conceptionally designed the screen for new clock components in the network neighborhood and prepared 
the figure. Data presented here are part of a genome-wide RNAi mediated screen for clock genes of Maier et al. 
unpublished data.   
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4.5 A Dynamic Circadian PPI Network 
At what time of day do the PPIs in the circadian network occur or – in other words – can we 
elucidate dynamic properties of our (still static) network? Again, hypothesizing that a PPI 
more likely happens at times, when the interaction partners are co-expressed, we again used 
mouse liver transcriptome data [27] as a validated proxy for protein abundance [59] – an 
approach successfully used also for the yeast interactome [60]. To first test this hypothesis for 
PPIs in general (i.e. beyond our circadian network), we compared the Pearson correlation 
coefficient (PCC) of transcript levels (as a measure for co-expression) for all pairs of 
interacting proteins present in the UNIHI interactome database and for which we have time-
resolved expression data [27] with the PCC of randomly chosen pairs. Interestingly, we found 
that interacting proteins are significantly more likely to be expressed at similar circadian times 
(PCC > 0.5 with PCC ranging from -1 to 1; p < 10-15 Chi-squared test; Figure 14 A left). 
These data suggest that circadian co-expression may be a common feature in cellular systems 
to restrict regulatory interactions to specific times of the day. This assumption is supported by 
the fact that proteins with many interaction partners – which are known to exert regulatory 
functions – are more likely to be rhythmically expressed (p < 10-10; Wilcoxon Rank test) and 
vice versa, i.e. proteins with rhythmic transcripts have statistically more interaction partners 
than constitutively expressed proteins (p < 10-5; Chi-squared test). Interestingly, also the 
circadian PPI network displays these properties: interaction between proteins occurs more 
likely when both proteins are co-expressed in time (Figure 14 A right). 
Based on our results above, we assume that many PPIs happen at specific times of the day. 
Therefore, we assigned to each PPI in our network a circadian phase, at which the 
corresponding components are likely to interact based on their transcript expression. To this 
end, we approximated the abundance of the complex of two proteins as the product of their 
expression profiles. Derived time series for the interaction complexes were subsequently 
examined for 24-hrs periodicity with a stringent threshold (FDR < 10-5) resulting in a dynamic 
circadian PPI network with 190 individual protein pairs that likely interact at specific 
circadian phases (Figure 14 B). Interestingly, PPIs seem to be distributed over the whole 
circadian cycle. Beyond the dynamic interactions that occur among circadian core 
components, we identify many time-of-day specific putative regulatory interactions within the 
neighborhood. For example, the lysine acetyltransferase KAT2B binds to the nuclear receptor 
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coactivator NCOA1 – two proteins involved in transcriptional regulation – during the late 
day, which may hint to a time-of-day specific function of these proteins. Nevertheless, we are 
aware that the restriction to transcript (and not protein) profiles and also a potential 
competitive nature of the possible interactions pose limitations to this analysis. However, such 
a framework offers the possibility to globally analyze processes controlled by circadian PPIs 
in a time-specific manner. The analysis concerning network dynamics was conceptionally 
designed by me and the analyses were performed by Dr. Matthias Futschik. 
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Figure 14. Interaction Dynamics within the Circadian Protein-Protein Network. 
(A) Interacting proteins are more likely to be co-expressed in time. Left: Co-expression of all proteins, for which 
literature-derived PPI information is stored in the UNIHI database, was calculated using the Pearson correlation 
coefficient (PCC) based on published circadian liver transcriptome data [27] and were compared with randomly 
selected protein pairs. Among interacting proteins co-expressed proteins (i.e. a PCC > 0.5) are significantly 
overrepresented (Chi squared test: p < 10-15). 13% of interacting proteins have a PCC > 0.5 compared to 4% for 
random pairs. Right: Analogous analysis performed for the circadian PPI network. Interacting proteins that are 
co-expressed (PCC > 0.5) are highly overrepresented (Chi squared test: p < 10-15; 22% compared to 4% with 
PCC > 0.5). 
(B) Left: Heat map representing the dynamics of PPI (lines: 190 interactions) based on their liver RNA 
expression level. Interactions were classified as rhythmic if the product of their expression vectors shows highly 
significant periodic expression (FDR < 10-5). Black and grey bars represent subjective night and day, 
respectively. Right: Representative examples for four interaction pairs and their corresponding predicted 
interaction phase. Red lines represent products of individual transcript profiles of two interacting proteins (black 
and grey lines). Dotted rectangles highlight likely phase of interaction. I have conceptionally designed the 
analyses and prepared the figure. Dr. Matthias Futschik preformed the presented analyses. 
4.6 Role of Dynamic Interactions for the Circadian Oscillator 
Network components interacting with many partners – so-called `hubs´- not only have 
important organizing properties in scale-free networks; they are also (controversially) 
discussed to be more essential for life (at least in yeast, Drosophila and C. elegans; [44]).  
To test, whether in our network dynamic interactions and/or `hub´ proteins are essential for 
the trait `circadian rhythmicity´ – i.e. for generating and maintaining circadian rhythms – I 
have correlated circadian phenotypes obtained upon genetic perturbation experiments with 
topological characteristics of the network components. For perturbing the network 
experimentally and assigning an essentiality score (for circadian rhythmicity) to each 
component, I have (i) systematically knocked down and (ii) overexpressed every component 
of the core and the regulatory part of the network (see Methods for score criteria). These 
experiments were performed in human U2OS reporter cells (as described above) and the 
effect on circadian dynamics was analyzed. While I could reproduce most of the phenotypes 
that have been known from studies with classical knockout models (e.g. the opposite period 
phenotypes upon Cry1 and Cry2 deletion as well as arrhythmicity upon Bmal1 and Clock 
knockout), I have detected interesting novel phenotypes such period shortening for Per3 
knockdown and period lengthening for Rev-ErbB (Nr1d2) downregulation (Figure 15 A and 
B; Figure 16 A and B). 
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Figure 15. Visualization of Altered Circadian Phenotypes for Clock Core and Regulatory Components 
Upon Genetic Perturbation. 
(A) Systematic gene silencing. RNAi constructs were lentivirally delivered into U2OS cells carrying the Bmal1-
promoter luciferase reporter and oscillation dynamics were monitored for several days. Data were detrended 
using the Chronostar analysis software. Black lines show non-silencing controls. Red dotted lines depict 
phenotypes for one RNAi construct. Period differences from mean are given (ar: arrhythmic, amp: low 
amplitude, damp: high damping, mag: magnitude).   
(B) Systematic overexpression. GFP overexpression was used as controls (black curves). Phenotypes were 
visualized as described in (A). 
As examples for phenotypes detected upon clock protein overexpression, Dec1 or Dec2 as 
well as Fbxl15 (the homolog to Drosophila Jetlag) led to a substantial period lengthening 
(~1.5 hrs and ~6 hrs, respectively) (Figure 15 B, Figure 16 B). For each network component, 
the downregulation and overexpression phenotypes were combined in a `phenotypic score´ 
(for rules, see Methods and also Appendix) to be able to correlate it with network properties 
of the individual components. There was no correlation of the phenotypic score with the 
number of interactions as it has been observed in more global networks of yeast, Drosophila 
and C. elegans [44]. In other words, `hub´ proteins apparently are not more important for 
circadian rhythmicity than components with a lower connectivity. However, proteins that are 
involved in dynamic interactions turned out to be more essential for circadian rhythm 
generation (t-test: p < 0.01; Mann-Whitney U test: p < 0.01; Figure 16 C). 
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Figure 16. Dynamic Interactions are Important for Circadian Rhythmicity.  
(A) Systematic RNAi-mediated silencing of circadian clock core and regulatory components. RNAi constructs 
were lentivirally delivered into U2OS cells harboring a Bmal1-promoter luciferase reporter and oscillation 
dynamics were monitored for several days. Circles represent the difference in period (± s.e.m.; n = 3 independent 
experiments) relative to non-silencing controls (n > 10) for two RNAi constructs (if available). Filled circles 
show additional amplitude and/or damping phenotypes. Cells were classified as arrhythmic (ar) if the fit to a 
cosine function resulted in a low correlation coefficient (see Methods). Period deviations of more than 2 hrs are 
given.  
(B) Systematic overexpression of circadian clock core and regulatory components. Experiments were performed 
with lentivirally delivered overexpression constructs as described in (A). Results of three independent 
experiments (± s.e.m.) are given.  
(C) Correlation of circadian phenotype with number of dynamic interactions. The combined phenotypic score 
from silencing and overexpression experiments is significantly different for components with many dynamic 
interactions (≥ 5) compared to those with few (< 5) (t-test: ** p < 0.01; Mann Whitney test: ** p < 0.01). 
For example, CLOCK, BMAL1, PER3 and CRY1 – which undergo 24, 21, 18 and 9 dynamic 
interactions, respectively – are especially important for circadian dynamics (Figure 16 A-C). 
This suggests that the more rhythmic interactions a protein is involved in the more important 
it is for normal circadian rhythmicity. 
4.7 Regulation of Cellular Processes via Dynamic PPIs 
Are dynamic PPIs also important for the regulation of cellular events? To identify such 
processes, we first assigned to each network component one or more specific GO categories. 
Secondly, using the information whether a PPI is dynamic or not (see Figure 14 B) we 
investigated, which cellular processes are significantly connected via dynamic PPIs. In other 
words, we tested whether dynamic interactions were over-represented in the total set of 
interactions between a pair of GO categories. This resulted in a network with twelve dynamic 
links between eleven biological processes with `Circadian rhythm´ as the central `hub´ 
rhythmically connected with processes such as `DNA repair´, `Transcriptional regulation´ and 
`Response to external stimulus´ (Figure 17 A) (see also Appendix section).  
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Figure 17. Dynamic Regulation of Circadian Output. 
(A) Coupling of biological processes (as represented by the corresponding GO terms) via dynamic PPIs within 
the circadian PPI network. Node size represents the number of associated genes in the corresponding GO 
category. Nodes color shows significance of overrepresented GO category from yellow (low significance, FDR < 
0.25) over orange (FDR < 0.01) to red (high significance, p < 0.0001). Edge width corresponds to the number of 
interactions between biological processes. Edge color represents enrichment in dynamic interactions between 
processes (blue: p < 0.001; green: p < 0.1). I prepared the figure. Analysis in (A) was conceptionally designed by 
me and performed by Dr. Matthias Futschik.  
(B) KEGG pathway analysis of proteins within network neighborhood. Colors show significance of enrichment 
from yellow (low significance, p < 0.02) over orange (p < 0.0005) to red (high significance, p < 0.0002). Font 
size represents the number of components in each category.  
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(C) Identification of highly connected clusters within the circadian PPI network (for details see Methods). 
Depicted are four representative functional modules that show significant enrichment in the following GO 
categrory from left to right: `Histone methyltransferase complex´, `Transcription coactivator activity´, `Response 
to DNA damage stimulus´ as well as `Histone acetyltranferase activity´. Grey nodes: network neighborhood 
components; red nodes: core clock component. Yellow borders indicated a circadian transcript profile in murine 
liver with peak expression time (circadian time) given as numbers in the nodes. Border width represents the 
significance for rhythmic expression.  
(D) Left: Identification of dynamic PPIs within the proteome. Identified interactions are visualized as a heat 
map. Middle: Coupling of biological processes via dynamic interactions within the proteome. 20 processes are 
linked with 89 connections. Node color: significance of enrichment in components with dynamic interactions 
(yellow: p < 0.25; orange: p < 0.0001; red: p < 10-8); node size: number of genes per category; edge color: 
enrichment in dynamic interactions between processes (blue: p < 10-16; green: p < 10-5); edge width: number of 
dynamic interactions. Right: A dynamic global PPI network consisting of 1,979 proteins with 2,788 dynamic 
interactions. Interactions/edges were colored based on their peak times: dark red (CT 18-24), light green (CT 0-
6), dark green (CT 6-12) and light red (CT 12-18). Proteins/nodes were colored with the respect to the five most 
significant biological processes and are associated with: `Cell cycle´ (green), `Cell death´ (red), `Protein 
modification´ (yellow), `Signal transduction´ (blue) and `Transcription´ (orange). The four proteins with most 
dynamic interactions (> 40) are highlighted. Analysis in (D) was conceptionally designed by me and performed 
by Dr. Matthias Futschik and Dr. Ravi Kalathur.  
A strong association of the circadian clock network with these processes relevant for e.g. 
cancer and cell-cycle is supported by (i) KEGG pathway analysis of the network 
neighborhood only (Figure 17 B) and (ii) the significant (p < 10-8; Chi-squared test) 
enrichment of the network neighborhood with cancer-associated genes (as reported in the 
Cancer Gene Census; for identity of cancer associated genes see Methods section). 
 Are these rhythmically regulated processes mediated by individual components or rather 
by functional modules within the network consisting of interconnected components? To 
answer this question, I have explored the circadian PPI network topology for clusters of 
highly connected proteins (structural modules) and identified eleven different modules within 
the circadian network (Figure 17 C, Figure 18 A).  
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Figure 18. Identification of Functional Modules within the Circadian PPI Network and Dynamic 
Regulation within the Global Interactome. 
(A) Highly connected clusters were identified using the Cytoscape plugins MCODE or the ClusterOne algorithm 
(for details on analysis see Methods). Node colors: grey – network neighborhood, red – clock core, green – 
regulatory components. Yellow circles highlight rhythmic RNA profiles. Numbers are mRNA peak times in 
circadian time (CT). Modules were analyzed for enrichment of processes using GO, KEGG and Pfam family 
annotations.    
(B) Construction of a global dynamic protein-protein interactome. 
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(C) Coupling of biological processes within the interactome via rhythmic PPIs. Significance of connections was 
calculated based on the comparison with randomized versions of the dynamic interactome. Connections, for 
which no more than ten out of 1,000 random networks show a larger number of rhythmic interactions are 
displayed. In total, 26 processes are linked via 52 connections. Node color: significance of enrichment in 
components with dynamic interactions (yellow: p < 0.25; orange: p < 10-4; red: p < 10-8); node size: number of 
genes per category; edge color: number of random networks with larger number of rhythmic interactions 
between processes (blue: n = 0; green: n ≤ 10); edge width: number of rhythmic interactions. Processes, for 
which n ≤ 10 random networks have more internal dynamic interactions than observed in the global interaction 
network, were highlighted with a dark red border. I have prepared the figure. Analysis in (C) was performed by 
Dr. Matthias Futschik. 
Modules were enriched with components e.g. relevant for the regulation of chromatin states 
(GO terms: `Histone methyltransferase complex´ and `Histone acetyltransferase activity´), 
DNA repair (GO term: `Nucleotide excision repair´) and transcriptional regulation (GO term: 
`Transcription coactivator activity´). Notably, the GO and KEGG terms derived from the 
analysis of the whole circadian network matched with the terms achieved for the structural 
modules. In addition, transcript levels of five of seven components of the `Histone 
methyltransferase´ module (consisting of ASH2L, HCFC1/2, MEN1, MLL, RBBP5 and 
WDR5; Figure 17 C left) are rhythmic and peak at similar circadian times. Co-expression in 
time was also observed within other highly connected clusters such as the `Histone 
acetyltransferase´ module (Figure 17 C right). Together, this suggests that modular 
organization within the circadian PPI network is contributing to a coherent functional 
regulation of cellular processes by the circadian clock. 
 Is a time-of-day dependent interaction of cellular processes via PPIs a general feature? 
To test this, we first identified 2,788 rhythmic PPIs (as described above – Figure 14 B) for the 
whole human proteome (Figure 17 D left) and then searched for biological processes that are 
significantly connected via dynamic PPIs (Figure 18 B). We constructed a network of 20 
biological processes with 89 dynamic links. The central `hub´ of this `process network´ 
constitutes the term `Signal transduction´ (Figure 17 D middle) suggesting a time-of-day 
dependent modulation of a huge variety of cellular events such as `Protein transport´, 
`Response to stress´ and `Cell death´ by signaling pathways via rhythmic PPIs. This is also 
the case if we use randomized versions of our interactome as a background model (Figure 18 
D). Interestingly, in this case we also observe an overrepresentation of dynamic PPIs within 
the individual processes (Figure 18 D).  
 To characterize the underlying PPI network properties, we constructed a dynamic PPI 
network for the whole proteome. We found that it again has `scale-free´ properties and 
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identified 269 dynamic `hubs´, i.e. proteins with at least five dynamic interactions. The 
protein with the most rhythmic interactions (79 of 105 in total) is heat-shock protein 
HSP90AA1 – a factor required for proper protein folding upon heat stress. Notably, three of 
the four interaction-richest proteins (with more than 40 interactions) are cell-surface receptors 
(ESR1, PDGFRB and TGFBR1) again highlighting the central role of signaling pathways for 
dynamic regulation (Figure 17 D right). The construction of the process networks and 
dynamic interactome was conceptionally designed by me and the analysis was performed by 
Dr. Matthias Futschik and Dr. Ravi Kalathur.  
4.8 Protein Phosphatase 1 Modulates CLOCK/BMAL1-Dependent Transactivation 
The Systems Biology analysis of the circadian interactome points to a timely regulated action 
of chromatin modifying enzymes (see Figure 17 A-C). It is known that at the heart of the 
circadian oscillator binding of the transcription factor heterodimer CLOCK/BMAL1 is 
controlled by methylation and acetylation states of histones at specific promoter regions [29, 
61-64]. In addition, CLOCK/BMAL1 transactivation activity is modulated by a precisely 
timed acting repressor complex. In the Y2H screen, 15 new interaction partners for 
CLOCK/BMAL1 were discoverd, which might play a role in modulating their function in 
cells. Therefore, I have systematically tested whether these interactors (and their paralogs – in 
total 28 components) are able to modulate CLOCK/BMAL1 transactivation measured from an 
E-box containing artificial promoter with firefly luciferase as reporter.  
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Figure 19. Systematic Screen for New Modulators of CLOCK/BMAL1 Transactivation. 
All CLOCK and BMAL1 interactors identified in the Y2H experiments and their paralogs were co-transfected 
with CLOCK/BMAL1 together with an artificial 6 E-box-luciferase containing reporter. Normalization was 
performed to Renilla-luciferase signal. Shown is one representative result (n = 3; ± s.d.) of three independent 
experiments. Among new CLOCK/BMAL1 interactors RORs and PPP1CA showed consistent suppression of 
CLOCK/BMAL1 transactivation. 
As expected, already characterized CLOCK/BMAL1 repressors such as CRYs, PER2 and 
DECs (Figure 19) [19, 55, 65] substantially inhibited transactivation. Interestingly, among the 
15 new interactors (including their paralogs) PPP1CA (protein phosphatase 1 alpha, catalytic 
subunit), but not PPP1CB severely and RORs moderately reduced the reporter signal (Figure 
20 A). The effect of PPP1CA on CLOCK/BMAL1-mediated transactivation was dose 
dependent (Figure 20 B). 
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Figure 20. Protein Phosphatase 1 Modulates CLOCK/BMAL1 Function.  
(A) New modulators of CLOCK/BMAL1 function. All CLOCK and BMAL1 interactors identified in the Y2H 
screen and their paralogs were co-transfected with CLOCK/BMAL1 and an E-box containing luciferase reporter 
construct. Visualized is an experiment with those components interacting with CLOCK/BMAL1 that displayed a 
similar effect in three previously performed co-transactivation assays. Shown are means ± s.d. (n = 3; *** p < 
0.001, t-test).  
(B) PPP1CA dose-dependently reduces CLOCK/BMAL1 mediated co-transactivation of the luciferase reporter. 
Assay was performed as in (A) (n = 3; means ± s.d.).  
(C) PPP1CA is present in the CLOCK/BMAL1 complex in mouse liver. Livers were harvested at indicated 
circadian time points (CT) and co-immunprecipitations and Western blots were performed with indicated 
antibodies. LC (antibody light chain) and HC (antibody heavy chain) of used antibodies. Dashed lines indicate 
higher exposure times. Shown is one representative of two independently performed experiments.   
(D) PPP1CA destabilizes BMAL1. Left: HEK293 cells stably expressing CLOCK luciferase fusions were 
transduced with virus containing GFP or PPP1CA. After 24 hrs, luciferase activity was measured (n = 6; means 
± s.d.; *** p < 0.001, t-test). Right: HEK293 cells stably expressing BMAL1 luciferase fusions were transduced 
with virus containing GFP or PPP1CA. After 24 hrs, luciferase activity was measured (n = 6; means ± s.d.). 
(E) Endogenous BMAL1 levels are reduced upon stable PPP1CA overexpression in U2OS cells. β-Actin signals 
were used for quantification. Depicted are two independent experiments.  
(F) PPP1CA leads to reduced BMAL1 stability. U2OS cells stably overexpressing PPP1CA or GFP were 
harvested at the indicated time points after CHX application and protein levels were analyzed by Western blot 
analysis. Shown is one representative of two independently performed experiments.  
Endogenous PPP1CA binds to the CLOCK/BMAL1 complex in mouse liver, which was 
tested by co-IP experiments (Figure 20 C). As predicted by the dynamic interaction analysis 
based on transcript data (see Figure 14 B) I have detected an association of endogenous 
PPP1CA with CLOCK/BMAL1 at CT0 while only little PPP1CA-CLOCK/BMAL1 complex 
was present at CT12 suggesting a circadian time-dependent modulation on CLOCK/BMAL1 
function. As CLOCK and BMAL1 phosphorylation have been described to affect their 
stability [66, 67], I have tested whether PPP1CA acts on this level. HEK293 cells stably 
expressing CLOCK or BMAL1-luciferase fusions were transduced with PPP1CA or GFP as a 
control and luciferase activity was measured as readout for protein abundance. Whereas no 
drastic difference of CLOCK-luciferase signal in the presence of PPP1CA was observed 
(Figure 20 D, left), a significant signal reduction was detected for the BMLA1-luciferase 
(Figure 20 D, right). In addition, endogenous BMAL1 levels were reduced by about 50% 
upon stably overexpression of PPP1CA in U2OS cells (Figure 20 E). Lower BMAL1 
abundance in the presence of PPP1CA is likely due to reduced BMAL1 stability since CHX 
treated cells (in which de novo protein synthesis is blocked) revealed a much faster 
degradation of endogenous BMAL1 when PPP1CA is overexpressed (Figure 20 F). Circadian 
dynamics monitored with the Bmal1-luciferase reporter are unaffected in human U2OS cells 
(Figure 21 A) overexpressing PPP1CA (see Figure 21 B for overexpression efficiency). This 
is in line with the finding that the expression of a selection of clock output genes (Per1, Dbp 
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and Nr1d1) in U2OS is unaltered when PPP1CA is overexpressed 24 hrs after dexametasone 
treatment – where clock output gene levels are expected to be high (Figure 21 C left) – or 36 
hrs after dexamethasone synchronization – where low levels in clock output gene expression 
are expected (Figure 21 C right) [68]. Differences in clock output gene expression between 
the two selected time points serve as proof-of-concept for the differences of mRNA levels of 
the indicated genes at the chosen time points (Figure 21 D).  
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Figure 21. Protein Phospatase 1 Overexpression Does Not Affect Circadian Dynamics and Clock Output 
Gene Expression. 
(A) U20S cells carrying the Bmal1-promoter luciferase reporter stably expressing GFP (green) or PPP1CA (red) 
in 35 mm dishes. Bioluminescence recordings were performed for several days.  
(B) PPP1CA mRNA overexpression (OE) efficiency for cells used in (A) detected via q-PCR. Normalization 
was performed to GFP overexpressing cells. 
(C) Left: Clock output gene RNA levels in U2OS cells overexpressing PPP1CA 24 hrs after dexametasone 
synchronization. Right: Clock output gene RNA levels in U2OS cells overexpressing PPP1CA 36 hrs after 
dexamethasone synchronization. Normalization was performed to the corresponding GFP controls.  
(D) Clock output gene level at the indicated time point in GFP overexpressing cells (24 or 36 hrs after 
dexamethasone treatment). Normalization was performed to GFP signals at the 36 hrs-time points.  
(B-D) Shown are means ± s.d (n = 3).  
It is described that in the case of protein phosphatses  (as PP1) substrate specifity is mediated 
by regulatory phosphatase subunits that form complexes with their corresponding catalytic 
subunits [69]. Gene silencing data of Zhang et al. [35] show an altered circadian phenotype 
(severe period lengthening effect) in U2OS cells when the PPP1R15B (protein phosphatase 1, 
regulatory subunit 15B) subunit is knocked-down (Figure 22 A) indicating an involvement of 
this subunit in the maintenance of circadian periodicity. Endogenous PPP1R15B is not 
rhythmically expressed in mouse liver neither at the transcript level (see [27]) nor at the 
protein level (Figure 22 B) but present at the CLOCK/BMAL1 complex at CT0.  
Together, these data indicate that BMAL1 stability and probably thereby transactivation is 
regulated by the PPP1R15B/PPP1CA complex in a time-of-day dependent manner.  
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Figure 22. PPP1R15B Silencing Alters Circadian Dynamics and PPP1R15B is Present at the 
CLOCK/BMAL1 Complex. 
(A) siRNA mediated gene silencing in U20S cells carrying the Bmal1-promoter luciferase reporter leads to 
severe period lengthening phenotypes (see red curves for effects of four individual siRNAs). Green curves: Cry2 
knockdown as positive control, blue curves: GL2 siRNA (designed against the Luc in the pGL2 vecotor) was 
used as a negative control. Period values for red curves are given from Circadian BIOGPS database [35]. 
(B) Endogenous PPP1R15B in mouse liver at the CT12 or CT0. Pull-downs and Western blot analysis were 
performed with the indicated antibodies (n = 2). 
(C) PPP1R15B is present at CT20 at the CLOCK/BMAL1 complex. Pull-downs and Western blot analysis was 
performed with the indicated antibodies (n = 1). HC: heavy chain of used antibody, LC: light chain of used 
antibody.  
(D) Determination of pull-down efficiency for co-IP experiments performed in (C). Western blot analysis was 
performed with the indicated antibody (n = 1). 
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5 DISCUSSION 
5.1 Novel PPIs within the Molecular Oscillator 
PPIs among circadian clock proteins are often time-of-day dependent, which is crucial for the 
function of the molecular circadian oscillator. While the recent years have witnessed the 
identification of an increasing number of clock proteins or modulators [22, 35, 61, 70, 71] a 
comprehensive analysis of PPIs within the circadian clockwork – in particular with respect to 
the timing of the PPIs – is still missing. Here, I have identified 109 so far uncharacterized 
interactions within the circadian clockwork in yeast and successfully validated a sub-fraction 
in mammalian cells. While the matrix screen design allowed me to perform independent 
replica experiments thereby reducing the risk of false positives, it is clear that due to the 
obvious limitations of the Y2H system [43] this network is likely still far away from 
saturation. For example, interactions that depend on posttranslational modifications or on 
more than two proteins are difficult to detect in Y2H assays. Nevertheless, Y2H approaches 
led to the discovery of crucial clock components such as BMAL1 [19] and large scale 
interaction networks have proven to be invaluable for a systems-wide understanding of 
physiology and disease [40, 48]. 
Interestingly, many of the new interactions occurred between core clock components and 
regulatory components such as kinases e.g., CSNK2Β, phosphatases (e.g., PP2, PP1), and F-
box proteins (e.g. FBXW11). Hence, these data should be a valuable resource for studying 
molecular events within the circadian system with so far uncharacterized posttranslational 
mechanisms being especially interesting. Whereas phosphorylation of clock proteins is 
increasingly recognized as crucial for circadian dynamics, de-phosphorylation events have not 
been studied as extensively [23]. Therefore, I have characterized the newly discovered 
interaction between PPP1CΑ and the CLOCK/BMAL1 heterodimer. The data suggest that a 
time-of-day specific action of PPP1CΑ negatively regulates BMAL1 abundance (see Figure 
20), whereas others propose PER proteins as substrates of PP1 (Figure 23) [72, 73].  
Furthermore, PPP1R15B was identified as a potential candidate that mediates BMAL1 
substrate specifity for PP1 action. However, these findings suggest the existence of timely 
regulated stabilizing phosphosites, which are involved in the regulation of BMAL1 abundance 
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as proposed for other circadian proteins such as PER2 [22, 74]. Additional work using state of 
the art mass spectrometry approaches should be performed to identify the site/s of PP1 action 
on BMAL1 protein and the corresponding kinase/s acting at this site/s that regulate BMAL1 
turnover.  
In genetic perturbation studies, knockdown or overexpression of PPP1CA did not result in 
altered circadian dynamics in U2OS Bmal1-promoter luciferase reporter cells (see Figure 16 
A and B; Figure 21 A) and clock output gene expression was unaffected (Figure 21 C).  
In the case of gene silencing, one possible explanation for that observation could be paralog 
compensation effects by PPP1CB and/or PPP1CC (two additional PP1 catalytic subunits also 
expressed in these cells [73]). In line with my PPP1CA knockdown data, Schmutz et al. did 
not observe an altered circadian phenotype when PPP1CA was silenced via RNAi using the 
same reporter cell line [73]. Further investigations (e.g. single, double and triple knockdowns 
of PP1 catalytic subunits and the determination of the corresponding gene products via q-PCR 
experiments) are needed to support this interpretation.  
In PPP1CA overexpression experiments, endogenous BMAL1 protein is reduced to about 
50% (see Figure 20 E). Maier et al. [22] observe only a drastic altered circadian phenotype 
(arrhythmicity) when Bmal1 mRMA is reduced in RNAi experiments by more than 50%. The 
remaining BMAL1 protein in my experiments could be still sufficient to drive normal 
circadian dynamics and output. In the overexpression experiments PPP1CA levels are about 
six-fold increased (Figure 21 B and C) which represents a relative low overexpression in 
comparison to overexpression rates usually achieved in transient transfection experiments. 
Dose dependent PPP1CA/PPP1R15B overexpression experiments combined with dynamic 
oscillation recordings should be addressed in this context.  
However, a recent study suggests that Bmal1 is not essential for the mammalian oscillator and 
that the circadian phenotype can be rescued by constitutive expression of its paralog Bmal2 (= 
Arntl2) in a Bmal1 knockout background [75]. The authors propose that Baml1 and Bmal2 are 
forming a circadian paralog pair that is functionally redundant and that Bmal1 is a 
transcriptional regulator of Bmal2. In this scenario, a Bmal1 knockout alone would result in a 
Bmal1 and Bmal2 double depletion that is probably responsible for the arrhythmic phenotype 
of Bmal1 single knockout mice [76]. This could also be the case in the U2OS reporter cells 
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when Bmal1 is silenced via RNAi. In my overexpression experiments a ~50% reduction in 
BMAL1 protein would imply that BMAL2 is also expressed to a certain extend and that the 
remaining BMAL1 and BMAL2 protein in concert could still drive normal circadian 
dynamics and cellular output processes. Further experiments are needed to clarify the role of 
PP1 action on BMAL1 and additively BMAL2 transcript and protein. 
Clock output genes levels are not altered in U2OS cells when PPP1CA is overexpressed 
(Figure 21 C). But why does PPP1CA reduce severly the CLOCK/BMAL1 mediated reporter 
induction in the co-transactivation experiments (Figure 19 and Figure 20 A and B)?  
One explanation might imply a higher overexpression efficiency reached by transient 
transfection in this artificial system (co-transactivation assay) and therefore a stronger 
destabilizing effect on BMAL1 protein. In addition, a change in the phosphorlyation state and 
stability of BMAL1 via PP1 could have additional effects on the CLOCK/BMAL1 
heretodimer formation and function (e.g. DNA-binding and/or transactivation) or influence 
CLOCK stability. Such effects would also synergistically lead to a drastic reduction of 
CLOCK/BMAL1 transactivation. Precedence for such scenarios were described by Kondratov 
et al. where the formation of the CLOCK/BMAL1 heterodimer is leading to phosphorylation 
of both interactors as well as to CLOCK nuclear translocation and degradation [66]. 
Furthermore, Spengler et al. described that BMAL1 is involved in phosphorlylation-mediated 
degradation of CLOCK protein through a phosphor-degron site within the CLOCK protein 
[77].  
It is also known that clock proteins have different phosphorylation states depending on the 
progress of the circadian cycle (see [20, 72]). E.g. recent data suggests that CLOCK is kept 
most of the time in a phosphorylated state whereas hyperphosporlyted CLOCK contributes to 
the suppression of CLOCK/BMAL1 mediated tranactivation [67]. Since different BMAL1 
phosporylation states exist (see [20]) PP1 could possibly mediate its effect in U2OS cells on 
one BMAL1 protein fraction/state that could not be primarily involved in the regulation of 
transcription. Determinations of BMAL1 stability in nuclear and cytosolic fractions cloud 
reveal additional information of PP1 function.   
In a simplified model, PP1 (complex of PPP1R15B and PPP1CA) dephosphorylates and 
therefore destabilizes BMAL1 at the end of a circadian cycle (late night) contributing to its 
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proteasomal degradation and therefore reduction of transactivation. In addition, it is described 
that phosphorylation of BMAL1 by GSK3B that was shown to destabilize BMAL1 protein is 
involved in the regulation of BMAL1 decay [78]. Further studies should be performed to 
uncover the mechanisms between the counterbalancing effects of PP1 and kinases for 
BMAL1 turnover and circadian functionality.   
 
 
Figure 23. Speculative Model for the Negative-Feedback Mechanism with Kinase and Phosphatase Action.  
The Y2H screen led to the identification of circadian components newly present at the negative-feedback or 
positive-regulator complex (e.g. RORs, CSNK2 and PP1). In this model, PP1 action at the end of the night (as 
indicated by interaction experiments around CT0 (CT: circadian time)) dephosphorylates BMAL1 at potential 
stabilizing phosphosites leading to a less stable BMAL1 protein and therefore reduced transactivation. 
Furthermore, additional phosphorylation events as mediated by e.g. GSK3B are involved in the regulation of 
BMAL1 decay. Kinases: CSNK1E/D, CSNK2, PKCA, GSK3B, AMPK; phosphatases: PPP1; E-box: enhancer 
element in Per and Cry promoter.   
5.2 Network Neighborhood Contains Genes that are Required for Normal Circadian 
Dynamics 
Our systematically generated network extension/neighborhood contains 88 proteins that are 
linked to circadian clock core via physical interactions indicating a potential relevance for 
these components to be also involved in the regulation of circadian dynamics. Indeed after our 
systematic RNAi mediated perturbation study we could identify 21 genes that displayed an 
altered circadian phenotype of which several are described to be involved in transcriptional 
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and epigenetic regulation as well as nucleotide repair events. In agreement with this finding, 
three genes of our extension (DDB1, EPAS1 and HCFC1) have been previously shown to 
alter circadian dynamics when silenced by siRNA in U2OS cells [35]. Additionally, our 
neighborhood harbors six genes/or paralogs (CHD4, HDAC1, HSFPAA90, MLL, NCOR1 
and PML), for which a role for the molecular clock as well as circadian physiology was 
proposed in different model organisms [61, 64, 79-82]. These findings together with our 
altered phenotypes support my hypothesis that the network neighborhood contains a relative 
high fraction of proteins mediating additional mechanisms that are involved in keeping the 
circadian pace. Interestingly, genes of our neighborhood that have been sensitive to RNAi 
mediated genetic perturbation are also present in the identified functional highly connected 
clusters (see Figure 17 and Figure 18) indicating a relevance for module function in keeping 
the circadian pace. It is apparent that the situation in the U2OS reporter cell line does not 
necessarily represent the conditions in a living organism and the relevance of the identified 
components for peripheral oscillators and SCN (and other tissues) still remains to be 
addressed. Interestingly, our neighborhood is highly significantly enriched in genes that are 
associated with Huntington’s disease (see Figure 17 B) and one structural module is 
significantly enriched with htt related gens (see Methods for significance of enrichment). This 
is in line with observed altered circadian sleep-wake cycles in this disease [83]. Based on our 
liver specific trancriptome analysis, I can only speculate about the corresponding interaction 
dynamics within e.g. the CNS. However, network topology (not including dynamic 
information) can serve as a resource for interaction events e.g. within brain areas. In 
combination with other or newly generated expression profiles (from different tissues than 
liver) at RNA and protein level (or with the integration of information of different disease 
progression states) the constructed network could again be used to study network dynamics.    
5.3 Circadian Protein-Protein Networks 
The circadian PPI network is very densely connected. How can such a network function? We 
analyzed both temporal organization, which separate PPIs in time as well as modular 
organization, which organize the network in functional complexes. To investigate temporal 
organization, we have integrated circadian expression profiles from mouse liver for the 
interacting pairs of proteins assuming that co-expression on transcript level can represent 
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individual protein abundance probably as one limiting factor for physical interaction. Such an 
approach has been used when large-scale protein abundance data are lacking [47]. Our 
transcript-based analysis led to the construction of a dynamic circadian (albeit only liver-
specific) PPI network, in which PPIs are formed at all circadian phases (see Figure 14 B). 
Obviously, our analysis harbors several limitations, since PPIs in vivo depend on a variety of 
factors such as spatial restrains, restriction to specific tissues, relative protein abundance, 
mRNA processing, stoichiometry and interaction kinetics, complex formation and 
posttranslational modifications. All these parameters are not represented by the corresponding 
mRNA profiles of interaction partners. However, our assumption that indeed dynamic binding 
events can be approximated by such an approach is supported by (i) our finding that co-
expression of transcripts at similar circadian phases more often occurs among interacting 
proteins (see Figure 14 A) and (ii) known interaction dynamics between components of the 
circadian system can be reproduced (see Figure 14 B), e.g. the circadian phase-specific 
CLOCK/CRY1 interaction [20].  
Beyond the dynamic interactions that occur among circadian core components, we have 
identified many time-of-day specific PPIs between core and neighborhood proteins. For 
example, the circadian core component BMAL1 binds to EPAS1 (endothelial PAS domain 
protein 1) and HIF1A (hypoxia inducible factor 1, alpha subunit), two proteins involved in 
hemopoiesis during the late night (see Appendix and Figure 17 A). Interestingly, Bozek et al. 
[30] proposed a circadian regulation of the Erythropoietin (Epo) gene with HIF1A (and not 
the CLOCK/BMAL1 hererodimer) being its transcritonal activator. The construction of the 
dynamic circadian protein-protein network suggests that BMAL1 could recruit HIF1A to 
DNA to drive Epo transcription in a dynamic range. Hemopoetic Epo expression is restricted 
to the adult kidney [84]. Therefore, systematic circadian chromatin binding studies using 
CLOCK/BMAL1 and HIF1A antibodies for pull-downs in chromatin immunoprecipitation 
assays as performed by Rey et al. [29] in mouse liver would represent experiments to support 
this hypothesis. However, further validations of our predicted interaction dynamics e.g. via 
rhythmic co-IPs or FRET (fluorescence resonance energy transfer) experiments are needed.    
5.4 Dynamic Hubs 
Dynamic `hubs´ (proteins involved in many rhythmic PPIs) are especially important for 
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circadian rhythms (see Figure 16 C) as revealed by my genetic perturbation analyses. Thus, it 
seems that not the absolute number of interactions is crucial for the importance of a clock 
protein but the degree of dynamic PPIs. This is not too surprising, since precisely timed 
interactions between activators and their repressors is the fundamental principle of the 
circadian negative feedback mechanism. Interestingly, this principle may be translated to the 
global proteome: we find that proteins with a rhythmic transcript have significantly more 
interaction partners than non-rhythmic proteins (p < 10-10, Wilcoxon Rank test). In addition, 
proteins that qualify as regulatory components (as defined by their GO category `Regulation 
of biological process´) have significantly more interaction partners than non-regulatory 
proteins (p < 10-15, Wilcoxon Rank test). Together, this indicates that rhythmic control of PPIs 
is an essential feature of biological networks. 
5.5 Regulation of Cellular Physiology by Dynamic Protein-Protein Interactions 
In the last decade, transcriptome analyses were successfully used to study circadian dynamics 
on a systems-wide level [27, 28] with mRNA rhythms serving as indicators for output control. 
Corresponding comprehensive studies on the level of the proteome are still largely missing. 
To get novel insights into the time-of-day dependent regulation of cellular processes, we have 
constructed a circadian interactome (see Figure 17 D) allowing us to study circadian 
regulation at the level of protein complexes rather than looking at mRNA profiles of 
individual components. Based on this dynamic interactome, we have constructed a process 
network demonstrating that many important processes are strongly connected by dynamic 
PPIs (see Figure 17 D and Figure 18 C). Interestingly, `Signal transduction´ is the central hub 
in this process network and cellular surface receptors are the proteins with the most dynamic 
interactions. This implies that circadian regulation is especially important for cells responding 
to external stimuli. Reported examples include the daytime dependent response to UV-
induced DNA damage [85] – for which I have also identified a clock-controlled module in our 
network (Figure 17 C) – or endotoxin-triggered secretion of proinflammatory cytokines [13]. 
Timing of biological functions via PPIs that occur at specific circadian phases seems 
to be accomplished by co-expression of module components (see Figure 17 C), but also in 
more general terms: interacting proteins are expressed significantly more likely at similar 
times (Figure 14 A) probably to restrict regulatory interactions to specific circadian phases.  
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Overall, data accumulated during my PhD work provide a global view and valualbe 
resource on the circadian control of PPIs important not only for the circadian oscillator but 
also for the temporal orchestration of many essential cellular processes. 
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APPENDIX 
Table 1. 46 Components for Interaction Mapping. 
Gene ID h Gene ID m Symbol h Symbol m References 
5187 18626 PER1 Per1 [1] 
8864 18627 PER2 Per2 [1] 
8863 18628 PER3 Per3 [1] 
1407 12952 CRY1 Cry1 [1] 
1408 12953 CRY2 Cry2 [1] 
4841 53610 NONO Nono [62] 
11091 140858 WDR5 Wdr5 [62] 
8914 21853 TIMELESS Timeless [1, 54] 
85457 217732 CIPC Cipc [55] 
8553 20893 DEC1 Dec1 [65] 
79365 79362 DEC2 Dec2 [65] 
9575 12753 CLOCK Clock [1] 
4862 18143 NPAS2 Npas2 [1] 
406 11865 BMAL1 Bmal1 [1, 19] 
56938 272322 BMAL2 Bmal2 [1, 19] 
9572 217166 NR1D1 Nr1d1 [1, 86] 
9975 353187 NR1D2 Nr1d2 [1] 
6095 19883 RORA Rora [1] 
6096 225998 RORB Rorb [1] 
6097 19885 RORC Rorc [1] 
1628 13170 DBP Dbp [87] 
4783 18030 NFIL3 Nfil3 [88] 
2146 14056 EZH2 Ezh2 [89] 
51655 19416 RASD1 Rasd1 [90] 
1453 104318 CSNK1D Csnk1d [1] 
1454 27373 CSNK1E Csnk1e [1] 
2932 56637 GSK3B Gsk3b [1] 
1457 12995 CSNK2A1 Csnk2a1 [1, 22] 
1459 13000 CSNK2A2 Csnk2a2 [22] 
1460 13001 CSNK2B Csnk2b [22] 
5566 18747 PRKACA Prkaca [51] 
5578 18750 PRKCA Prkca [50] 
5499 19045 PPP1CA Ppp1ca [1] 
5500 19046 PPP1CB Ppp1cb [1] 
5501 19047 PPP1CC Ppp1cc [1] 
5515 19052 PPP2CA Ppp2ca [1] 
5516 19053 PPP2CB Ppp2cb [1] 
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5518 51792 PPP2R1A Ppp2r1a [1] 
5519 73699 PPP2R1B Ppp2r1b [1] 
5528 21770 PPP2R5D Ppp2r5d [1] 
5529 26932 PPP2R5E Ppp2r5e [1] 
5536 19060 PPP5C Ppp5c [91] 
8945 12234 BTRC Btrc [92] 
23291 103583 FBXW11 Fbxw11 [92] 
26224 50789 FBXL3 Fbxl3 [21, 52] 
79176 68431 FBXL15 Fbxl15 [53] 
Table 2. Detected Interactions in Y2H Screen and Interaction Score. 
No. Gene A h Gene B Gene ID A h Gene ID B h Score 
1 BMAL1 CLOCK 406 9575 4 
2 BMAL1 CRY1 406 1407 4 
3 BMAL1 CRY2 406 1408 4 
4 BMAL1 CSNK2B 406 1460 4 
5 BMAL1 DEC1 406 8553 4 
6 BMAL1 NPAS2 406 4862 4 
7 CIPC CLOCK 85457 9575 4 
8 CIPC CSNK2B 85457 1460 4 
9 CIPC DEC1 85457 8553 4 
10 CIPC RORC 85457 6097 4 
11 CLOCK CRY1 9575 1407 4 
12 CLOCK CRY2 9575 1408 4 
13 CLOCK DEC1 9575 8553 4 
14 CLOCK DEC2 9575 79365 4 
15 CLOCK NPAS2 9575 4862 4 
16 CLOCK PPP2R5D 9575 5528 4 
17 CLOCK PPP2R5E 9575 5529 4 
18 CRY1 CSNK2B 1407 1460 4 
19 CRY1 DEC1 1407 8553 4 
20 CRY1 DEC2 1407 79365 4 
21 CRY1 NPAS2 1407 4862 4 
22 CRY1 PER2 1407 8864 4 
23 CRY1 PPP2R5E 1407 5529 4 
24 CRY2 DEC1 1408 8553 4 
25 CRY2 DEC2 1408 79365 4 
26 CRY2 PER1 1408 5187 4 
27 CRY2 PER2 1408 8864 4 
28 CSNK1E DEC1 1454 8553 4 
29 CSNK1E DEC2 1454 79365 4 
30 CSNK1E PER1 1454 5187 4 
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31 CSNK1E PER2 1454 8864 4 
32 CSNK1E PPP1CC 1454 5501 4 
33 CSNK1E PPP2R5E 1454 5529 4 
34 CSNK1E RORC 1454 6097 4 
35 CSNK2A1 CSNK2B 1457 1460 4 
36 CSNK2A1 DEC1 1457 8553 4 
37 CSNK2A1 DEC2 1457 79365 4 
38 CSNK2A2 CSNK2B 1459 1460 4 
39 CSNK2A2 DEC1 1459 8553 4 
40 CSNK2A2 DEC2 1459 79365 4 
41 CSNK2A2 NR1D2 1459 9975 4 
42 CSNK2B DEC1 1460 8553 4 
43 CSNK2B DEC2 1460 79365 4 
44 CSNK2B EZH2 1460 2146 4 
45 CSNK2B FBXL15 1460 79176 4 
46 CSNK2B NPAS2 1460 4862 4 
47 CSNK2B PER1 1460 5187 4 
48 CSNK2B PER2 1460 8864 4 
49 CSNK2B PPP1CA 1460 5499 4 
50 CSNK2B PPP1CB 1460 5500 4 
51 CSNK2B PPP1CC 1460 5501 4 
52 CSNK2B PPP2R1A 1460 5518 4 
53 CSNK2B PPP2R1B 1460 5519 4 
54 CSNK2B PPP2R5D 1460 5528 4 
55 CSNK2B PPP2R5E 1460 5529 4 
56 DEC1 DEC1 8553 8553 4 
57 DEC1 DEC2 8553 79365 4 
58 DEC1 EZH2 8553 2146 4 
59 DEC1 FBXL15 8553 79176 4 
60 DEC1 GSK3B 8553 2932 4 
61 DEC1 NPAS2 8553 4862 4 
62 DEC1 PER1 8553 5187 4 
63 DEC1 PER2 8553 8864 4 
64 DEC1 PPP1CA 8553 5499 4 
65 DEC1 PPP1CB 8553 5500 4 
66 DEC1 PPP1CC 8553 5501 4 
67 DEC1 PPP2R1A 8553 5518 4 
68 DEC1 PPP2R1B 8553 5519 4 
69 DEC1 PPP2R5D 8553 5528 4 
70 DEC1 PPP2R5E 8553 5529 4 
71 DEC1 RORC 8553 6097 4 
72 DEC2 FBXW11 79365 23291 4 
73 DEC2 GSK3B 79365 2932 4 
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74 DEC2 NONO 79365 4841 4 
75 DEC2 PPP2R5E 79365 5529 4 
76 DEC2 RORC 79365 6097 4 
77 FBXW11 PPP1CC 23291 5501 4 
78 FBXW11 PPP2R5E 23291 5529 4 
79 NONO NONO 4841 4841 4 
80 NPAS2 RORC 4862 6097 4 
81 NR1D2 RORC 9975 6097 4 
82 PPP1CA RORC 5499 6097 4 
83 PPP1CC RORC 5501 6097 4 
84 PPP2R1A PPP2R5D 5518 5528 4 
85 PPP2R1A PPP2R5E 5518 5529 4 
86 PPP2R1B PPP2R5D 5519 5528 4 
87 PPP2R1B PPP2R5E 5519 5529 4 
88 PPP2R1B RORC 5519 6097 4 
89 PPP2R5D RORC 5528 6097 4 
90 PPP2R5E RORC 5529 6097 4 
91 BMAL1 WDR5 406 11091 3 
92 CLOCK CSNK2B 9575 1460 3 
93 CLOCK PPP2R1B 9575 5519 3 
94 CRY2 PPP2R5D 1408 5528 3 
95 CSNK1D PER2 1453 8864 3 
96 CSNK2B PPP2CA 1460 5515 3 
97 DEC1 NONO 8553 4841 3 
98 DEC1 PPP2CA 8553 5515 3 
99 DEC2 DEC2 79365 79365 3 
100 DEC2 WDR5 79365 11091 3 
101 PER2 RORC 8864 6097 3 
102 RORB RORC 6096 6097 3 
103 BMAL1 RORC 406 6097 2 
104 CLOCK NR1D2 9575 9975 2 
105 CLOCK PER2 9575 8864 2 
106 CLOCK PPP1CA 9575 5499 2 
107 CLOCK PPP1CB 9575 5500 2 
108 CLOCK PPP1CC 9575 5501 2 
109 CLOCK RORB 9575 6096 2 
110 CRY1 CSNK1E 1407 1454 2 
111 CRY1 PER1 1407 5187 2 
112 CRY1 PPP2R1B 1407 5519 2 
113 CRY1 PPP2R5D 1407 5528 2 
114 CRY2 PPP2R1B 1408 5519 2 
115 CRY2 PPP2R5E 1408 5529 2 
116 CSNK1E CSNK2B 1454 1460 2 
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117 CSNK1E FBXW11 1454 23291 2 
118 CSNK1E NR1D2 1454 9975 2 
119 CSNK2B CSNK2B 1460 1460 2 
120 CSNK2B RORB 1460 6096 2 
121 DEC1 NFIL3 8553 4783 2 
122 DEC1 NR1D2 8553 9975 2 
123 DEC1 RORB 8553 6096 2 
124 DEC2 PER2 79365 8864 2 
125 DEC2 PPP2R1B 79365 5519 2 
126 DEC2 RASD1 79365 51655 2 
127 FBXW11 PPP2R1B 23291 5519 2 
128 FBXW11 PRKACA 23291 5566 2 
129 PPP2R1A RORC 5518 6097 2 
130 PPP2R1B PPP2R1B 5519 5519 2 
131 PPP2R5E PPP2R5E 5529 5529 2 
132 BMAL1 CSNK1E 406 1454 1 
133 BMAL2 RORC 56938 6097 1 
134 CLOCK CSNK1E 9575 1454 1 
135 CLOCK DBP 9575 1628 1 
136 CLOCK RORC 9575 6097 1 
137 CRY1 NR1D2 1407 9975 1 
138 CRY2 EZH2 1408 2146 1 
139 CRY2 NPAS2 1408 4862 1 
140 CSNK1E CSNK1E 1454 1454 1 
141 CSNK1E PPP2R5D 1454 5528 1 
142 CSNK1E RORA 1454 6095 1 
143 CSNK2B GSK3B 1460 2932 1 
144 DEC2 PPP2CB 79365 5516 1 
145 DEC2 RORA 79365 6095 1 
146 FBXL15 RORC 79176 6097 1 
147 FBXW11 GSK3B 23291 2932 1 
148 PPP1CA PPP2R5E 5499 5529 1 
149 PPP1CB RORC 5500 6097 1 
150 PPP2CA RORC 5515 6097 1 
Table 3. Reproduced Protein-Protein Interactions by Y2H Screen. 
No. Gene A h Gene B h ID A h ID B h Exp. type References 
1 PER1 CSNK1E 5187 1454 In Vivo; In Vitro [93, 94] 
2 PER1 PER2 5187 8864 In Vivo [93] 
3 PER1 CRY2 5187 1408 In Vivo; In Vitro [95, 96] 
4 PER1 CRY1 5187 1407 Y2H; In Vivo  [95, 96] 
5 PER2 CSNK1E 8864 1454 In Vitro; In Vivo [97-99] 
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6 PER2 CRY2 8864 1408 Y2H; In Vivo [95, 100] 
7 PER2 CRY1 8864 1407 Y2H; In Vivo  [95, 100, 101] 
8 PER2 CSNK1D 8864 1453 In Vitro [102] 
9 CRY1 BMAL1 1407 406 Y2H [103] 
10 CRY1 CSNK1E 1407 1454 In Vivo [104, 105] 
11 CRY1 PER1 1407 5187 Y2H; In Vivo [95, 96] 
12 CRY1 PER2 1407 8864 Y2H; In Vivo [95, 100, 101] 
13 DEC1 BMAL1 8553 406 Y2H  [65] 
14 DEC1 DEC2 8553 79365 In Vivo [106] 
15 DEC1 DEC1 8553 8553 In Vivo [106] 
16 CLOCK BMAL1 9575 406 Y2H [19] 
17 NPAS2 BMAL1 4862 406 Y2H; In Vivo [107, 108] 
18 BMAL1 CSNK1E 406 1454 In Vitro [104, 105] 
19 CSNK1E CSNK1E 1454 1454 In Vitro [109] 
20 CSNK2A1 CSNK2B 1457 1460 Y2H; In Vivo [110-112] 
21 CSNK2B CSNK2A2 1460 1459 Y2H; In Vivo  [110-112] 
22 CSNK2B CSNK2B 1460 1460 Y2H; In Vivo [112-114] 
23 PPP2R1B PPP2R5E 5519 5529 In Vivo [115] 
24 PPP2R1B PPP2R5D 5519 5528 Y2H [116] 
25 PPP2R1B PPP2R1B 5519 5519 In Vitro [117] 
26 PPP2R5D PPP2R1A 5528 5518 In Vivo [118] 
27 PPP2R5E PPP2R1A 5529 5518 In Vivo [118] 
28 PPP2R1B PPP2R5D 5519 5528 In Vivo [118] 
29 CRY2 CLOCK 1408 9575 Y2H [95] 
30 BMAL1 CRY2 406 1408 Y2H [103] 
31 CLOCK CRY1 9575 1407 Y2H [103] 
32 CLOCK CRY2 9575 1408 Y2H [103] 
33 NPAS2 CRY1 4862 1407 Y2H [103] 
34 NPAS2 CRY2 4862 1408 Y2H [103] 
35 DEC1 CLOCK 8553 9575 Y2H [65] 
36 DEC2 CLOCK 79365 9575 Y2H [65] 
37 CIPC CLOCK 85457 9575 Y2H [55] 
38 NONO NONO 4841 4841 Y2H [40] 
39 PER2 CSNK2B 8864 1460 In Vivo [22] 
40 BMAL1 CSNK2B 406 1460 In Vivo [119] 
41 CLOCK PER2 9575 8864 In Vivo [20, 120] 
Table 4. Enriched Interactions from UNIHI Database. 
No. Gene A h Gene B h Gene ID A h Gene ID B h Source References 
1 ARNTL PER3 406 8863 UNIHI [56, 121] 
2 CRY1 PER3 1407 8863 UNIHI [56, 121] 
3 CRY1 TIMELESS 1407 8914 UNIHI [56, 121] 
4 CRY2 PPP5C 1408 5536 UNIHI [56, 121] 
5 CRY2 PER3 1408 8863 UNIHI [56, 121] 
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6 CRY2 TIMELESS 1408 8914 UNIHI [56, 121] 
7 CSNK1D PER1 1453 5187 UNIHI [56, 121] 
8 CSNK1D PER3 1453 8863 UNIHI [56, 121] 
9 CSNK1E PER3 1454 8863 UNIHI [56, 121] 
10 CSNK2A1 CSNK2A1 1457 1457 UNIHI [56, 121] 
11 GSK3B PRKACA 2932 5566 UNIHI [56, 121] 
12 GSK3B GSK3B 2932 2932 UNIHI [56, 121] 
13 GSK3B PPP1CA 2932 5499 UNIHI [56, 121] 
14 NFIL3 NFIL3 4783 4783 UNIHI [56, 121] 
15 PER1 PER3 5187 8863 UNIHI [56, 121] 
16 PER1 PER2 5187 8864 UNIHI [56, 121] 
17 PER1 TIMELESS 5187 8914 UNIHI [56, 121] 
18 PPP1CA PPP2CA 5499 5515 UNIHI [56, 121] 
19 PPP1CA PPP1CA 5499 5499 UNIHI [56, 121] 
20 PPP2CA PPP2R5E 5515 5529 UNIHI [56, 121] 
21 PPP2CA PPP2R1A 5515 5518 UNIHI [56, 121] 
22 PPP2R1A PPP5C 5518 5536 UNIHI [56, 121] 
23 PPP5C PPP5C 5536 5536 UNIHI [56, 121] 
24 PRKCA PRKCA 5578 5578 UNIHI [56, 121] 
25 RORA RORA 6095 6095 UNIHI [56, 121] 
26 PER3 CLOCK 8863 9575 UNIHI [56, 121] 
27 PER3 PER2 8863 8864 UNIHI [56, 121] 
28 PER2 TIMELESS 8864 8914 UNIHI [56, 121] 
29 BTRC BTRC 8945 8945 UNIHI [56, 121] 
30 NR1D1 NR1D1 9572 9572 UNIHI [56, 121] 
31 CLOCK ARNTL2 9575 56938 UNIHI [56, 121] 
Table 5. Enriched Interactions from Manual Curation. 
No. Gene A h Gene B h Gene ID A h Gene ID B h Source References 
1 PER1 PER1 5187 5187 MAN [122] 
2 PER1 PER2 5187 8864 MAN [122] 
3 PER2 PER2 8864 8864 MAN [122] 
4 NONO PER1 4841 5187 MAN [122] 
5 PER1 WDR5 5187 11091 MAN [122] 
6 NONO PER2 4841 8864 MAN [62] 
7 PER2 WDR5 8864 11091 MAN [62] 
8 PPP1CA PER2 5499 8864 MAN [123] 
9 GSK3B PER2 2932 8864 MAN [124] 
10 CSNK2A1 PER2 1457 8864 MAN [22] 
11 PER2 BTRC 8864 8945 MAN [92] 
12 NFIL3 PER2 4783 8864 MAN [88, 125] 
13 PRKCA PER2 5578 8864 MAN [50] 
14 CRY1 PPP5C 1407 5536 MAN [91] 
15 CRY2 GSK3B 1408 2932 MAN [126] 
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16 CRY1 FBXL3 1407 26224 MAN [21, 52] 
17 CRY2 FBXL3 1408 26224 MAN [21, 52] 
18 CRY2 NFIL3 1408 4783 MAN [88] 
19 ARNTL DEC2 406 79365 MAN [65] 
20 ARNTL CSNK2A1 406 1457 MAN [119] 
21 CSNK2A1 PPP2CA 1457 5515 MAN [127] 
22 EZH2 CLOCK 2146 9575 MAN [89] 
23 ARNTL EZH2 406 2146 MAN [89] 
24 PPP2CA PPP2CA 5515 5515 MAN [128] 
25 PPP2CA PPP5C 5515 5536 MAN [129] 
26 PER2 FBXW11 8864 23291 MAN [92] 
27 GSK3B NR1D1 2932 9572 MAN [86, 130] 
28 PER2 NR1D1 8864 9572 MAN [131] 
29 BTRC FBXW11 8945 23291 MAN [132] 
30 CRY1 CSNK1D 1407 1453 MAN [20] 
31 CRY2 CSNK1D 1408 1453 MAN [20] 
32 CSNK1E PPP5C 1454 5536 MAN [91] 
Table 6. Components of Network Extension. 
No. Gene ID h Gene ID m Symbol h Symbol m Source 
1 207 11651 AKT1 Akt1 UNIHI 
2 367 11835 AR Ar UNIHI 
3 466 11908 ATF1 Atf1 UNIHI 
4 1050 12606 CEBPA Cebpa UNIHI 
5 1111 12649 CHEK1 Chek1 UNIHI 
6 1387 12914 CREBBP Crebbp UNIHI 
7 1390 12916 CREM Crem UNIHI 
8 1649 13198 DDIT3 Ddit3 UNIHI 
9 2033 328572 EP300 Ep300 UNIHI 
10 2034 13819 EPAS1 Epas1 UNIHI 
11 3054 15161 HCFC1 Hcfc1 UNIHI 
12 3065 433759 HDAC1 Hdac1 UNIHI 
13 3091 15251 HIF1A Hif1a UNIHI 
14 3320 15519 HSP90AA1 Hsp90aa1 UNIHI 
15 4163 328949 MCC Mcc UNIHI 
16 4609 17869 MYC Myc UNIHI 
17 4654 17927 MYOD1 Myod1 UNIHI 
18 4830 18102 NME1 Nme1 UNIHI 
19 4831 18103 NME2 Nme2 UNIHI 
20 4842 18125 NOS1 Nos1 UNIHI 
21 5111 18538 PCNA Pcna UNIHI 
22 6667 20683 SP1 Sp1 UNIHI 
23 8850 18519 KAT2B Kat2b UNIHI 
24 9611 20185 NCOR1 Ncor1 UNIHI 
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25 190 11614 NR0B1 Nr0b1 UNIHI 
26 196 11622 AHR Ahr UNIHI 
27 546 22589 ATRX Atrx UNIHI 
28 760 12349 CA2 Car2 UNIHI 
29 1054 12611 CEBPG Cebpg UNIHI 
30 1108 107932 CHD4 Chd4 UNIHI 
31 1642 13194 DDB1 Ddb1 UNIHI 
32 1786 13433 DNMT1 Dnmt1 UNIHI 
33 1788 13435 DNMT3A Dnmt3a UNIHI 
34 1789 13436 DNMT3B Dnmt3b UNIHI 
35 1810 13486 DR1 Dr1 UNIHI 
36 1822 13498 ATN1 Atn1 UNIHI 
37 1876 50496 E2F6 E2f6 UNIHI 
38 2770 14677 GNAI1 Gnai1 UNIHI 
39 2771 14678 GNAI2 Gnai2 UNIHI 
40 2782 14688 GNB1 Gnb1 UNIHI 
41 4221 17283 MEN1 Men1 UNIHI 
42 4297 214162 MLL Mll1 UNIHI 
43 5469 19014 MED1 Med1 UNIHI 
44 5705 19184 PSMC5 Psmc5 UNIHI 
45 5929 213464 RBBP5 Rbbp5 UNIHI 
46 6774 20848 STAT3 Stat3 UNIHI 
47 7329 22196 UBE2I Ube2i UNIHI 
48 8450 72584 CUL4B Cul4b UNIHI 
49 8451 99375 CUL4A Cul4a UNIHI 
50 9070 23808 ASH2L Ash2l UNIHI 
51 9410 66585 WDR57 Wdr57 UNIHI 
52 9722 70729 NOS1AP Nos1ap UNIHI 
53 3131 217082 HLF Hlf UNIHI 
54 3066 15182 HDAC2 Hdac2 UNIHI 
55 6688 20375 SPI1 Sfpi1 UNIHI 
56 5914 19401 RARA Rara UNIHI 
57 8726 13626 EED Eed UNIHI 
58 5829 19303 PXN Pxn UNIHI 
59 7414 22330 VCL Vcl UNIHI 
60 266743 225872 NPAS4 Npas4 UNIHI 
61 7008 21685 TEF Tef UNIHI 
62 5371 18854 PML Pml UNIHI 
63 7409 22324 VAV1 Vav1 UNIHI 
64 23512 52615 SUZ12 Suz12 UNIHI 
65 23649 18969 POLA2 Pola2 UNIHI 
66 5252 21652 PHF1 Phf1 UNIHI 
67 10538 53314 BATF Batf UNIHI 
68 90993 26427 CREB3L1 Creb3l1 UNIHI 
69 10488 12913 CREB3 Creb3 UNIHI 
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70 5430 20020 POLR2A Polr2a UNIHI 
71 6421 71514 SFPQ Sfpq UNIHI 
72 55269 66645 PSPC1 Pspc1 UNIHI 
73 6256 20181 RXRA Rxra UNIHI 
74 8202 17979 NCOA3 Ncoa3 UNIHI 
75 9737 67298 GPRASP1 Gprasp1 UNIHI 
76 10499 17978 NCOA2 Ncoa2 UNIHI 
77 55885 109593 LMO3 Lmo3 UNIHI 
78 8648 17977 NCOA1 Ncoa1 UNIHI 
79 83714 60345 NRIP2 Nrip2 UNIHI 
80 11277 22040 TREX1 Trex1 UNIHI 
81 54962 66131 TIPIN Tipin UNIHI 
82 9612 20602 NCOR2 Ncor2 UNIHI 
83 10002 23958 NR2E3 Nr2e3 UNIHI 
84 57727 228869 NCOA5 Ncoa5 UNIHI 
85 23178 269224 PASK Pask UNIHI 
86 29915 67933 HCFC2 Hcfc2 UNIHI 
87 51514 76843 DTL Dtl UNIHI 
88 83743 101612 GRWD1 Grwd1 UNIHI 
Table 7. Additional Interactions of Neighborhood Components. 
No. Gene ID A h Gene ID B h Gene A h Gene B h Source 
1 190 6095 NR0B1 RORA UNIHI 
2 196 406 AHR ARNTL UNIHI 
3 207 2146 AKT1 EZH2 UNIHI 
4 367 4841 AR NONO UNIHI 
5 406 2033 ARNTL EP300 UNIHI 
6 406 2034 ARNTL EPAS1 UNIHI 
7 406 3091 ARNTL HIF1A UNIHI 
8 406 3320 ARNTL HSP90AA1 UNIHI 
9 406 8850 ARNTL KAT2B UNIHI 
10 406 3131 ARNTL HLF UNIHI 
11 406 266743 ARNTL NPAS4 UNIHI 
12 466 4783 ATF1 NFIL3 UNIHI 
13 546 2146 ATRX EZH2 UNIHI 
14 760 4841 CA2 NONO UNIHI 
15 1050 1628 CEBPA DBP UNIHI 
16 1054 4783 CEBPG NFIL3 UNIHI 
17 1108 6097 CHD4 RORC UNIHI 
18 1111 8914 CHEK1 TIMELESS UNIHI 
19 1387 4862 CREBBP NPAS2 UNIHI 
20 1390 4783 CREM NFIL3 UNIHI 
21 1628 2033 DBP EP300 UNIHI 
Appendix              - 11 - 
 
22 1628 3131 DBP HLF UNIHI 
23 1628 7008 DBP TEF UNIHI 
24 1642 11091 DDB1 WDR5 UNIHI 
25 1649 4783 DDIT3 NFIL3 UNIHI 
26 1786 2146 DNMT1 EZH2 UNIHI 
27 1788 2146 DNMT3A EZH2 UNIHI 
28 1789 2146 DNMT3B EZH2 UNIHI 
29 1810 4783 DR1 NFIL3 UNIHI 
30 1822 11091 ATN1 WDR5 UNIHI 
31 1876 2146 E2F6 EZH2 UNIHI 
32 2033 9575 EP300 CLOCK UNIHI 
33 2033 4862 EP300 NPAS2 UNIHI 
34 2033 6095 EP300 RORA UNIHI 
35 2034 56938 EPAS1 ARNTL2 UNIHI 
36 2146 3065 EZH2 HDAC1 UNIHI 
37 2146 3066 EZH2 HDAC2 UNIHI 
38 2146 5371 EZH2 PML UNIHI 
39 2146 5914 EZH2 RARA UNIHI 
40 2146 7409 EZH2 VAV1 UNIHI 
41 2146 8726 EZH2 EED UNIHI 
42 2146 23512 EZH2 SUZ12 UNIHI 
43 2146 23649 EZH2 POLA2 UNIHI 
44 2146 5252 EZH2 PHF1 UNIHI 
45 2770 51655 GNAI1 RASD1 UNIHI 
46 2771 51655 GNAI2 RASD1 UNIHI 
47 2782 51655 GNB1 RASD1 UNIHI 
48 3054 11091 HCFC1 WDR5 UNIHI 
49 3091 5187 HIF1A PER1 UNIHI 
50 3320 4862 HSP90AA1 NPAS2 UNIHI 
51 4163 11091 MCC WDR5 UNIHI 
52 4221 11091 MEN1 WDR5 UNIHI 
53 4297 11091 MLL WDR5 UNIHI 
54 4609 11091 MYC WDR5 UNIHI 
55 4654 79365 MYOD1 BHLHE41 UNIHI 
56 4654 6095 MYOD1 RORA UNIHI 
57 4783 10538 NFIL3 BATF UNIHI 
58 4783 90993 NFIL3 CREB3L1 UNIHI 
59 4783 10488 NFIL3 CREB3 UNIHI 
60 4830 6095 NME1 RORA UNIHI 
61 4830 6096 NME1 RORB UNIHI 
62 4831 6095 NME2 RORA UNIHI 
63 4831 6096 NME2 RORB UNIHI 
64 4841 5111 NONO PCNA UNIHI 
Appendix              - 12 - 
 
65 4841 5430 NONO POLR2A UNIHI 
66 4841 5829 NONO PXN UNIHI 
67 4841 6421 NONO SFPQ UNIHI 
68 4841 6688 NONO SPI1 UNIHI 
69 4841 7414 NONO VCL UNIHI 
70 4841 55269 NONO PSPC1 UNIHI 
71 4842 51655 NOS1 RASD1 UNIHI 
72 4862 5914 NPAS2 RARA UNIHI 
73 4862 6256 NPAS2 RXRA UNIHI 
74 4862 8202 NPAS2 NCOA3 UNIHI 
75 4862 8850 NPAS2 KAT2B UNIHI 
76 5187 9737 PER1 GPRASP1 UNIHI 
77 5469 6095 MED1 RORA UNIHI 
78 5705 6095 PSMC5 RORA UNIHI 
79 5929 11091 RBBP5 WDR5 UNIHI 
80 6095 10499 RORA NCOA2 UNIHI 
81 6095 55885 RORA LMO3 UNIHI 
82 6096 8648 RORB NCOA1 UNIHI 
83 6096 83714 RORB NRIP2 UNIHI 
84 6667 8863 SP1 PER3 UNIHI 
85 6774 8553 STAT3 BHLHE40 UNIHI 
86 7329 8553 UBE2I BHLHE40 UNIHI 
87 8450 11091 CUL4B WDR5 UNIHI 
88 8451 11091 CUL4A WDR5 UNIHI 
89 8850 9575 KAT2B CLOCK UNIHI 
90 8914 11277 TIMELESS TREX1 UNIHI 
91 8914 54962 TIMELESS TIPIN UNIHI 
92 9070 11091 ASH2L WDR5 UNIHI 
93 9410 11091 SNRNP40 WDR5 UNIHI 
94 9572 9611 NR1D1 NCOR1 UNIHI 
95 9572 9612 NR1D1 NCOR2 UNIHI 
96 9572 10002 NR1D1 NR2E3 UNIHI 
97 9611 9975 NCOR1 NR1D2 UNIHI 
98 9722 51655 NOS1AP RASD1 UNIHI 
99 9975 57727 NR1D2 NCOA5 UNIHI 
100 11091 23178 WDR5 PASK UNIHI 
101 11091 29915 WDR5 HCFC2 UNIHI 
102 11091 51514 WDR5 DTL UNIHI 
103 11091 83743 WDR5 GRWD1 UNIHI 
104 190 367 NR0B1 AR UNIHI 
105 196 10499 AHR NCOA2 UNIHI 
106 196 9612 AHR NCOR2 UNIHI 
107 196 2033 AHR EP300 UNIHI 
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108 196 3320 AHR HSP90AA1 UNIHI 
109 196 8648 AHR NCOA1 UNIHI 
110 196 196 AHR AHR UNIHI 
111 196 6667 AHR SP1 UNIHI 
112 207 2033 AKT1 EP300 UNIHI 
113 207 3320 AKT1 HSP90AA1 UNIHI 
114 207 367 AKT1 AR UNIHI 
115 207 2932 AKT1 GSK3B UNIHI 
116 207 1111 AKT1 CHEK1 UNIHI 
117 207 207 AKT1 AKT1 UNIHI 
118 207 5515 AKT1 PPP2CA UNIHI 
119 367 10499 AR NCOA2 UNIHI 
120 367 1387 AR CREBBP UNIHI 
121 367 9612 AR NCOR2 UNIHI 
122 367 9611 AR NCOR1 UNIHI 
123 367 6667 AR SP1 UNIHI 
124 367 2033 AR EP300 UNIHI 
125 367 3065 AR HDAC1 UNIHI 
126 367 6774 AR STAT3 UNIHI 
127 367 3320 AR HSP90AA1 UNIHI 
128 367 367 AR AR UNIHI 
129 367 5829 AR PXN UNIHI 
130 367 8850 AR KAT2B UNIHI 
131 367 8202 AR NCOA3 UNIHI 
132 367 8648 AR NCOA1 UNIHI 
133 367 5469 AR MED1 UNIHI 
134 367 7329 AR UBE2I UNIHI 
135 367 55269 AR PSPC1 UNIHI 
136 367 2932 AR GSK3B UNIHI 
137 367 3091 AR HIF1A UNIHI 
138 466 1457 ATF1 CSNK2A1 UNIHI 
139 466 1387 ATF1 CREBBP UNIHI 
140 466 5566 ATF1 PRKACA UNIHI 
141 466 1459 ATF1 CSNK2A2 UNIHI 
142 466 466 ATF1 ATF1 UNIHI 
143 466 1390 ATF1 CREM UNIHI 
144 466 6688 ATF1 SPI1 UNIHI 
145 466 1460 ATF1 CSNK2B UNIHI 
146 546 3065 ATRX HDAC1 UNIHI 
147 546 1822 ATRX ATN1 UNIHI 
148 1050 1387 CEBPA CREBBP UNIHI 
149 1050 4609 CEBPA MYC UNIHI 
150 1050 2033 CEBPA EP300 UNIHI 
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151 1050 1050 CEBPA CEBPA UNIHI 
152 1050 6688 CEBPA SPI1 UNIHI 
153 1050 2932 CEBPA GSK3B UNIHI 
154 1050 1054 CEBPA CEBPG UNIHI 
155 1050 10538 CEBPA BATF UNIHI 
156 1054 1054 CEBPG CEBPG UNIHI 
157 1054 3131 CEBPG HLF UNIHI 
158 1054 7008 CEBPG TEF UNIHI 
159 1054 10488 CEBPG CREB3 UNIHI 
160 1054 10538 CEBPG BATF UNIHI 
161 1054 90993 CEBPG CREB3L1 UNIHI 
162 1054 1649 CEBPG DDIT3 UNIHI 
163 1108 2033 CHD4 EP300 UNIHI 
164 1108 3065 CHD4 HDAC1 UNIHI 
165 1108 3066 CHD4 HDAC2 UNIHI 
166 1108 4609 CHD4 MYC UNIHI 
167 1111 3320 CHEK1 HSP90AA1 UNIHI 
168 1111 1460 CHEK1 CSNK2B UNIHI 
169 1111 8451 CHEK1 CUL4A UNIHI 
170 1111 1457 CHEK1 CSNK2A1 UNIHI 
171 1387 1457 CREBBP CSNK2A1 UNIHI 
172 1387 10499 CREBBP NCOA2 UNIHI 
173 1387 5371 CREBBP PML UNIHI 
174 1387 6774 CREBBP STAT3 UNIHI 
175 1387 1459 CREBBP CSNK2A2 UNIHI 
176 1387 4297 CREBBP MLL UNIHI 
177 1387 4654 CREBBP MYOD1 UNIHI 
178 1387 1387 CREBBP CREBBP UNIHI 
179 1387 8648 CREBBP NCOA1 UNIHI 
180 1387 2033 CREBBP EP300 UNIHI 
181 1387 8850 CREBBP KAT2B UNIHI 
182 1387 3065 CREBBP HDAC1 UNIHI 
183 1387 1390 CREBBP CREM UNIHI 
184 1387 3131 CREBBP HLF UNIHI 
185 1387 6688 CREBBP SPI1 UNIHI 
186 1387 4609 CREBBP MYC UNIHI 
187 1387 8202 CREBBP NCOA3 UNIHI 
188 1387 3091 CREBBP HIF1A UNIHI 
189 1387 5430 CREBBP POLR2A UNIHI 
190 1390 1457 CREM CSNK2A1 UNIHI 
191 1390 5578 CREM PRKCA UNIHI 
192 1390 5566 CREM PRKACA UNIHI 
193 1390 2932 CREM GSK3B UNIHI 
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194 1390 1459 CREM CSNK2A2 UNIHI 
195 1390 6688 CREM SPI1 UNIHI 
196 1390 1390 CREM CREM UNIHI 
197 1390 90993 CREM CREB3L1 UNIHI 
198 1453 4163 CSNK1D MCC UNIHI 
199 1454 4163 CSNK1E MCC UNIHI 
200 1457 3065 CSNK2A1 HDAC1 UNIHI 
201 1457 3066 CSNK2A1 HDAC2 UNIHI 
202 1457 1649 CSNK2A1 DDIT3 UNIHI 
203 1457 3320 CSNK2A1 HSP90AA1 UNIHI 
204 1457 6667 CSNK2A1 SP1 UNIHI 
205 1457 4609 CSNK2A1 MYC UNIHI 
206 1457 3091 CSNK2A1 HIF1A UNIHI 
207 1457 6688 CSNK2A1 SPI1 UNIHI 
208 1459 4609 CSNK2A2 MYC UNIHI 
209 1459 3065 CSNK2A2 HDAC1 UNIHI 
210 1459 3320 CSNK2A2 HSP90AA1 UNIHI 
211 1459 3066 CSNK2A2 HDAC2 UNIHI 
212 1642 8451 DDB1 CUL4A UNIHI 
213 1642 9410 DDB1 SNRNP40 UNIHI 
214 1642 5929 DDB1 RBBP5 UNIHI 
215 1642 8450 DDB1 CUL4B UNIHI 
216 1642 51514 DDB1 DTL UNIHI 
217 1649 10538 DDIT3 BATF UNIHI 
218 1649 3131 DDIT3 HLF UNIHI 
219 1649 1649 DDIT3 DDIT3 UNIHI 
220 1649 7008 DDIT3 TEF UNIHI 
221 1649 10488 DDIT3 CREB3 UNIHI 
222 1786 5111 DNMT1 PCNA UNIHI 
223 1786 3065 DNMT1 HDAC1 UNIHI 
224 1786 3066 DNMT1 HDAC2 UNIHI 
225 1786 1786 DNMT1 DNMT1 UNIHI 
226 1786 1788 DNMT1 DNMT3A UNIHI 
227 1786 1789 DNMT1 DNMT3B UNIHI 
228 1788 4609 DNMT3A MYC UNIHI 
229 1788 3065 DNMT3A HDAC1 UNIHI 
230 1788 7329 DNMT3A UBE2I UNIHI 
231 1788 1789 DNMT3A DNMT3B UNIHI 
232 1789 3065 DNMT3B HDAC1 UNIHI 
233 1789 3066 DNMT3B HDAC2 UNIHI 
234 1789 7329 DNMT3B UBE2I UNIHI 
235 1822 1822 ATN1 ATN1 UNIHI 
236 2033 10499 EP300 NCOA2 UNIHI 
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237 2033 5371 EP300 PML UNIHI 
238 2033 6667 EP300 SP1 UNIHI 
239 2033 4609 EP300 MYC UNIHI 
240 2033 6774 EP300 STAT3 UNIHI 
241 2033 4654 EP300 MYOD1 UNIHI 
242 2033 5111 EP300 PCNA UNIHI 
243 2033 8202 EP300 NCOA3 UNIHI 
244 2033 3091 EP300 HIF1A UNIHI 
245 2033 8850 EP300 KAT2B UNIHI 
246 2033 2033 EP300 EP300 UNIHI 
247 2033 8648 EP300 NCOA1 UNIHI 
248 2033 2034 EP300 EPAS1 UNIHI 
249 2033 7329 EP300 UBE2I UNIHI 
250 2033 5430 EP300 POLR2A UNIHI 
251 2770 2770 GNAI1 GNAI1 UNIHI 
252 2782 4831 GNB1 NME2 UNIHI 
253 2782 4163 GNB1 MCC UNIHI 
254 2932 4609 GSK3B MYC UNIHI 
255 2932 5829 GSK3B PXN UNIHI 
256 3054 6667 HCFC1 SP1 UNIHI 
257 3054 3054 HCFC1 HCFC1 UNIHI 
258 3054 10488 HCFC1 CREB3 UNIHI 
259 3054 5501 HCFC1 PPP1CC UNIHI 
260 3054 3065 HCFC1 HDAC1 UNIHI 
261 3054 3320 HCFC1 HSP90AA1 UNIHI 
262 3054 3066 HCFC1 HDAC2 UNIHI 
263 3054 29915 HCFC1 HCFC2 UNIHI 
264 3054 4221 HCFC1 MEN1 UNIHI 
265 3054 5929 HCFC1 RBBP5 UNIHI 
266 3054 9070 HCFC1 ASH2L UNIHI 
267 3054 4297 HCFC1 MLL UNIHI 
268 3065 5371 HDAC1 PML UNIHI 
269 3065 9612 HDAC1 NCOR2 UNIHI 
270 3065 6667 HDAC1 SP1 UNIHI 
271 3065 5111 HDAC1 PCNA UNIHI 
272 3065 6774 HDAC1 STAT3 UNIHI 
273 3065 4654 HDAC1 MYOD1 UNIHI 
274 3065 3065 HDAC1 HDAC1 UNIHI 
275 3065 3066 HDAC1 HDAC2 UNIHI 
276 3065 7329 HDAC1 UBE2I UNIHI 
277 3065 8726 HDAC1 EED UNIHI 
278 3065 3091 HDAC1 HIF1A UNIHI 
279 3065 4297 HDAC1 MLL UNIHI 
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280 3065 4609 HDAC1 MYC UNIHI 
281 3065 5519 HDAC1 PPP2R1B UNIHI 
282 3065 5518 HDAC1 PPP2R1A UNIHI 
283 3066 5371 HDAC2 PML UNIHI 
284 3066 6667 HDAC2 SP1 UNIHI 
285 3066 6774 HDAC2 STAT3 UNIHI 
286 3066 8726 HDAC2 EED UNIHI 
287 3066 9612 HDAC2 NCOR2 UNIHI 
288 3066 3091 HDAC2 HIF1A UNIHI 
289 3066 3066 HDAC2 HDAC2 UNIHI 
290 3066 4609 HDAC2 MYC UNIHI 
291 3091 10499 HIF1A NCOA2 UNIHI 
292 3091 3320 HIF1A HSP90AA1 UNIHI 
293 3091 8648 HIF1A NCOA1 UNIHI 
294 3091 8850 HIF1A KAT2B UNIHI 
295 3131 10538 HLF BATF UNIHI 
296 3131 3131 HLF HLF UNIHI 
297 3131 7008 HLF TEF UNIHI 
298 3320 4609 HSP90AA1 MYC UNIHI 
299 3320 6774 HSP90AA1 STAT3 UNIHI 
300 3320 3320 HSP90AA1 HSP90AA1 UNIHI 
301 3320 4842 HSP90AA1 NOS1 UNIHI 
302 3320 4654 HSP90AA1 MYOD1 UNIHI 
303 3320 5536 HSP90AA1 PPP5C UNIHI 
304 4163 5518 MCC PPP2R1A UNIHI 
305 4163 5516 MCC PPP2CB UNIHI 
306 4163 5111 MCC PCNA UNIHI 
307 4221 5929 MEN1 RBBP5 UNIHI 
308 4221 9070 MEN1 ASH2L UNIHI 
309 4221 29915 MEN1 HCFC2 UNIHI 
310 4221 4297 MEN1 MLL UNIHI 
311 4297 4297 MLL MLL UNIHI 
312 4297 5929 MLL RBBP5 UNIHI 
313 4297 9070 MLL ASH2L UNIHI 
314 4297 29915 MLL HCFC2 UNIHI 
315 4609 5371 MYC PML UNIHI 
316 4609 6667 MYC SP1 UNIHI 
317 4609 8850 MYC KAT2B UNIHI 
318 4609 5430 MYC POLR2A UNIHI 
319 4609 5499 MYC PPP1CA UNIHI 
320 4654 9612 MYOD1 NCOR2 UNIHI 
321 4654 6667 MYOD1 SP1 UNIHI 
322 4654 6774 MYOD1 STAT3 UNIHI 
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323 4654 4654 MYOD1 MYOD1 UNIHI 
324 4654 5578 MYOD1 PRKCA UNIHI 
325 4654 6256 MYOD1 RXRA UNIHI 
326 4654 8850 MYOD1 KAT2B UNIHI 
327 4654 9611 MYOD1 NCOR1 UNIHI 
328 4830 4830 NME1 NME1 UNIHI 
329 4831 5515 NME2 PPP2CA UNIHI 
330 4831 4831 NME2 NME2 UNIHI 
331 4831 5518 NME2 PPP2R1A UNIHI 
332 4842 5578 NOS1 PRKCA UNIHI 
333 4842 5566 NOS1 PRKACA UNIHI 
334 4842 9722 NOS1 NOS1AP UNIHI 
335 5111 5111 PCNA PCNA UNIHI 
336 5111 5501 PCNA PPP1CC UNIHI 
337 5371 5371 PML PML UNIHI 
338 5371 6774 PML STAT3 UNIHI 
339 5371 9612 PML NCOR2 UNIHI 
340 5371 9611 PML NCOR1 UNIHI 
341 5371 5914 PML RARA UNIHI 
342 5371 6667 PML SP1 UNIHI 
343 5371 6256 PML RXRA UNIHI 
344 5371 23512 PML SUZ12 UNIHI 
345 5430 8850 POLR2A KAT2B UNIHI 
346 5469 5914 MED1 RARA UNIHI 
347 5469 6256 MED1 RXRA UNIHI 
348 5469 5469 MED1 MED1 UNIHI 
349 5499 8726 PPP1CA EED UNIHI 
350 5515 5829 PPP2CA PXN UNIHI 
351 5578 5914 PRKCA RARA UNIHI 
352 5578 7414 PRKCA VCL UNIHI 
353 5705 6667 PSMC5 SP1 UNIHI 
354 5705 6256 PSMC5 RXRA UNIHI 
355 5829 7414 PXN VCL UNIHI 
356 5829 5829 PXN PXN UNIHI 
357 5829 6421 PXN SFPQ UNIHI 
358 5914 9612 RARA NCOR2 UNIHI 
359 5914 6256 RARA RXRA UNIHI 
360 5914 6667 RARA SP1 UNIHI 
361 5914 8648 RARA NCOA1 UNIHI 
362 5914 10002 RARA NR2E3 UNIHI 
363 5914 8850 RARA KAT2B UNIHI 
364 5914 83714 RARA NRIP2 UNIHI 
365 5914 8202 RARA NCOA3 UNIHI 
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366 5914 5914 RARA RARA UNIHI 
367 5929 8450 RBBP5 CUL4B UNIHI 
368 5929 8451 RBBP5 CUL4A UNIHI 
369 5929 9070 RBBP5 ASH2L UNIHI 
370 5929 29915 RBBP5 HCFC2 UNIHI 
371 6256 10499 RXRA NCOA2 UNIHI 
372 6256 9612 RXRA NCOR2 UNIHI 
373 6256 6667 RXRA SP1 UNIHI 
374 6256 8648 RXRA NCOA1 UNIHI 
375 6256 8202 RXRA NCOA3 UNIHI 
376 6256 6256 RXRA RXRA UNIHI 
377 6421 55269 SFPQ PSPC1 UNIHI 
378 6667 9612 SP1 NCOR2 UNIHI 
379 6667 9611 SP1 NCOR1 UNIHI 
380 6667 6667 SP1 SP1 UNIHI 
381 6667 9070 SP1 ASH2L UNIHI 
382 6774 6774 STAT3 STAT3 UNIHI 
383 6774 8648 STAT3 NCOA1 UNIHI 
384 7008 10538 TEF BATF UNIHI 
385 7008 7008 TEF TEF UNIHI 
386 7414 7414 VCL VCL UNIHI 
387 8202 9612 NCOA3 NCOR2 UNIHI 
388 8202 8202 NCOA3 NCOA3 UNIHI 
389 8202 8850 NCOA3 KAT2B UNIHI 
390 8450 9410 CUL4B SNRNP40 UNIHI 
391 8450 8451 CUL4B CUL4A UNIHI 
392 8450 83743 CUL4B GRWD1 UNIHI 
393 8450 51514 CUL4B DTL UNIHI 
394 8648 8648 NCOA1 NCOA1 UNIHI 
395 8648 8850 NCOA1 KAT2B UNIHI 
396 8648 9611 NCOA1 NCOR1 UNIHI 
397 8648 10499 NCOA1 NCOA2 UNIHI 
398 8726 8726 EED EED UNIHI 
399 8850 8850 KAT2B KAT2B UNIHI 
400 9070 9070 ASH2L ASH2L UNIHI 
401 9070 29915 ASH2L HCFC2 UNIHI 
402 9410 9410 SNRNP40 SNRNP40 UNIHI 
403 9410 83743 SNRNP40 GRWD1 UNIHI 
404 9611 9611 NCOR1 NCOR1 UNIHI 
405 9611 9612 NCOR1 NCOR2 UNIHI 
406 10488 90993 CREB3 CREB3L1 UNIHI 
407 10488 10488 CREB3 CREB3 UNIHI 
408 10499 10499 NCOA2 NCOA2 UNIHI 
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409 10538 10538 BATF BATF UNIHI 
410 23178 23178 PASK PASK UNIHI 
411 51514 83743 DTL GRWD1 UNIHI 
412 90993 90993 CREB3L1 CREB3L1 UNIHI 
Table 8. Hits of RNAi Screen of Network Neighborhood. 
Gene ID h RNAi construt Period  Delta period Amp Damp Corr. coeff. Hit 
367 AR_1 23.22 -0.78 0.53 55.55 0.98 sp 
367 AR_2 23.07 -0.93 0.44 35.72 0.96 sp 
1108 CHD4_1 24.58 0.58 0.31 47.15 0.93 lp 
1108 CHD4_2 25.55 1.55 0.49 29.98 0.93 lp 
1111 CHEK1_1 23.06 -0.94 0.36 48.17 0.95 sp 
1111 CHEK1_2 22.56 -1.44 0.41 32.16 0.94 sp 
90993 CREB3L1 23.48 -0.52 0.44 38.10 0.98 sp 
8450 CUL4B 23.41 -0.59 0.36 32.47 0.97 sp 
1642 DDB1_1 23.21 -0.79 0.64 35.33 0.96 sp 
1642 DDB1_2 23.75 -0.25 0.33 28.98 0.859 ar 
1810 DR1 23.33 -0.67 0.48 34.28 0.97 sp 
9737 GPRASP1 23.17 -0.83 0.45 32.41 0.94 sp 
3066 HDAC2 24.88 0.88 0.41 32.03 0.98 lp 
4654 MYOD1 24.56 0.56 0.57 41.58 0.98 lp 
8202 NCOA3_1 24.77 0.77 0.46 43.33 0.98 lp 
8202 NCOA3_2 24.56 0.56 0.54 34.76 0.98 lp 
190 NR0B1_1 24.85 0.85 0.52 39.83 0.97 lp 
190 NR0B1_2 25.29 1.29 0.43 43.24 0.93 lp 
23178 PASK 23.44 -0.56 0.55 43.52 0.95 sp 
5111 PCNA 22.12 -1.88 0.35 22.27 0.95 sp 
5111 PCNA 23.34 -0.66 0.48 34.88 0.95 sp 
5430 POLR2A 25.38 1.38 0.63 40.65 0.98 lp 
5705 PSMC5_1 25.57 1.57 0.38 17.08 0.91 lp 
5705 PSMC5_2 25.11 1.11 0.22 8.38 0.96 lp 
5929 RBBP5_1 23.41 -0.59 0.56 45.34 0.97 sp 
5929 RBBP5_2 23.49 -0.51 0.57 40.86 0.97 sp 
6688 SPI1 25.00 1.00 0.50 34.84 0.98 lp 
7008 TEF_1 23.19 -0.81 0.53 34.36 0.96 sp 
7008 TEF_2 23.05 -0.95 0.54 33.32 0.95 sp 
7329 UBE2I_2 24.52 0.52 0.51 39.22 0.98 lp 
7329 UBE2I_2 26.53 2.53 0.19 274.01 0.75 lp, ar 
7409 VAV1_1 25.13 1.13 0.52 41.71 0.97 lp 
7409 VAV1_2 25.39 1.39 0.64 44.22 0.96 lp 
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Table 9. Interaction Dynamics within the Circadian PPI Network.  
No. Gene ID h A Gene ID h B Sym. h A Sym. h B FDR PPI  Time PPI CT 
1 406 9575 ARNTL CLOCK 0.00000 22.6 
2 406 4862 ARNTL NPAS2 0.00000 23.5 
3 406 1407 ARNTL CRY1 0.00000 21.2 
4 406 1408 ARNTL CRY2 0.00000 22.5 
5 406 1460 ARNTL CSNK2B 0.00000 22.5 
6 406 8553 ARNTL BHLHE40 0.00000 21.5 
7 406 11091 ARNTL WDR5 0.00000 22.5 
8 406 6097 ARNTL RORC 0.00000 21.1 
9 406 1454 ARNTL CSNK1E 0.00000 22.1 
10 1407 5528 CRY1 PPP2R5D 0.00000 19.8 
11 1407 5529 CRY1 PPP2R5E 0.00000 19.4 
12 1407 9575 CRY1 CLOCK 0.00000 20.7 
13 1407 4862 CRY1 NPAS2 0.00000 22.1 
14 1407 79365 CRY1 BHLHE41 0.00000 19.6 
15 1407 5519 CRY1 PPP2R1B 0.00000 20.5 
16 1407 5187 CRY1 PER1 0.00000 18.6 
17 1407 1460 CRY1 CSNK2B 0.00000 19.9 
18 1407 1454 CRY1 CSNK1E 0.00000 19.6 
19 1407 9975 CRY1 NR1D2 0.00000 16.7 
20 1407 8553 CRY1 BHLHE40 0.00000 18.6 
21 1407 8864 CRY1 PER2 0.00000 17.1 
22 1408 9575 CRY2 CLOCK 0.00000 0 
23 1408 4862 CRY2 NPAS2 0.00000 1.6 
24 1408 8864 CRY2 PER2 0.00000 13.5 
25 1453 8864 CSNK1D PER2 0.00000 14 
26 1454 5529 CSNK1E PPP2R5E 0.00000 13.3 
27 1454 9575 CSNK1E CLOCK 0.00000 22.4 
28 1454 5187 CSNK1E PER1 0.00000 12.4 
29 1454 8864 CSNK1E PER2 0.00000 14.2 
30 1454 6097 CSNK1E RORC 0.00000 18.5 
31 1454 9975 CSNK1E NR1D2 0.00000 10.1 
32 1459 9975 CSNK2A2 NR1D2 0.00000 9.1 
33 1460 9575 CSNK2B CLOCK 0.00000 23.5 
34 1460 4862 CSNK2B NPAS2 0.00000 1.1 
35 1460 8864 CSNK2B PER2 0.00000 13.9 
36 1628 9575 DBP CLOCK 0.00000 9.9 
37 4841 4841 NONO NONO 0.00000 4.1 
38 4862 9575 NPAS2 CLOCK 0.00000 0.3 
39 4862 6097 NPAS2 RORC 0.00000 22.2 
40 5187 8553 PER1 BHLHE40 0.00000 11.9 
41 5499 9575 PPP1CA CLOCK 0.00000 23.5 
42 5499 6097 PPP1CA RORC 0.00000 18.9 
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43 5500 9575 PPP1CB CLOCK 0.00000 22.8 
44 5500 6097 PPP1CB RORC 0.00000 18.6 
45 5501 9575 PPP1CC CLOCK 0.00000 23.6 
46 5501 6097 PPP1CC RORC 0.00000 18.4 
47 5501 23291 PPP1CC FBXW11 0.00000 6.9 
48 5515 6097 PPP2CA RORC 0.00000 18.4 
49 5518 6097 PPP2R1A RORC 0.00000 19.5 
50 5519 5528 PPP2R1B PPP2R5D 0.00000 3.5 
51 5519 9575 PPP2R1B CLOCK 0.00000 0.1 
52 5519 6097 PPP2R1B RORC 0.00000 19.7 
53 5519 5519 PPP2R1B PPP2R1B 0.00000 2.7 
54 5519 23291 PPP2R1B FBXW11 0.00000 3.2 
55 5528 6097 PPP2R5D RORC 0.00000 18.6 
56 5528 9575 PPP2R5D CLOCK 0.00000 23.3 
57 5529 6097 PPP2R5E RORC 0.00000 18 
58 5529 9575 PPP2R5E CLOCK 0.00000 22.8 
59 5529 8553 PPP2R5E BHLHE40 0.00000 12.1 
60 5529 5529 PPP2R5E PPP2R5E 0.00000 11.7 
61 6096 9575 RORB CLOCK 0.00000 23 
62 6096 6097 RORB RORC 0.00000 18.9 
63 6097 79365 RORC BHLHE41 0.00000 18.4 
64 6097 56938 RORC ARNTL2 0.00000 18.6 
65 6097 85457 RORC KIAA1737 0.00000 18.3 
66 6097 79176 RORC FBXL15 0.00000 18.7 
67 6097 8864 RORC PER2 0.00000 15.9 
68 6097 8553 RORC BHLHE40 0.00000 16.9 
69 6097 9975 RORC NR1D2 0.00000 13.5 
70 6097 9575 RORC CLOCK 0.00000 20.3 
71 8553 9975 BHLHE40 NR1D2 0.00000 10.4 
72 8553 8864 BHLHE40 PER2 0.00000 13.6 
73 8864 9575 PER2 CLOCK 0.00000 15.8 
74 8864 79365 PER2 BHLHE41 0.00000 14.1 
75 9575 79365 CLOCK BHLHE41 0.00000 22.4 
76 9575 85457 CLOCK KIAA1737 0.00000 21.7 
77 9575 9975 CLOCK NR1D2 0.00000 8.5 
78 5187 5187 PER1 PER1 0.00000 11.6 
79 5187 8864 PER1 PER2 0.00000 13.3 
80 8864 8864 PER2 PER2 0.00000 14 
81 4841 5187 NONO PER1 0.00000 11.3 
82 5187 11091 PER1 WDR5 0.00000 11.2 
83 4841 8864 NONO PER2 0.00000 14 
84 8864 11091 PER2 WDR5 0.00000 13.9 
85 5499 8864 PPP1CA PER2 0.00000 13.9 
86 2932 8864 GSK3B PER2 0.00000 13.7 
87 1457 8864 CSNK2A1 PER2 0.00000 13.5 
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88 8864 8945 PER2 BTRC 0.00000 13.8 
89 4783 8864 NFIL3 PER2 0.00000 16.7 
90 5578 8864 PRKCA PER2 0.00000 13.6 
91 1407 5536 CRY1 PPP5C 0.00000 19.9 
92 1407 26224 CRY1 FBXL3 0.00000 20.1 
93 406 79365 ARNTL BHLHE41 0.00000 22.1 
94 406 1457 ARNTL CSNK2A1 0.00000 22.8 
95 2146 9575 EZH2 CLOCK 0.00000 0.4 
96 406 2146 ARNTL EZH2 0.00000 22.8 
97 8864 23291 PER2 FBXW11 0.00000 13.9 
98 2932 9572 GSK3B NR1D1 0.00000 6.3 
99 8864 9572 PER2 NR1D1 0.00000 10.8 
100 1407 1453 CRY1 CSNK1D 0.00000 20.2 
101 406 8863 ARNTL PER3 0.00000 20 
102 1407 8863 CRY1 PER3 0.00000 16.7 
103 1407 8914 CRY1 TIMELESS 0.00000 19.8 
104 1408 8863 CRY2 PER3 0.00000 11.4 
105 1453 8863 CSNK1D PER3 0.00000 11.5 
106 1454 8863 CSNK1E PER3 0.00000 12.2 
107 4783 4783 NFIL3 NFIL3 0.00000 22.9 
108 5187 8863 PER1 PER3 0.00000 11.7 
109 5515 5529 PPP2CA PPP2R5E 0.00000 10.8 
110 8863 9575 PER3 CLOCK 0.00000 12.9 
111 8863 8864 PER3 PER2 0.00000 13 
112 8864 8914 PER2 TIMELESS 0.00000 14.4 
113 9572 9572 NR1D1 NR1D1 0.00000 6.7 
114 9575 56938 CLOCK ARNTL2 0.00000 22.6 
115 190 6095 NR0B1 RORA 0.00000 21.1 
116 196 406 AHR ARNTL 0.00000 22.8 
117 406 2033 ARNTL EP300 0.00000 22.9 
118 406 2034 ARNTL EPAS1 0.00000 22.5 
119 406 3091 ARNTL HIF1A 0.00000 22.4 
120 406 3320 ARNTL HSP90AA1 0.00000 21.7 
121 406 8850 ARNTL KAT2B 0.00000 22.6 
122 406 3131 ARNTL HLF 0.00000 22.1 
123 406 266743 ARNTL NPAS4 0.00000 22.2 
124 466 4783 ATF1 NFIL3 0.00000 23.2 
125 1050 1628 CEBPA DBP 0.00000 9.9 
126 1054 4783 CEBPG NFIL3 0.00000 22.5 
127 1108 6097 CHD4 RORC 0.00000 19.9 
128 1387 4862 CREBBP NPAS2 0.00000 1.8 
129 1390 4783 CREM NFIL3 0.00000 22.9 
130 1628 2033 DBP EP300 0.00000 9.8 
131 1628 3131 DBP HLF 0.00000 10.2 
132 1628 7008 DBP TEF 0.00000 10.3 
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133 1649 4783 DDIT3 NFIL3 0.00000 22.5 
134 1788 2146 DNMT3A EZH2 0.00000 5 
135 1789 2146 DNMT3B EZH2 0.00000 23.6 
136 1810 4783 DR1 NFIL3 0.00000 22.6 
137 2033 9575 EP300 CLOCK 0.00000 0.6 
138 2033 4862 EP300 NPAS2 0.00000 1.6 
139 3091 5187 HIF1A PER1 0.00000 11.4 
140 3320 4862 HSP90AA1 NPAS2 0.00000 23.5 
141 4783 10538 NFIL3 BATF 0.00000 22.7 
142 4783 90993 NFIL3 CREB3L1 0.00000 23 
143 4783 10488 NFIL3 CREB3 0.00000 22.6 
144 4830 6095 NME1 RORA 0.00000 21.3 
145 4831 6095 NME2 RORA 0.00000 21.8 
146 4841 5829 NONO PXN 0.00000 4.4 
147 4841 55269 NONO PSPC1 0.00000 5.8 
148 4862 5914 NPAS2 RARA 0.00000 0.6 
149 4862 6256 NPAS2 RXRA 0.00000 1.6 
150 4862 8202 NPAS2 NCOA3 0.00000 1.3 
151 4862 8850 NPAS2 KAT2B 0.00000 1.6 
152 6095 55885 RORA LMO3 0.00000 20.8 
153 6667 8863 SP1 PER3 0.00000 11.3 
154 8450 11091 CUL4B WDR5 0.00000 7.9 
155 8850 9575 KAT2B CLOCK 0.00000 0.3 
156 9572 9611 NR1D1 NCOR1 0.00000 6.4 
157 9572 9612 NR1D1 NCOR2 0.00000 6.6 
158 9572 10002 NR1D1 NR2E3 0.00000 6.9 
159 9611 9975 NCOR1 NR1D2 0.00000 9.1 
160 9975 57727 NR1D2 NCOA5 0.00000 9.7 
161 196 3320 AHR HSP90AA1 0.00000 20.7 
162 207 3320 AKT1 HSP90AA1 0.00000 18.5 
163 367 3320 AR HSP90AA1 0.00000 18.4 
164 466 1390 ATF1 CREM 0.00000 0.1 
165 1054 7008 CEBPG TEF 0.00000 11.7 
166 1054 10488 CEBPG CREB3 0.00000 13.2 
167 1108 3065 CHD4 HDAC1 0.00000 0.6 
168 1111 3320 CHEK1 HSP90AA1 0.00000 18.2 
169 1111 8451 CHEK1 CUL4A 0.00000 11.3 
170 1387 1390 CREBBP CREM 0.00000 2.3 
171 1390 5566 CREM PRKACA 0.00000 0.5 
172 1390 2932 CREM GSK3B 0.00000 1.1 
173 1390 1459 CREM CSNK2A2 0.00000 1.7 
174 1390 1390 CREM CREM 0.00000 23.2 
175 1457 6667 CSNK2A1 SP1 0.00000 4.6 
176 1457 3091 CSNK2A1 HIF1A 0.00000 7.4 
177 1649 7008 DDIT3 TEF 0.00000 11.9 
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178 1786 1789 DNMT1 DNMT3B 0.00000 23.8 
179 1788 3065 DNMT3A HDAC1 0.00000 4.7 
180 1788 7329 DNMT3A UBE2I 0.00000 4.8 
181 1788 1789 DNMT3A DNMT3B 0.00000 0.3 
182 1789 3065 DNMT3B HDAC1 0.00000 22.7 
183 1789 3066 DNMT3B HDAC2 0.00000 23.1 
184 1789 7329 DNMT3B UBE2I 0.00000 23.5 
185 3065 5519 HDAC1 PPP2R1B 0.00000 2.8 
186 3091 3320 HIF1A HSP90AA1 0.00000 18.7 
187 3091 8850 HIF1A KAT2B 0.00000 8.8 
188 3131 7008 HLF TEF 0.00000 11.6 
189 3320 4609 HSP90AA1 MYC 0.00000 18.7 
190 3320 3320 HSP90AA1 HSP90AA1 0.00000 19.1 
191 3320 4842 HSP90AA1 NOS1 0.00000 18.3 
192 3320 4654 HSP90AA1 MYOD1 0.00000 18.6 
193 3320 5536 HSP90AA1 PPP5C 0.00000 19.5 
194 5430 8850 POLR2A KAT2B 0.00000 7.1 
195 6667 9611 SP1 NCOR1 0.00000 2.9 
196 6667 6667 SP1 SP1 0.00000 2.8 
197 7008 10538 TEF BATF 0.00000 11.7 
198 7008 7008 TEF TEF 0.00000 11.4 
199 8450 8451 CUL4B CUL4A 0.00000 9.4 
200 8648 8850 NCOA1 KAT2B 0.00000 6.3 
201 8850 8850 KAT2B KAT2B 0.00000 8.4 
202 10499 10499 NCOA2 NCOA2 0.00000 5.7 
203 5529 79365 PPP2R5E BHLHE41 0.00000 13 
204 4830 4830 NME1 NME1 0.00000 20.3 
205 6095 6095 RORA RORA 0.00000 21.9 
206 4163 5518 MCC PPP2R1A 0.00000 2.6 
207 1459 3065 CSNK2A2 HDAC1 0.00000 5.5 
208 3054 29915 HCFC1 HCFC2 0.00000 4.3 
209 5929 29915 RBBP5 HCFC2 0.00001 3.2 
210 1453 4163 CSNK1D MCC 0.00001 2.2 
211 1459 3320 CSNK2A2 HSP90AA1 0.00001 20.7 
212 3320 6774 HSP90AA1 STAT3 0.00001 22.3 
213 466 1457 ATF1 CSNK2A1 0.00002 5.4 
214 2033 8850 EP300 KAT2B 0.00002 7 
215 4654 8850 MYOD1 KAT2B 0.00003 10 
216 5500 8553 PPP1CB BHLHE40 0.00003 12.5 
217 1408 5187 CRY2 PER1 0.00003 10.9 
218 6667 9070 SP1 ASH2L 0.00003 3.6 
219 1408 4783 CRY2 NFIL3 0.00003 23.3 
220 546 1822 ATRX ATN1 0.00003 6.5 
221 466 1459 ATF1 CSNK2A2 0.00003 4.7 
222 8553 79365 BHLHE40 BHLHE41 0.00003 12.9 
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223 5469 6095 MED1 RORA 0.00003 22.4 
224 4163 11091 MCC WDR5 0.00003 2.5 
225 196 10499 AHR NCOA2 0.00003 5.4 
226 1457 1457 CSNK2A1 CSNK2A1 0.00003 6.5 
227 8648 10499 NCOA1 NCOA2 0.00003 5.3 
228 11091 29915 WDR5 HCFC2 0.00003 4.9 
229 1387 1459 CREBBP CSNK2A2 0.00003 4.1 
230 1054 3131 CEBPG HLF 0.00003 12.7 
231 1387 8850 CREBBP KAT2B 0.00003 4.7 
232 5501 8553 PPP1CC BHLHE40 0.00003 11.6 
233 1387 1457 CREBBP CSNK2A1 0.00003 4.3 
234 196 6667 AHR SP1 0.00004 3.8 
235 5515 8553 PPP2CA BHLHE40 0.00004 11.9 
236 3054 5929 HCFC1 RBBP5 0.00004 3.5 
237 5371 9611 PML NCOR1 0.00004 2.6 
238 5371 6667 PML SP1 0.00005 2.5 
239 5705 6667 PSMC5 SP1 0.00005 2.5 
240 3054 5501 HCFC1 PPP1CC 0.00005 5.3 
241 1387 10499 CREBBP NCOA2 0.00005 4.4 
242 546 2146 ATRX EZH2 0.00005 6.4 
243 1460 5187 CSNK2B PER1 0.00005 11.2 
244 9611 9611 NCOR1 NCOR1 0.00005 3.1 
245 3065 6667 HDAC1 SP1 0.00005 3 
246 6256 10499 RXRA NCOA2 0.00005 6.2 
247 8553 85457 BHLHE40 KIAA1737 0.00005 13.6 
248 5187 8914 PER1 TIMELESS 0.00005 12.4 
249 9070 29915 ASH2L HCFC2 0.00005 4.4 
250 1786 1788 DNMT1 DNMT3A 0.00005 3.8 
251 1390 1457 CREM CSNK2A1 0.00005 1.9 
252 3054 6667 HCFC1 SP1 0.00005 3.7 
253 4841 5430 NONO POLR2A 0.00005 5.6 
254 8648 9611 NCOA1 NCOR1 0.00005 4.1 
255 4297 29915 MLL HCFC2 0.00005 4.2 
256 1390 90993 CREM CREB3L1 0.00006 23.4 
257 3091 10499 HIF1A NCOA2 0.00006 6.5 
258 1457 5515 CSNK2A1 PPP2CA 0.00006 7.3 
259 1387 5371 CREBBP PML 0.00006 3.3 
260 5929 9070 RBBP5 ASH2L 0.00006 3.3 
261 4297 9070 MLL ASH2L 0.00006 4.2 
262 1387 8648 CREBBP NCOA1 0.00006 4 
263 1387 3065 CREBBP HDAC1 0.00008 3.7 
264 4221 5929 MEN1 RBBP5 0.00008 1.9 
265 3131 3131 HLF HLF 0.00008 12.2 
266 4831 5518 NME2 PPP2R1A 0.00008 3.5 
267 2782 4163 GNB1 MCC 0.00009 1.1 
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268 1387 1387 CREBBP CREBBP 0.00009 3.7 
269 466 1387 ATF1 CREBBP 0.00009 3.6 
270 4862 8553 NPAS2 BHLHE40 0.00009 1.1 
271 8945 23291 BTRC FBXW11 0.00009 5 
272 5187 9737 PER1 GPRASP1 0.00009 10.7 
273 4163 5516 MCC PPP2CB 0.00009 2.8 
274 1387 6774 CREBBP STAT3 0.00010 3.5 
275 1454 8553 CSNK1E BHLHE40 0.00010 13 
276 4163 5111 MCC PCNA 0.00010 1.7 
277 1108 3066 CHD4 HDAC2 0.00010 0.9 
278 1457 3065 CSNK2A1 HDAC1 0.00010 6.7 
279 1387 4297 CREBBP MLL 0.00010 3.9 
280 5829 5829 PXN PXN 0.00010 4.5 
281 4841 7414 NONO VCL 0.00011 1 
282 3054 9070 HCFC1 ASH2L 0.00011 4.3 
283 1454 4163 CSNK1E MCC 0.00011 1.3 
284 8451 11091 CUL4A WDR5 0.00011 9.2 
285 1457 8553 CSNK2A1 BHLHE40 0.00011 10.8 
286 2146 23512 EZH2 SUZ12 0.00011 5.4 
287 1387 6688 CREBBP SPI1 0.00011 3.6 
288 2932 5566 GSK3B PRKACA 0.00011 3.2 
289 3066 6774 HDAC2 STAT3 0.00012 3 
290 2932 23291 GSK3B FBXW11 0.00013 3.8 
291 5929 11091 RBBP5 WDR5 0.00013 3.1 
292 2146 5371 EZH2 PML 0.00014 4 
293 3054 4297 HCFC1 MLL 0.00014 4.1 
294 1454 6095 CSNK1E RORA 0.00014 20.2 
295 5566 23291 PRKACA FBXW11 0.00014 3.4 
296 1387 5430 CREBBP POLR2A 0.00014 4.3 
297 466 5566 ATF1 PRKACA 0.00015 2.9 
298 1390 6688 CREM SPI1 0.00015 23.6 
299 2033 10499 EP300 NCOA2 0.00016 5.7 
300 4297 5929 MLL RBBP5 0.00016 3.5 
301 8553 8553 BHLHE40 BHLHE40 0.00016 12.3 
302 8648 8648 NCOA1 NCOA1 0.00017 4.7 
303 2932 5829 GSK3B PXN 0.00017 4 
304 6421 55269 SFPQ PSPC1 0.00017 5.8 
305 3131 10538 HLF BATF 0.00017 13 
306 196 8648 AHR NCOA1 0.00017 4.8 
307 1408 5529 CRY2 PPP2R5E 0.00019 10.3 
308 546 3065 ATRX HDAC1 0.00020 7.6 
309 10488 10488 CREB3 CREB3 0.00020 12.4 
310 3054 3054 HCFC1 HCFC1 0.00020 4.2 
311 6774 8648 STAT3 NCOA1 0.00021 3.9 
312 4221 29915 MEN1 HCFC2 0.00021 3.2 
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313 1457 1460 CSNK2A1 CSNK2B 0.00026 6.3 
314 5705 6095 PSMC5 RORA 0.00026 22.9 
315 1387 2033 CREBBP EP300 0.00027 4.2 
316 6256 8648 RXRA NCOA1 0.00029 5.8 
317 51514 83743 DTL GRWD1 0.00030 16 
318 3054 3320 HCFC1 HSP90AA1 0.00031 22.3 
319 367 8850 AR KAT2B 0.00032 11.6 
320 5371 23512 PML SUZ12 0.00032 3.4 
321 5528 8553 PPP2R5D BHLHE40 0.00032 12 
322 5515 5829 PPP2CA PXN 0.00034 5.5 
323 207 1111 AKT1 CHEK1 0.00034 11.2 
324 4841 8553 NONO BHLHE40 0.00035 11.9 
325 3054 3066 HCFC1 HDAC2 0.00036 3.7 
326 2146 5252 EZH2 PHF1 0.00038 5.8 
327 6256 6667 RXRA SP1 0.00039 5 
328 5529 23291 PPP2R5E FBXW11 0.00039 9.7 
329 1050 1387 CEBPA CREBBP 0.00039 4.3 
330 2146 8726 EZH2 EED 0.00039 6.2 
331 4783 8553 NFIL3 BHLHE40 0.00040 20.9 
332 1387 3091 CREBBP HIF1A 0.00041 4.1 
333 1390 5578 CREM PRKCA 0.00042 1.4 
334 6256 6256 RXRA RXRA 0.00043 7 
335 5111 5501 PCNA PPP1CC 0.00045 10.5 
336 3065 7329 HDAC1 UBE2I 0.00046 5.4 
337 3066 5371 HDAC2 PML 0.00047 2.2 
338 3054 11091 HCFC1 WDR5 0.00047 4.5 
339 1108 2033 CHD4 EP300 0.00047 2.7 
340 3054 3065 HCFC1 HDAC1 0.00050 4.3 
341 23291 23291 FBXW11 FBXW11 0.00052 4.6 
342 1457 3320 CSNK2A1 HSP90AA1 0.00053 19.8 
343 4221 4297 MEN1 MLL 0.00053 3.5 
344 2932 5499 GSK3B PPP1CA 0.00055 3.7 
345 5371 6774 PML STAT3 0.00058 2.9 
346 1111 1457 CHEK1 CSNK2A1 0.00058 8.5 
347 6774 6774 STAT3 STAT3 0.00059 3.3 
348 9070 11091 ASH2L WDR5 0.00062 4.9 
349 1457 6688 CSNK2A1 SPI1 0.00065 5.8 
350 2770 2770 GNAI1 GNAI1 0.00065 10.9 
351 2033 6667 EP300 SP1 0.00066 4.3 
352 3054 4221 HCFC1 MEN1 0.00069 3.5 
353 2033 8648 EP300 NCOA1 0.00071 5.1 
354 1408 8553 CRY2 BHLHE40 0.00071 11.3 
355 5929 8450 RBBP5 CUL4B 0.00072 5.7 
356 2932 2932 GSK3B GSK3B 0.00072 3.5 
357 1453 5187 CSNK1D PER1 0.00075 10.8 
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358 3065 6774 HDAC1 STAT3 0.00075 3.3 
359 6095 79365 RORA BHLHE41 0.00079 19.7 
360 1387 4654 CREBBP MYOD1 0.00079 3.7 
361 2033 7329 EP300 UBE2I 0.00080 5.4 
362 7414 7414 VCL VCL 0.00080 0.4 
363 5499 5529 PPP1CA PPP2R5E 0.00080 10.2 
364 1408 2146 CRY2 EZH2 0.00085 7.6 
365 1786 2146 DNMT1 EZH2 0.00086 4 
366 3091 8648 HIF1A NCOA1 0.00087 5.8 
367 2146 8553 EZH2 BHLHE40 0.00088 10.6 
368 2146 23649 EZH2 POLA2 0.00088 5.2 
369 3065 4297 HDAC1 MLL 0.00088 4.2 
370 196 2033 AHR EP300 0.00088 5.3 
371 1387 8202 CREBBP NCOA3 0.00088 3.8 
372 1649 3131 DDIT3 HLF 0.00089 13.1 
373 4297 11091 MLL WDR5 0.00091 4.3 
374 2033 5430 EP300 POLR2A 0.00091 5.8 
375 3054 10488 HCFC1 CREB3 0.00091 5.2 
376 3065 5518 HDAC1 PPP2R1A 0.00092 3.9 
377 8202 8850 NCOA3 KAT2B 0.00094 6.6 
378 5518 5528 PPP2R1A PPP2R5D 0.00096 4.6 
379 6096 8553 RORB BHLHE40 0.00098 12.7 
380 5515 5518 PPP2CA PPP2R1A 0.00098 5.1 
381 4297 4297 MLL MLL 0.00100 4.1 
382 2033 6774 EP300 STAT3 0.00102 4.2 
383 5829 6421 PXN SFPQ 0.00110 4.9 
384 207 2146 AKT1 EZH2 0.00111 7.2 
385 8553 79176 BHLHE40 FBXL15 0.00113 13.8 
386 1459 3066 CSNK2A2 HDAC2 0.00114 4.3 
387 9070 9070 ASH2L ASH2L 0.00114 4.4 
388 1460 5519 CSNK2B PPP2R1B 0.00114 3.3 
389 5519 5529 PPP2R1B PPP2R5E 0.00120 5.6 
390 4221 9070 MEN1 ASH2L 0.00122 3.3 
391 1460 2146 CSNK2B EZH2 0.00127 5.8 
392 3066 6667 HDAC2 SP1 0.00128 2.6 
393 1459 1460 CSNK2A2 CSNK2B 0.00142 5.5 
394 5829 7414 PXN VCL 0.00143 2.4 
395 466 466 ATF1 ATF1 0.00167 3.2 
396 5578 5578 PRKCA PRKCA 0.00171 7.5 
397 5499 8553 PPP1CA BHLHE40 0.00173 11.9 
398 5371 5371 PML PML 0.00173 2.2 
399 6095 10499 RORA NCOA2 0.00175 3.4 
400 2033 5371 EP300 PML 0.00179 4 
401 6096 8648 RORB NCOA1 0.00181 3.9 
402 367 3091 AR HIF1A 0.00189 14.2 
Appendix              - 30 - 
 
403 1459 8553 CSNK2A2 BHLHE40 0.00190 10.5 
404 1050 1050 CEBPA CEBPA 0.00192 7.4 
405 1642 8450 DDB1 CUL4B 0.00199 8 
406 8450 9410 CUL4B SNRNP40 0.00204 6.4 
407 367 1387 AR CREBBP 0.00210 3.4 
408 4842 51655 NOS1 RASD1 0.00215 15.4 
409 1050 2033 CEBPA EP300 0.00242 6.3 
410 5578 7414 PRKCA VCL 0.00250 2.8 
411 5914 8850 RARA KAT2B 0.00268 9.4 
412 1050 2932 CEBPA GSK3B 0.00276 5 
413 4841 6421 NONO SFPQ 0.00283 5 
414 207 367 AKT1 AR 0.00292 14 
415 1457 79365 CSNK2A1 BHLHE41 0.00325 8.6 
416 1786 3066 DNMT1 HDAC2 0.00335 2.8 
417 2770 51655 GNAI1 RASD1 0.00343 12.1 
418 5371 6256 PML RXRA 0.00353 4.6 
419 196 196 AHR AHR 0.00359 4.9 
420 1054 10538 CEBPG BATF 0.00362 15.9 
421 8945 8945 BTRC BTRC 0.00369 5.3 
422 367 367 AR AR 0.00371 16.1 
423 1822 11091 ATN1 WDR5 0.00372 5.8 
424 5705 6256 PSMC5 RXRA 0.00372 5.9 
425 7329 8553 UBE2I BHLHE40 0.00409 10.8 
426 207 5515 AKT1 PPP2CA 0.00412 9.7 
427 2146 3065 EZH2 HDAC1 0.00415 5.9 
428 1054 1054 CEBPG CEBPG 0.00426 14 
429 1460 5501 CSNK2B PPP1CC 0.00467 7.7 
430 190 367 NR0B1 AR 0.00509 17.5 
431 1786 1786 DNMT1 DNMT1 0.00533 3 
432 1460 8553 CSNK2B BHLHE40 0.00534 11.8 
433 1408 79365 CRY2 BHLHE41 0.00559 10.9 
434 2033 2033 EP300 EP300 0.00575 5.6 
435 5499 8726 PPP1CA EED 0.00575 6 
436 2033 3091 EP300 HIF1A 0.00620 6.6 
437 3065 5371 HDAC1 PML 0.00621 2.4 
438 5499 5515 PPP1CA PPP2CA 0.00656 7.2 
439 1822 1822 ATN1 ATN1 0.00672 5.6 
440 5914 83714 RARA NRIP2 0.00673 16.2 
441 1408 5528 CRY2 PPP2R5D 0.00712 9.1 
442 8450 51514 CUL4B DTL 0.00734 12 
443 5515 5515 PPP2CA PPP2CA 0.00742 9.1 
444 1786 3065 DNMT1 HDAC1 0.00838 3.1 
445 4830 6096 NME1 RORB 0.00911 20.9 
446 9410 9410 SNRNP40 SNRNP40 0.00920 1 
447 1454 79365 CSNK1E BHLHE41 0.00942 15.9 
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448 5518 5536 PPP2R1A PPP5C 0.00966 4.2 
449 367 5469 AR MED1 0.00982 18.3 
450 4654 79365 MYOD1 BHLHE41 0.00988 15.1 
451 1460 5529 CSNK2B PPP2R5E 0.00989 10.3 
452 1408 26224 CRY2 FBXL3 0.00990 7.3 
453 5518 5529 PPP2R1A PPP2R5E 0.00994 6.9 
454 4654 6256 MYOD1 RXRA 0.01024 8.5 
455 1387 3131 CREBBP HLF 0.01027 5 
456 1454 5501 CSNK1E PPP1CC 0.01031 12 
457 3065 3091 HDAC1 HIF1A 0.01076 9.9 
458 1408 5519 CRY2 PPP2R1B 0.01086 5.8 
459 4221 11091 MEN1 WDR5 0.01102 3.1 
460 367 3065 AR HDAC1 0.01115 15.8 
461 4654 6095 MYOD1 RORA 0.01243 19.9 
462 1460 2932 CSNK2B GSK3B 0.01354 4 
463 6256 8202 RXRA NCOA3 0.01377 5.8 
464 1459 79365 CSNK2A2 BHLHE41 0.01460 6.9 
465 9410 11091 SNRNP40 WDR5 0.01498 3 
466 8726 8726 EED EED 0.01575 7.5 
467 2146 3066 EZH2 HDAC2 0.01635 4.6 
468 1460 5518 CSNK2B PPP2R1A 0.01638 4.3 
469 5469 5469 MED1 MED1 0.01805 23.2 
470 11091 51514 WDR5 DTL 0.01862 14.1 
471 4654 6774 MYOD1 STAT3 0.01936 3.4 
472 5516 79365 PPP2CB BHLHE41 0.01942 12.5 
473 5519 79365 PPP2R1B BHLHE41 0.01960 2.3 
474 2033 8202 EP300 NCOA3 0.01978 5 
475 1642 5929 DDB1 RBBP5 0.01981 3.1 
476 1786 5111 DNMT1 PCNA 0.01990 2.8 
477 2033 6095 EP300 RORA 0.02050 2.6 
478 1457 3066 CSNK2A1 HDAC2 0.02160 5.2 
479 1054 1649 CEBPG DDIT3 0.02164 14.7 
480 1649 10488 DDIT3 CREB3 0.02168 13.8 
481 1050 6688 CEBPA SPI1 0.02241 6.4 
482 207 2033 AKT1 EP300 0.02244 7 
483 367 10499 AR NCOA2 0.02318 7.2 
484 1050 1054 CEBPA CEBPG 0.02423 9.4 
485 2033 2034 EP300 EPAS1 0.02480 6.3 
486 51655 79365 RASD1 BHLHE41 0.02499 15.5 
487 1111 1460 CHEK1 CSNK2B 0.02517 10.1 
488 6667 9612 SP1 NCOR2 0.02527 4.1 
489 196 9612 AHR NCOR2 0.02550 5.3 
490 207 207 AKT1 AKT1 0.02572 10.3 
491 1642 8451 DDB1 CUL4A 0.02679 9.3 
492 5499 5499 PPP1CA PPP1CA 0.02796 4.4 
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493 6256 9612 RXRA NCOR2 0.02816 6.4 
494 5914 6667 RARA SP1 0.02825 1.5 
495 2782 51655 GNB1 RASD1 0.02838 16.9 
496 4842 5578 NOS1 PRKCA 0.02873 11.4 
497 9611 9612 NCOR1 NCOR2 0.02882 4.4 
498 5518 8553 PPP2R1A BHLHE40 0.02900 10.6 
499 4831 5515 NME2 PPP2CA 0.02929 9.4 
500 2033 5111 EP300 PCNA 0.02989 6.1 
501 1454 1454 CSNK1E CSNK1E 0.03016 16.6 
502 5929 8451 RBBP5 CUL4A 0.03082 5.8 
503 1408 2932 CRY2 GSK3B 0.03279 6.3 
504 5914 8648 RARA NCOA1 0.03287 4.3 
505 466 6688 ATF1 SPI1 0.03346 3 
506 207 2932 AKT1 GSK3B 0.03423 5.2 
507 8450 83743 CUL4B GRWD1 0.03752 10.3 
508 79365 79365 BHLHE41 BHLHE41 0.03763 15.2 
509 5469 6256 MED1 RXRA 0.03801 5.3 
510 1642 51514 DDB1 DTL 0.03820 14.1 
511 5469 5914 MED1 RARA 0.03884 21.1 
512 1050 10538 CEBPA BATF 0.03919 7.5 
513 2782 4831 GNB1 NME2 0.03978 18.1 
514 2033 4654 EP300 MYOD1 0.03981 6.8 
515 1457 1649 CSNK2A1 DDIT3 0.04126 8.1 
516 8553 9575 BHLHE40 CLOCK 0.04525 19.8 
517 5515 5536 PPP2CA PPP5C 0.04570 7.6 
518 5371 9612 PML NCOR2 0.04665 3.7 
519 1460 5515 CSNK2B PPP2CA 0.04779 7.8 
520 4841 6688 NONO SPI1 0.05013 3.4 
521 1408 5536 CRY2 PPP5C 0.05065 8.5 
522 2932 8553 GSK3B BHLHE40 0.05720 10.3 
523 367 4841 AR NONO 0.06169 16.1 
524 5111 5111 PCNA PCNA 0.06488 15.9 
525 5914 10002 RARA NR2E3 0.06528 17.7 
526 367 6774 AR STAT3 0.06574 2.5 
527 2932 79365 GSK3B BHLHE41 0.06601 3.7 
528 5519 8553 PPP2R1B BHLHE40 0.06837 10.5 
529 2146 7409 EZH2 VAV1 0.06989 4.6 
530 466 1460 ATF1 CSNK2B 0.07002 4.3 
531 10538 10538 BATF BATF 0.07411 19.2 
532 8202 8202 NCOA3 NCOA3 0.07578 4.2 
533 5371 5914 PML RARA 0.07940 1 
534 1408 1453 CRY2 CSNK1D 0.08198 7.1 
535 4654 5578 MYOD1 PRKCA 0.08753 9.7 
536 3065 8726 HDAC1 EED 0.09452 8.1 
537 1387 4609 CREBBP MYC 0.09501 3.3 
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538 3066 9612 HDAC2 NCOR2 0.10113 4.4 
539 5914 6256 RARA RXRA 0.11084 7.3 
540 4654 6667 MYOD1 SP1 0.11097 2.7 
541 760 4841 CA2 NONO 0.11148 22.4 
542 4842 9722 NOS1 NOS1AP 0.11363 17.1 
543 1649 10538 DDIT3 BATF 0.11451 16.7 
544 6096 83714 RORB NRIP2 0.11496 16.9 
545 1642 11091 DDB1 WDR5 0.11506 6.2 
546 1108 4609 CHD4 MYC 0.12002 22.4 
547 367 55269 AR PSPC1 0.12376 8.5 
548 1111 8914 CHEK1 TIMELESS 0.12388 14.8 
549 8202 9612 NCOA3 NCOR2 0.12540 5 
550 3065 4654 HDAC1 MYOD1 0.12707 14.5 
551 1876 2146 E2F6 EZH2 0.13082 6.2 
552 1454 5528 CSNK1E PPP2R5D 0.13304 14.3 
553 1642 9410 DDB1 SNRNP40 0.13761 3 
554 4654 4654 MYOD1 MYOD1 0.14013 14.9 
555 1460 5528 CSNK2B PPP2R5D 0.14494 7.1 
556 9410 83743 SNRNP40 GRWD1 0.15728 21.7 
557 1460 5499 CSNK2B PPP1CA 0.15760 5.2 
558 6774 8553 STAT3 BHLHE40 0.17728 9.1 
559 4654 9611 MYOD1 NCOR1 0.19612 3.3 
560 3065 9612 HDAC1 NCOR2 0.20420 5.9 
561 2146 5914 EZH2 RARA 0.20932 5.5 
562 1788 4609 DNMT3A MYC 0.21010 4.6 
563 11091 79365 WDR5 BHLHE41 0.21458 12.5 
564 5914 5914 RARA RARA 0.22076 18 
565 1649 1649 DDIT3 DDIT3 0.22308 15.4 
566 1460 85457 CSNK2B KIAA1737 0.22873 15.9 
567 3066 8726 HDAC2 EED 0.23436 4.4 
568 3065 5111 HDAC1 PCNA 0.24236 15.1 
569 367 8648 AR NCOA1 0.24738 5.7 
570 4609 8850 MYC KAT2B 0.25294 11.2 
571 5578 5914 PRKCA RARA 0.26351 8.5 
572 9722 51655 NOS1AP RASD1 0.26424 18.8 
573 4831 4831 NME2 NME2 0.26884 19.5 
574 5536 5536 PPP5C PPP5C 0.27750 5.8 
575 3065 4609 HDAC1 MYC 0.32005 16.4 
576 11091 23178 WDR5 PASK 0.32149 6.3 
577 3066 3091 HDAC2 HIF1A 0.32396 5.6 
578 367 5829 AR PXN 0.32469 5.1 
579 4831 6096 NME2 RORB 0.32521 21.6 
580 3066 3066 HDAC2 HDAC2 0.33227 2.2 
581 1408 8914 CRY2 TIMELESS 0.34715 10.3 
582 1460 5500 CSNK2B PPP1CB 0.35403 7.9 
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583 367 2932 AR GSK3B 0.36136 2.2 
584 367 6667 AR SP1 0.36143 23.2 
585 1460 1460 CSNK2B CSNK2B 0.37420 6.1 
586 367 2033 AR EP300 0.38343 8.2 
587 8914 11277 TIMELESS TREX1 0.38536 23.8 
588 2034 56938 EPAS1 ARNTL2 0.39896 9.4 
589 4841 79365 NONO BHLHE41 0.41593 14.2 
590 4654 9612 MYOD1 NCOR2 0.42311 7.4 
591 3065 3066 HDAC1 HDAC2 0.42424 2.6 
592 1460 79176 CSNK2B FBXL15 0.43850 18.6 
593 5914 8202 RARA NCOA3 0.46803 3 
594 1460 79365 CSNK2B BHLHE41 0.48701 12.7 
595 90993 90993 CREB3L1 CREB3L1 0.53640 23.9 
596 1460 6096 CSNK2B RORB 0.55999 2.5 
597 2771 51655 GNAI2 RASD1 0.56085 6.2 
598 8914 54962 TIMELESS TIPIN 0.57695 0.3 
599 367 9611 AR NCOR1 0.59594 22.2 
600 5914 9612 RARA NCOR2 0.59873 5.4 
601 23291 79365 FBXW11 BHLHE41 0.61187 11.4 
602 367 7329 AR UBE2I 0.63770 9.5 
603 4609 5371 MYC PML 0.66318 23.1 
604 4609 5430 MYC POLR2A 0.70136 7.7 
605 1457 4609 CSNK2A1 MYC 0.71785 9.5 
606 1050 4609 CEBPA MYC 0.72718 11.7 
607 3066 4609 HDAC2 MYC 0.75330 19.3 
608 4609 6667 MYC SP1 0.75748 23.6 
609 1054 90993 CEBPG CREB3L1 0.75767 17.2 
610 4609 5499 MYC PPP1CA 0.76405 16.9 
611 4609 11091 MYC WDR5 0.76588 15.5 
612 367 9612 AR NCOR2 0.76665 10 
613 2932 4609 GSK3B MYC 0.79008 1.8 
614 2033 4609 EP300 MYC 0.79695 7.3 
615 1454 1460 CSNK1E CSNK2B 0.79800 14.6 
616 3065 3065 HDAC1 HDAC1 0.81467 11.7 
617 1459 4609 CSNK2A2 MYC 0.82263 6.9 
618 1454 5536 CSNK1E PPP5C 0.82865 14.3 
619 10488 90993 CREB3 CREB3L1 0.84222 13 
620 4842 5566 NOS1 PRKACA 0.90796 0 
621 11091 83743 WDR5 GRWD1 0.91140 16 
622 23178 23178 PASK PASK 0.97684 16.6 
623 4841 5111 NONO PCNA 0.99172 7.6 
624 1454 23291 CSNK1E FBXW11 0.99264 17.9 
625 367 8202 AR NCOA3 0.99928 15.1 
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Table 10. Score for RNAi Mediated Perturbation of 46 Network Components. 
Gene ID h Sym. h Degree Dyn. degree Corr. Coeff. Period Amp/damp Score 
5187 PER1 14 9 0 0 1 1 
8864 PER2  23 23 0 0 1 1 
8863 PER3  9 9 0 2 0 2 
1407 CRY1 18 18 0 3 1 4 
1408 CRY2 18 5 0 2 0 2 
4841 NONO 14 5 0 0 0 0 
11091 WDR5 20 4 0 0 0 0 
8914 TIM 7 2 0 0 0 0 
85457 CIPC 4 2 0 0 0 0 
8553 DEC1 32 7 no construct       
79365 DEC2 22 6 0 0 0 0 
9575 CLOCK 25 24 4 0 0 4 
4862 NPAS2 14 13 0 0 0 0 
406 BMAL1 21 21 4 0 0 4 
56938 BMAL2 3 2 0 0 0 0 
9572 NR1D1 6 6 0 0 0 0 
9975 NR1D2 8 8 0 1 0 1 
6095 RORA 12 5 0 0 0 0 
6096 RORB 8 2 0 0 0 0 
6097 RORC 21 21 0 0 0 0 
1628 DBP 5 5 0 0 0 0 
4783 NFIL3 12 10 0 0 0 0 
2146 EZH2 20 4 0 0 0 0 
51655 RASD1 6 0 0 1 0 1 
1453 CSNK1E 6 3 0 0 0 0 
1454 CSNK1D 19 9 0 0 0 0 
2932 GSK3B 16 3 0 1 0 1 
1457 CSNK2A1 19 4 0 3 0 3 
1459 CSNK2A2 11 3 0 2 0 2 
1460 CSNK2B 27 5 0 3 1 4 
5566 PRKACA 5 1 
    5578 PRKCA 7 1 0 0 0 0 
5499 PPP1CA 11 3 0 0 0 0 
5500 PPP1CB 4 2 0 0 0 0 
5501 PPP1CC 8 3 0 0 0 0 
5515 PPP2CA  12 2 0 0 0 0 
5516 PPP2CB  2 0 0 0 0 0 
5518 PPP2R1A 10 2 0 0 1 1 
5519 PPP2R1B 12 7 0 0 0 0 
5528 PPP2R5D 9 4 0 0 0 0 
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5529 PPP2R5E 14 8 0 0 1 1 
5536 PPP5C 7 2 0 0 0 0 
8945 BTRC 3 1 0 2 0 2 
23291 FBXW11 10 3 0 2 0 2 
26224 FBXL3 2 1 4 0 0 4 
79176 FBXL15   3 1 0 0 0 0 
Table 11. Score for Overexpression of 46 Experimental Network Components. 
Gene ID h Sym. h Degree Dyn. degree Corr. Coeff. Period Amp/damp Score 
5187 PER1 14 9 4 0 0 4 
8864 PER2  23 23 4 0 0 4 
8863 PER3  9 9 4 0 0 4 
1407 CRY1 18 18 4 0 0 4 
1408 CRY2 18 5 4 0 0 4 
4841 NONO 14 5 0 0 1 1 
11091 WDR5 20 4 0 0 1 1 
8914 TIM 7 2 4 0 0 4 
85457 CIPC 4 2 0 2 1 3 
8553 DEC1 32 7 0 2 1 3 
79365 DEC2 22 6 0 2 1 3 
9575 CLOCK 25 24 0 0 0 0 
4862 NPAS2 14 13 4 0 0 4 
406 BMAL1 21 21 0 3 0 3 
56938 BMAL2 3 2 0 0 0 0 
9572 NR1D1 6 6 4 0 0 4 
9975 NR1D2 8 8 4 0 0 4 
6095 RORA 12 5 4 0 0 4 
6096 RORB 8 2 4 0 0 4 
6097 RORC 21 21 4 0 0 4 
1628 DBP 5 5 0 0 0 0 
4783 NFIL3 12 10 0 0 0 0 
2146 EZH2 20 4 0 0 0 0 
51655 RASD1 6 0 0 0 0 0 
1453 CSNK1E 6 3 0 3 0 3 
1454 CSNK1D 19 9 0 2 0 2 
2932 GSK3B 16 3 0 2 0 2 
1457 CSNK2A1 19 4 0 3 0 3 
1459 CSNK2A2 11 3 0 2 0 2 
1460 CSNK2B 27 5 0 2 0 2 
5566 PRKACA 5 1 lethal 
 
    
5578 PRKCA 7 1 0 1 0 1 
5499 PPP1CA 11 3 0 0 0 0 
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5500 PPP1CB 4 2 0 0 0 0 
5501 PPP1CC 8 3 0 1 0 1 
5515 PPP2CA  12 2 0 2 1 3 
5516 PPP2CB  2 0 0 0 0 0 
5518 PPP2R1A 10 2 0 0 0 0 
5519 PPP2R1B 12 7 0 0 0 0 
5528 PPP2R5D 9 4 0 0 0 0 
5529 PPP2R5E 14 8 0 0 0 0 
5536 PPP5C 7 2 0 0 0 0 
8945 BTRC 3 1 0 0 0 0 
23291 FBXW11 10 3 0 0 0 0 
26224 FBXL3 2 1 0 2 0 2 
79176 FBXL15   3 1 0 3 0 3 
Table 12. Phenotypic Score for 46 Network Components.  
The knockdown and overexpression score was combined to the phenotypic score. 
Gene ID h Sym. h Degree Dyn. degree Phenotypic score 
5187 PER1 14 9 5 
8864 PER2  23 23 5 
8863 PER3  9 9 6 
1407 CRY1 18 18 8 
1408 CRY2 18 5 6 
4841 NONO 14 5 1 
11091 WDR5 20 4 1 
8914 TIM 7 2 4 
85457 CIPC 4 2 3 
8553 DEC1 32 7   
79365 DEC2 22 6 3 
9575 CLOCK 25 24 4 
4862 NPAS2 14 13 4 
406 BMAL1 21 21 7 
56938 BMAL2 3 2 0 
9572 NR1D1 6 6 4 
9975 NR1D2 8 8 5 
6095 RORA 12 5 4 
6096 RORB 8 2 4 
6097 RORC 21 21 4 
1628 DBP 5 5 0 
4783 NFIL3 12 10 0 
2146 EZH2 20 4 0 
51655 RASD1 6 0 1 
1453 CSNK1E 6 3 3 
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1454 CSNK1D 19 9 2 
2932 GSK3B 16 3 3 
1457 CSNK2A1 19 4 6 
1459 CSNK2A2 11 3 4 
1460 CSNK2B 27 5 6 
5566 PRKACA 5 1   
5578 PRKCA 7 1 1 
5499 PPP1CA 11 3 0 
5500 PPP1CB 4 2 0 
5501 PPP1CC 8 3 1 
5515 PPP2CA  12 2 3 
5516 PPP2CB  2 0 0 
5518 PPP2R1A 10 2 1 
5519 PPP2R1B 12 7 0 
5528 PPP2R5D 9 4 0 
5529 PPP2R5E 14 8 1 
5536 PPP5C 7 2 0 
8945 BTRC 3 1 2 
23291 FBXW11 10 3 2 
26224 FBXL3 2 1 6 
79176 FBXL15   3 1 3 
Table 13. Process Network Underlying the Dynamic Circadian PPI Network. 
Sym. h A Sym. h B Time PPI CT GO A GO B 
ARNTL CLOCK 22.6 circadian rhythm circadian rhythm 
ARNTL NPAS2 23.5 circadian rhythm circadian rhythm 
ARNTL CRY1 21.2 circadian rhythm circadian rhythm 
ARNTL CRY2 22.5 circadian rhythm circadian rhythm 
ARNTL BHLHE40 21.5 circadian rhythm circadian rhythm 
CRY1 CLOCK 20.7 circadian rhythm circadian rhythm 
CRY1 NPAS2 22.1 circadian rhythm circadian rhythm 
CRY1 PER1 18.6 circadian rhythm circadian rhythm 
CRY1 BHLHE40 18.6 circadian rhythm circadian rhythm 
CRY1 PER2 17.1 circadian rhythm circadian rhythm 
CRY2 CLOCK 0 circadian rhythm circadian rhythm 
CRY2 NPAS2 1.6 circadian rhythm circadian rhythm 
CRY2 PER1 10.9 circadian rhythm circadian rhythm 
CRY2 BHLHE40 11.3 circadian rhythm circadian rhythm 
CRY2 PER2 13.5 circadian rhythm circadian rhythm 
NPAS2 CLOCK 0.3 circadian rhythm circadian rhythm 
NPAS2 BHLHE40 1.1 circadian rhythm circadian rhythm 
PER1 BHLHE40 11.9 circadian rhythm circadian rhythm 
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BHLHE40 CLOCK 19.8 circadian rhythm circadian rhythm 
BHLHE40 PER2 13.6 circadian rhythm circadian rhythm 
PER2 CLOCK 15.8 circadian rhythm circadian rhythm 
PER1 PER2 13.3 circadian rhythm circadian rhythm 
PER2 NR1D1 10.8 circadian rhythm circadian rhythm 
CRY1 TIMELESS 19.8 circadian rhythm circadian rhythm 
CRY2 TIMELESS 10.3 circadian rhythm circadian rhythm 
PER1 TIMELESS 12.4 circadian rhythm circadian rhythm 
PER2 TIMELESS 14.4 circadian rhythm circadian rhythm 
CLOCK ARNTL2 22.6 circadian rhythm circadian rhythm 
CRY2 EZH2 7.6 circadian rhythm chromatin modification 
ARNTL EZH2 22.8 circadian rhythm chromatin modification 
ARNTL EP300 22.9 circadian rhythm chromatin modification 
ARNTL KAT2B 22.6 circadian rhythm chromatin modification 
NPAS2 KAT2B 1.6 circadian rhythm chromatin modification 
NR1D1 NCOR1 6.4 circadian rhythm chromatin modification 
EZH2 BHLHE40 10.6 chromatin modification circadian rhythm 
EZH2 CLOCK 0.4 chromatin modification circadian rhythm 
CREBBP NPAS2 1.8 chromatin modification circadian rhythm 
EP300 CLOCK 0.6 chromatin modification circadian rhythm 
EP300 NPAS2 1.6 chromatin modification circadian rhythm 
KAT2B CLOCK 0.3 chromatin modification circadian rhythm 
ARNTL CRY1 21.2 circadian rhythm DNA repair 
ARNTL CRY2 22.5 circadian rhythm DNA repair 
ARNTL CSNK1E 22.1 circadian rhythm DNA repair 
CRY1 CSNK1E 19.6 circadian rhythm DNA repair 
CRY1 CSNK1D 20.2 circadian rhythm DNA repair 
CRY2 CSNK1D 7.1 circadian rhythm DNA repair 
TIM TREX1 23.8 circadian rhythm DNA repair 
CRY1 CLOCK 20.7 DNA repair circadian rhythm 
CRY1 NPAS2 22.1 DNA repair circadian rhythm 
CRY1 PER1 18.6 DNA repair circadian rhythm 
CRY1 BHLHE40 18.6 DNA repair circadian rhythm 
CRY1 PER2 17.1 DNA repair circadian rhythm 
CRY2 CLOCK 0 DNA repair circadian rhythm 
CRY2 NPAS2 1.6 DNA repair circadian rhythm 
CRY2 PER1 10.9 DNA repair circadian rhythm 
CRY2 BHLHE40 11.3 DNA repair circadian rhythm 
CRY2 PER2 13.5 DNA repair circadian rhythm 
CSNK1D PER2 14 DNA repair circadian rhythm 
CSNK1E CLOCK 22.4 DNA repair circadian rhythm 
CSNK1E PER1 12.4 DNA repair circadian rhythm 
CSNK1E PER2 14.2 DNA repair circadian rhythm 
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CSNK1E BHLHE40 13 DNA repair circadian rhythm 
NONO BHLHE40 11.9 DNA repair circadian rhythm 
NONO PER1 11.3 DNA repair circadian rhythm 
NONO PER2 14 DNA repair circadian rhythm 
CRY1 TIM 19.8 DNA repair circadian rhythm 
CRY2 TIM 10.3 DNA repair circadian rhythm 
CSNK1D PER1 10.8 DNA repair circadian rhythm 
CHEK1 TIM 14.8 DNA repair circadian rhythm 
ARNTL EPAS1 22.5 circadian rhythm hemopoiesis 
ARNTL HIF1A 22.4 circadian rhythm hemopoiesis 
NPAS2 RARA 0.6 circadian rhythm hemopoiesis 
EPAS1 ARNTL2 9.4 hemopoiesis circadian rhythm 
HIF1A PER1 11.4 hemopoiesis circadian rhythm 
PER2 BTRC 13.8 circadian rhythm interaction between organisms 
ARNTL EP300 22.9 circadian rhythm interaction between organisms 
ARNTL KAT2B 22.6 circadian rhythm interaction between organisms 
NPAS2 RXRA 1.6 circadian rhythm interaction between organisms 
NPAS2 KAT2B 1.6 circadian rhythm interaction between organisms 
CREBBP NPAS2 1.8 
interaction between 
organisms circadian rhythm 
EP300 CLOCK 0.6 
interaction between 
organisms circadian rhythm 
EP300 NPAS2 1.6 
interaction between 
organisms circadian rhythm 
STAT3 BHLHE40 9.1 
interaction between 
organisms circadian rhythm 
UBE2I BHLHE40 10.8 
interaction between 
organisms circadian rhythm 
KAT2B CLOCK 0.3 
interaction between 
organisms circadian rhythm 
ARNTL HSP90AA1 21.7 circadian rhythm response to organic substance 
NPAS2 RARA 0.6 circadian rhythm response to organic substance 
PPP2CA BHLHE40 11.9 
response to organic 
substance circadian rhythm 
PPP2R1A BHLHE40 10.6 
response to organic 
substance circadian rhythm 
PRKCA PER2 13.6 
response to organic 
substance circadian rhythm 
HSP90AA1 NPAS2 23.5 
response to organic 
substance circadian rhythm 
STAT3 BHLHE40 9.1 
response to organic 
substance circadian rhythm 
PER2 BTRC 13.8 circadian rhythm positive regulation of molecular function 
ARNTL EP300 22.9 circadian rhythm positive regulation of molecular function 
ARNTL HIF1A 22.4 circadian rhythm positive regulation of molecular function 
EP300 CLOCK 0.6 
regulation of molecular 
function circadian rhythm 
EP300 NPAS2 1.6 
regulation of molecular 
function circadian rhythm 
HIF1A PER1 11.4 
regulation of molecular 
function circadian rhythm 
ARNTL CLOCK 22.6 circadian rhythm transcrip. from RNA poly. II promot. 
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ARNTL NPAS2 23.5 circadian rhythm transcrip. from RNA poly. II promot. 
CRY1 CLOCK 20.7 circadian rhythm transcrip. from RNA poly. II promot. 
CRY1 NPAS2 22.1 circadian rhythm transcrip. from RNA poly. II promot. 
CRY2 CLOCK 0 circadian rhythm transcrip. from RNA poly. II promot. 
CRY2 NPAS2 1.6 circadian rhythm transcrip. from RNA poly. II promot. 
NPAS2 CLOCK 0.3 circadian rhythm transcrip. from RNA poly. II promot. 
BHLHE40 CLOCK 19.8 circadian rhythm transcrip. from RNA poly. II promot. 
PER2 CLOCK 15.8 circadian rhythm transcrip. from RNA poly. II promot. 
ARNTL EP300 22.9 circadian rhythm transcrip. from RNA poly. II promot. 
ARNTL EPAS1 22.5 circadian rhythm transcrip. from RNA poly. II promot. 
ARNTL HIF1A 22.4 circadian rhythm transcrip. from RNA poly. II promot. 
ARNTL NPAS4 22.2 circadian rhythm transcrip. from RNA poly. II promot. 
NPAS2 RXRA 1.6 circadian rhythm transcrip. from RNA poly. II promot. 
ARNTL CRY1 21.2 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
ARNTL CRY2 22.5 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
ARNTL BHLHE40 21.5 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
NPAS2 BHLHE40 1.1 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
CLOCK ARNTL2 22.6 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
AHR ARNTL 22.8 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
EP300 CLOCK 0.6 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
EP300 NPAS2 1.6 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
EPAS1 ARNTL2 9.4 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
HIF1A PER1 11.4 
 transcrip. from RNA poly. 
II promot. circadian rhythm 
CRY1 TIM 19.8 circadian rhythm regulation of cell proliferation 
CRY2 TIM 10.3 circadian rhythm regulation of cell proliferation 
PER1 TIM 12.4 circadian rhythm regulation of cell proliferation 
PER2 TIM 14.4 circadian rhythm regulation of cell proliferation 
ARNTL HIF1A 22.4 circadian rhythm regulation of cell proliferation 
ARNTL KAT2B 22.6 circadian rhythm regulation of cell proliferation 
NPAS2 KAT2B 1.6 circadian rhythm regulation of cell proliferation 
TIM TIPIN 0.3 circadian rhythm regulation of cell proliferation 
DBP CLOCK 9.9 
regulation of cell 
proliferation circadian rhythm 
PRKCA PER2 13.6 
regulation of cell 
proliferation circadian rhythm 
CHEK1 TIM 14.8 
regulation of cell 
proliferation circadian rhythm 
HIF1A PER1 11.4 
regulation of cell 
proliferation circadian rhythm 
KAT2B CLOCK 0.3 
regulation of cell 
proliferation circadian rhythm 
CRY1 CLOCK 20.7 DNA repair transcrip. from RNA poly. II promot. 
CRY1 NPAS2 22.1 DNA repair transcrip. from RNA poly. II promot. 
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CRY2 CLOCK 0 DNA repair transcrip. from RNA poly. II promot. 
CRY2 NPAS2 1.6 DNA repair transcrip. from RNA poly. II promot. 
CSNK1E CLOCK 22.4 DNA repair transcrip. from RNA poly. II promot. 
CSNK1E RORA 20.2 DNA repair transcrip. from RNA poly. II promot. 
ATRX HDAC1 7.6 DNA repair transcrip. from RNA poly. II promot. 
ARNTL CRY1 21.2 
transcrip. from RNA poly. 
II promot. DNA repair 
ARNTL CRY2 22.5 
transcrip. from RNA poly. 
II promot. DNA repair 
ARNTL CSNK1E 22.1 
transcrip. from RNA poly. 
II promot. DNA repair 
AR NONO 16.1 
transcrip. from RNA poly. 
II promot. DNA repair 
CEBPA CEBPG 9.4 
transcrip. from RNA poly. 
II promot. DNA repair 
EP300 PCNA 6.1 
transcrip. from RNA poly. 
II promot. DNA repair 
HDAC1 PCNA 15.1 
transcrip. from RNA poly. 
II promot. DNA repair 
Table 14. KEGG Pathway Analysis of Network Extension Components. 
KEGG ID p-value FDR Term 
5200 0.0000 0.0000 Pathways in cancer 
5221 0.0000 0.0001 Acute myeloid leukemia 
4330 0.0000 0.0002 Notch signaling pathway 
5215 0.0001 0.0003 Prostate cancer 
5016 0.0001 0.0004 Huntington's disease 
4110 0.0006 0.0058 Cell cycle 
4916 0.0006 0.0058 Melanogenesis 
5211 0.0013 0.0106 Renal cell carcinoma 
4062 0.0054 0.0318 Chemokine signaling pathway 
4670 0.0071 0.0382 Leukocyte transendothelial migration 
4120 0.0149 0.0645 Ubiquitin mediated proteolysis 
4630 0.0279 0.1009 Jak-STAT signaling pathway 
Table 15. RNAi Constructs Used for Systematic Screen for Network Neighborhood Components. 
Gene ID h Sym. h RNAi clone ID Supplier 
196 AHR V2LHS_132480 Open Biosystems 
196 AHR V2LHS_132482 Open Biosystems 
207 AKT1 V2LHS_192049 Open Biosystems 
367 AR V2LHS_149847 Open Biosystems 
367 AR V2LHS_149850 Open Biosystems 
367 AR V2LHS_239220 Open Biosystems 
367 AR V2LHS_239574 Open Biosystems 
9070 ASH2L V2LHS_245205 Open Biosystems 
9070 ASH2L V2LHS_41272 Open Biosystems 
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466 ATF1 V2LHS_244510 Open Biosystems 
466 ATF1 V2LHS_48799 Open Biosystems 
466 ATF1 V2LHS_48799 Open Biosystems 
466 ATF1 V2LHS_48801 Open Biosystems 
1822 ATN1 V2LHS_151237 Open Biosystems 
546 ATRX V2LHS_11512 Open Biosystems 
546 ATRX V2LHS_201895 Open Biosystems 
546 ATRX V2LHS_202296 Open Biosystems 
546 ATRX V2LHS_202335 Open Biosystems 
546 ATRX V2LHS_202920 Open Biosystems 
546 ATRX V2LHS_228887 Open Biosystems 
546 ATRX V2LHS_93286 Open Biosystems 
10538 BATF V2LHS_197450 Open Biosystems 
10538 BATF V2LHS_200084 Open Biosystems 
10538 BATF V2LHS_254489 Open Biosystems 
760 CA2 V2LHS_89120 Open Biosystems 
1054 CEBPG V2LHS_150519 Open Biosystems 
1054 CEBPG V2LHS_150521 Open Biosystems 
1054 CEBPG V2LHS_150523 Open Biosystems 
1108 CHD4 V2LHS_112987 Open Biosystems 
1108 CHD4 V2LHS_112988 Open Biosystems 
1108 CHD4 V2LHS_112990 Open Biosystems 
1108 CHD4 V2LHS_14657 Open Biosystems 
1111 CHEK1 V2LHS_112994 Open Biosystems 
1111 CHEK1 V2LHS_112996 Open Biosystems 
10488 CREB3 V2LHS_197887 Open Biosystems 
10488 CREB3 V2LHS_199720 Open Biosystems 
90993 CREB3L1 V2LHS_99572 Open Biosystems 
1387 CREBBP V2LHS_24251 Open Biosystems 
1390 CREM V2LHS_150902 Open Biosystems 
1390 CREM V2LHS_150904 Open Biosystems 
1390 CREM V2LHS_150907 Open Biosystems 
1390 CREM V2LHS_7070 Open Biosystems 
8451 CUL4A V2LHS_32526 Open Biosystems 
8451 CUL4A V2LHS_32527 Open Biosystems 
8451 CUL4A V2LHS_32529 Open Biosystems 
8450 CUL4B V2LHS_32515 Open Biosystems 
8450 CUL4B V2LHS_32517 Open Biosystems 
1642 DDB1 V2LHS_151130 Open Biosystems 
1642 DDB1 V2LHS_151132 Open Biosystems 
1786 DNMT1 V2LHS_113503 Open Biosystems 
1786 DNMT1 V2LHS_113505 Open Biosystems 
1788 DNMT3A V2LHS_189136 Open Biosystems 
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1788 DNMT3A V2LHS_200445 Open Biosystems 
1788 DNMT3A V2LHS_201692 Open Biosystems 
1788 DNMT3A V2LHS_202364 Open Biosystems 
1788 DNMT3A V2LHS_202453 Open Biosystems 
1788 DNMT3A V2LHS_202509 Open Biosystems 
1788 DNMT3A V2LHS_74666 Open Biosystems 
1788 DNMT3A V2LHS_74667 Open Biosystems 
1788 DNMT3A V2LHS_74668 Open Biosystems 
1789 DNMT3B V2LHS_11913 Open Biosystems 
1789 DNMT3B V2LHS_77230 Open Biosystems 
1789 DNMT3B V2LHS_77233 Open Biosystems 
1789 DNMT3B V2LHS_77234 Open Biosystems 
1810 DR1 V2LHS_151221 Open Biosystems 
51514 DTL V2LHS_225424 Open Biosystems 
1876 E2F6 V2LHS_151292 Open Biosystems 
1876 E2F6 V2LHS_151297 Open Biosystems 
8726 EED V2LHS_23172 Open Biosystems 
2034 EPAS1 V2LHS_113750 Open Biosystems 
2034 EPAS1 V2LHS_113753 Open Biosystems 
2034 EPAS1 V2LHS_225592 Open Biosystems 
2770 GNAI1 V2LHS_114161 Open Biosystems 
2770 GNAI1 V2LHS_114162 Open Biosystems 
2771 GNAI2 V2LHS_114165 Open Biosystems 
2782 GNB1 V2LHS_114181 Open Biosystems 
2782 GNB1 V2LHS_114185 Open Biosystems 
2782 GNB1 V2LHS_114186 Open Biosystems 
9737 GPRASP1 V2LHS_259021 Open Biosystems 
83743 GRWD1 V2LHS_117549 Open Biosystems 
3054 HCFC1 V2LHS_37684 Open Biosystems 
3054 HCFC1 V2LHS_37685 Open Biosystems 
29915 HCFC2 V2LHS_247453 Open Biosystems 
29915 HCFC2 V2LHS_65548 Open Biosystems 
29915 HCFC2 V2LHS_65550 Open Biosystems 
3065 HDAC1 V2LHS_61808 Open Biosystems 
3065 HDAC1 V2LHS_61809 Open Biosystems 
3065 HDAC1 V2LHS_61813 Open Biosystems 
3066 HDAC2 V2LHS_132136 Open Biosystems 
3091 HIF1A V2LHS_132150 Open Biosystems 
3091 HIF1A V2LHS_132151 Open Biosystems 
3091 HIF1A V2LHS_132152 Open Biosystems 
3091 HIF1A V2LHS_236718 Open Biosystems 
3131 HLF V2LHS_133079 Open Biosystems 
3131 HLF V2LHS_133080 Open Biosystems 
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3131 HLF V2LHS_133082 Open Biosystems 
3131 HLF V2LHS_133083 Open Biosystems 
8850 KAT2B V2LHS_53088 Open Biosystems 
8850 KAT2B V2LHS_53089 Open Biosystems 
8850 KAT2B V2LHS_53090 Open Biosystems 
8850 KAT2B V2LHS_53091 Open Biosystems 
55885 LMO3 V2LHS_240458 Open Biosystems 
55885 LMO3 V2LHS_30925 Open Biosystems 
4163 MCC V2LHS_151622 Open Biosystems 
4163 MCC V2LHS_151627 Open Biosystems 
4163 MCC V2LHS_261826 Open Biosystems 
4163 MCC V2LHS_262535 Open Biosystems 
4163 MCC V2LHS_263032 Open Biosystems 
5469 MED1 V2LHS_35711 Open Biosystems 
5469 MED1 V2LHS_35711 Open Biosystems 
5469 MED1 V2LHS_35712 Open Biosystems 
5469 MED1 V2LHS_35713 Open Biosystems 
5469 MED1 V2LHS_35715 Open Biosystems 
4221 MEN1 V2LHS_76605 Open Biosystems 
4297 MLL V2LHS_196843 Open Biosystems 
4297 MLL V2LHS_198242 Open Biosystems 
4297 MLL V2LHS_198375 Open Biosystems 
4609 MYC V2LHS_152050 Open Biosystems 
4609 MYC V2LHS_152051 Open Biosystems 
4654 MYOD1 V2LHS_152109 Open Biosystems 
8648 NCOA1 V2LHS_23965 Open Biosystems 
8648 NCOA1 V2LHS_23968 Open Biosystems 
8648 NCOA1 V2LHS_23970 Open Biosystems 
10499 NCOA2 V2LHS_12526 Open Biosystems 
10499 NCOA2 V2LHS_199743 Open Biosystems 
8202 NCOA3 V2LHS_206733 Open Biosystems 
8202 NCOA3 V2LHS_206740 Open Biosystems 
8202 NCOA3 V2LHS_206781 Open Biosystems 
8202 NCOA3 V2LHS_207128 Open Biosystems 
8202 NCOA3 V2LHS_261936 Open Biosystems 
57727 NCOA5 V2LHS_200338 Open Biosystems 
57727 NCOA5 V2LHS_200715 Open Biosystems 
9611 NCOR1 V2LHS_196602 Open Biosystems 
9611 NCOR1 V2LHS_91777 Open Biosystems 
9611 NCOR1 V2LHS_91778 Open Biosystems 
9611 NCOR1 V2LHS_91779 Open Biosystems 
9612 NCOR2 V2LHS_196739 Open Biosystems 
9612 NCOR2 V2LHS_251658 Open Biosystems 
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4830 NME1 V2LHS_76045 Open Biosystems 
4830 NME1 V2LHS_76046 Open Biosystems 
4830 NME1 V2LHS_76050 Open Biosystems 
4831 NME2 V2LHS_152291 Open Biosystems 
9722 NOS1AP V2LHS_103917 Open Biosystems 
9722 NOS1AP V2LHS_103920 Open Biosystems 
266743 NPAS4 V2LHS_118806 Open Biosystems 
266743 NPAS4 V2LHS_118807 Open Biosystems 
266743 NPAS4 V2LHS_118808 Open Biosystems 
190 NR0B1 V2LHS_239255 Open Biosystems 
190 NR0B1 V2LHS_239628 Open Biosystems 
190 NR0B1 V2LHS_93206 Open Biosystems 
190 NR0B1 V2LHS_93207 Open Biosystems 
10002 NR2E3 V2LHS_199322 Open Biosystems 
10002 NR2E3 V2LHS_239554 Open Biosystems 
83714 NRIP2 V2LHS_117487 Open Biosystems 
83714 NRIP2 V2LHS_117489 Open Biosystems 
83714 NRIP2 V2LHS_117492 Open Biosystems 
23178 PASK V2LHS_87444 Open Biosystems 
23178 PASK V2LHS_87445 Open Biosystems 
5111 PCNA V2LHS_152708 Open Biosystems 
5111 PCNA V2LHS_152710 Open Biosystems 
5111 PCNA V2LHS_261970 Open Biosystems 
5252 PHF1 V2LHS_221739 Open Biosystems 
5371 PML V2LHS_194094 Open Biosystems 
23649 POLA2 V2LHS_170195 Open Biosystems 
23649 POLA2 V2LHS_170199 Open Biosystems 
5430 POLR2A V2LHS_131390 Open Biosystems 
5430 POLR2A V2LHS_131391 Open Biosystems 
5705 PSMC5 V2LHS_170781 Open Biosystems 
5705 PSMC5 V2LHS_170782 Open Biosystems 
5705 PSMC5 V2LHS_170783 Open Biosystems 
5705 PSMC5 V2LHS_170785 Open Biosystems 
5705 PSMC5 V2LHS_302 Open Biosystems 
5705 PSMC5 V2LHS_304 Open Biosystems 
55269 PSPC1 V2LHS_156677 Open Biosystems 
5914 RARA V2LHS_131536 Open Biosystems 
5929 RBBP5 V2LHS_19053 Open Biosystems 
5929 RBBP5 V2LHS_19056 Open Biosystems 
5929 RBBP5 V2LHS_19057 Open Biosystems 
6256 RXRA V2LHS_239551 Open Biosystems 
6256 RXRA V2LHS_31972 Open Biosystems 
6256 RXRA V2LHS_31973 Open Biosystems 
Appendix              - 47 - 
 
6421 SFPQ V2LHS_18691 Open Biosystems 
6421 SFPQ V2LHS_18692 Open Biosystems 
6421 SFPQ V2LHS_240572 Open Biosystems 
6421 SFPQ V2LHS_241826 Open Biosystems 
9410 SNRNP40 V2LHS_68716 Open Biosystems 
9410 SNRNP40 V2LHS_68717 Open Biosystems 
9410 SNRNP40 V2LHS_68720 Open Biosystems 
6667 SP1 V2LHS_179659 Open Biosystems 
6667 SP1 V2LHS_179661 Open Biosystems 
6667 SP1 V2LHS_179662 Open Biosystems 
6667 SP1 V2LHS_221748 Open Biosystems 
6667 SP1 V2LHS_68650 Open Biosystems 
6688 SPI1 V2LHS_278676 Open Biosystems 
6774 STAT3 V2LHS_262105 Open Biosystems 
6774 STAT3 V2LHS_88502 Open Biosystems 
23512 SUZ12 V2LHS_256397 Open Biosystems 
23512 SUZ12 V2LHS_74301 Open Biosystems 
7008 TEF V2LHS_153880 Open Biosystems 
7008 TEF V2LHS_153884 Open Biosystems 
7008 TEF V2LHS_153885 Open Biosystems 
54962 TIPIN V2LHS_174169 Open Biosystems 
54962 TIPIN V2LHS_174170 Open Biosystems 
54962 TIPIN V2LHS_222044 Open Biosystems 
11277 TREX1 V2LHS_115659 Open Biosystems 
11277 TREX1 V2LHS_115661 Open Biosystems 
11277 TREX1 V2LHS_263865 Open Biosystems 
7329 UBE2I V2LHS_171776 Open Biosystems 
7329 UBE2I V2LHS_171781 Open Biosystems 
7329 UBE2I V2LHS_254973 Open Biosystems 
7329 UBE2I V2LHS_8129 Open Biosystems 
7409 VAV1 V2LHS_69841 Open Biosystems 
7409 VAV1 V2LHS_69842 Open Biosystems 
7409 VAV1 V2LHS_69844 Open Biosystems 
7414 VCL V2LHS_171918 Open Biosystems 
7414 VCL V2LHS_171919 Open Biosystems 
Table 16. RNAi Constructs Used for Systematic Screen for 46 Network Components. 
Gene ID h Sym. h RNAi clone ID Supplier 
5187 PER1 V2HS_169842 Open Biosystems 
5187 PER1 V2HS_169845 Open Biosystems 
5187 PER1 V2MM_67435 Open Biosystems 
5187 PER1 V2LHS_169842 Open Biosystems 
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5187 PER1 V2LHS_169845 Open Biosystems 
8864 PER2  V2HS_52938 Open Biosystems 
8864 PER2  V2HS_52937 Open Biosystems 
8864 PER2  V2HS_53009 Open Biosystems 
8864 PER2  V2HS_52939 Open Biosystems 
8864 PER2 V2LHS_52937 Open Biosystems 
8863 PER3  V2HS_154125 Open Biosystems 
8863 PER3  V2HS_154121 Open Biosystems 
8863 PER3 V2LHS_154120 Open Biosystems 
1407 CRY1 V2HS_172866 Open Biosystems 
1407 CRY1 V2HS_172863 Open Biosystems 
1407 CRY1 V2HS_172862 Open Biosystems 
1408 CRY2 V2HS_67007 Open Biosystems 
1408 CRY2 V2HS_67010 Open Biosystems 
1408 CRY2 V2HS_67009 Open Biosystems 
1408 CRY2 V2LHS_67005 Open Biosystems 
8914 TIM V2HS_47525 Open Biosystems 
8914 TIM V2HS_47526 Open Biosystems 
8914 TIM V2LHS_245690 Open Biosystems 
9572 NR1D1 V2HS_239439 Open Biosystems 
9572 NR1D1 V2HS_87199 Open Biosystems 
9572 NR1D1 V2HS_239200 Open Biosystems 
9572 NR1D1 V2HS_239561 Open Biosystems 
9975 NR1D2 V2HS_239239 Open Biosystems 
9975 NR1D2 V2HS_239468 Open Biosystems 
9975 NR1D2 V2HS_49993 Open Biosystems 
9975 NR1D2 V2HS_239350 Open Biosystems 
9975 NR1D2 V2LHS_239488 Open Biosystems 
9975 NR1D2 V2LHS_239383 Open Biosystems 
9975 NR1D2 V2LHS_239570 Open Biosystems 
9975 NR1D2 V2LHS_49921 Open Biosystems 
9975 NR1D2 V2LHS_49922 Open Biosystems 
9975 NR1D2 V2LHS_49994 Open Biosystems 
85457 CIPC V2HS_178395 Open Biosystems 
85457 CIPC V2HS_178399 Open Biosystems 
85457 CIPC V2HS_275456 Open Biosystems 
85457 CIPC V2LHS_178399 Open Biosystems 
79365 DEC2 V2HS_116724 Open Biosystems 
79365 DEC2 V2LHS_116721 Open Biosystems 
79365 DEC2 V2LHS_116719 Open Biosystems 
79365 DEC2 V2LHS_116724 Open Biosystems 
9575 CLOCK V2HS_67386 Open Biosystems 
9575 CLOCK V2HS_67391 Open Biosystems 
4862 NPAS2 V2MM_38437 Open Biosystems 
4862 NPAS2 V2HS_152327 Open Biosystems 
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4862 NPAS2 V2HS_138097 Open Biosystems 
4862 NPAS2 V2HS_152324 Open Biosystems 
406 ARNTL  V2HS_94645 Open Biosystems 
406 ARNTL  V2HS_94643 Open Biosystems 
406 ARNTL  V2HS_94640 Open Biosystems 
56938 ARNTL2 V2HS_50998 Open Biosystems 
56938 ARNTL2 V2HS_51001 Open Biosystems 
56938 ARNTL2 V2LHS_51000 Open Biosystems 
6095 RORA V2HS_32210 Open Biosystems 
6095 RORA V2HS_239080 Open Biosystems 
6095 RORA V2HS_202956 Open Biosystems 
6095 RORA V2LHS_239222 Open Biosystems 
6095 RORA V2LHS_239238 Open Biosystems 
6095 RORA V2LHS_239416 Open Biosystems 
6095 RORA V2LHS_202317 Open Biosystems 
6095 RORA V2LHS_32209 Open Biosystems 
6095 RORA V2LHS_239707 Open Biosystems 
6096 RORB V2HS_94815 Open Biosystems 
6096 RORB V2HS_239246 Open Biosystems 
6096 RORB V2MM_24349 Open Biosystems 
6096 RORB V2LHS_94818 Open Biosystems 
6096 RORB V2LHS_8643 Open Biosystems 
6096 RORB V2LHS_94819 Open Biosystems 
6096 RORB V2LHS_239259 Open Biosystems 
6096 RORB V2LHS_239511 Open Biosystems 
6096 RORB V2LHS_94816 Open Biosystems 
6096 RORB V2LHS_239362 Open Biosystems 
6097 RORC V2HS_239620 Open Biosystems 
6097 RORC V2HS_18863 Open Biosystems 
6097 RORC V2HS_239366 Open Biosystems 
6097 RORC V2LHS_239280 Open Biosystems 
6097 RORC V2LHS_18859 Open Biosystems 
6097 RORC V2LHS_18861 Open Biosystems 
1454 CSNK1E V2HS_192204 Open Biosystems 
1454 CSNK1E V2MM_72981 Open Biosystems 
1453 CSNK1D V2LHS_150979 Open Biosystems 
2932 GSK3B V2HS_114291 Open Biosystems 
2932 GSK3B V2HS_114293 Open Biosystems 
2932 GSK3B V2HS_114292 Open Biosystems 
2932 GSK3B V2HS_114290 Open Biosystems 
1457 CSNK2A1 V2LHS_150990 Open Biosystems 
1457 CSNK2A1 V2LHS_283708 Open Biosystems 
1457 CSNK2A1 V2HS_200683 Open Biosystems 
1457 CSNK2A1 V2MM_34225 Open Biosystems 
1457 CSNK2A1 V2HS_150988 Open Biosystems 
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1459 CSNK2A2 V2LHS_150997 Open Biosystems 
1459 CSNK2A2 V2MM_70928 Open Biosystems 
1460 CSNK2B_1 Prof. Kramer Open Biosystems 
1460 CSNK2B_2 Prof. Kramer Open Biosystems 
1460 CSNK2B_3 Prof. Kramer Open Biosystems 
1460 CSNK2B_4 Prof. Kramer Open Biosystems 
5578 PRKCA V2LHS_218226 Open Biosystems 
5578 PRKCA V2LHS_87125 Open Biosystems 
5578 PRKCA V2LHS_87125 Open Biosystems 
5578 PRKCA V2LHS_170435 Open Biosystems 
5578 PRKCA V2LHS_218656 Open Biosystems 
5578 PRKCA V2LHS_218656 Open Biosystems 
5566 PRKACA V2LHS_170398 Open Biosystems 
5499 PPP1CA V2HS_170297 Open Biosystems 
5499 PPP1CA V2HS_262414 Open Biosystems 
5500 PPP1CB V2HS_220925 Open Biosystems 
5500 PPP1CB V2HS_223243 Open Biosystems 
5500 PPP1CB V2HS_276133 Open Biosystems 
5501 PPP1CC V2HS_170308 Open Biosystems 
5501 PPP1CC V2HS_170309 Open Biosystems 
5501 PPP1CC V2HS_170312 Open Biosystems 
5515 PPP2CA  V2HS_170340 Open Biosystems 
5515 PPP2CA  V2HS_170343 Open Biosystems 
5515 PPP2CA  V2HS_170338 Open Biosystems 
5515 PPP2CA V2LHS_218016 Open Biosystems 
5515 PPP2CA V2LHS_170340 Open Biosystems 
5516 PPP2CB  V2HS_173254 Open Biosystems 
5516 PPP2CB  V2HS_173251 Open Biosystems 
5516 PPP2CB  V2HS_220461 Open Biosystems 
5516 PPP2CB V2LHS_173252 Open Biosystems 
5516 PPP2CB V2LHS_262386 Open Biosystems 
5516 PPP2CB V2LHS_173256 Open Biosystems 
5518 PPP2R1A V2LHS_197495 Open Biosystems 
5518 PPP2R1A V2LHS_198701 Open Biosystems 
5519 PPP2R1B V2LHS_170346 Open Biosystems 
5528 PPP2R5D V2LHS_57934 Open Biosystems 
5528 PPP2R5D V2LHS_57937 Open Biosystems 
5529 PPP2R5E V2LHS_57881 Open Biosystems 
5529 PPP2R5E V2LHS_276146 Open Biosystems 
5529 PPP2R5E V2LHS_170347 Open Biosystems 
5529 PPP2R5E V2LHS_57882 Open Biosystems 
5529 PPP2R5E V2LHS_57880 Open Biosystems 
5536 PPP5C V2HS_57831 Open Biosystems 
5536 PPP5C V2HS_247322 Open Biosystems 
8945 BTRC V2LHS_277057 Open Biosystems 
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8945 BTRC V2LHS_177228 Open Biosystems 
8945 BTRC V2LHS_33329 Open Biosystems 
8945 BTRC V2LHS_33325 Open Biosystems 
8945 BTRC V2LHS_33330 Open Biosystems 
8945 BTRC V2LHS_177233 Open Biosystems 
23291 FBXW11 V2LHS_254528 Open Biosystems 
23291 FBXW11 V2LHS_265946 Open Biosystems 
23291 FBXW11 V2LHS_51187 Open Biosystems 
23291 FBXW11 V2LHS_51191 Open Biosystems 
26224 FBXL3 V2LHS_254736 Open Biosystems 
26224 FBXL3 V2LHS_16078 Open Biosystems 
26224 FBXL3 V2LHS_16079 Open Biosystems 
26224 FBXL3 V2LHS_254741 Open Biosystems 
26224 FBXL3 V2LHS_254986 Open Biosystems 
26224 FBXL3 V2LHS_16077 Open Biosystems 
79176 FBXL15   V2HS_135909 Open Biosystems 
79176 FBXL15 V2LHS_135909 Open Biosystems 
4841 NONO V2HS_52657 Open Biosystems 
4841 NONO V2HS_52659 Open Biosystems 
11091 WDR5 V2HS_140181 Open Biosystems 
51655 RASD1 V2HS_97482 Open Biosystems 
51655 RASD1 V2MM_19224 Open Biosystems 
51655 RASD1 V2LHS_97478 Open Biosystems 
51655 RASD1 V2LHS_97482 Open Biosystems 
2146 EZH2 V2LHS_63067 Open Biosystems 
2146 EZH2 V2LHS_63068 Open Biosystems 
2146 EZH2 V2LHS_17510 Open Biosystems 
2146 EZH2 V2LHS_63066 Open Biosystems 
2146 EZH2 V2LHS_238994 Open Biosystems 
2146 EZH2 V2LHS_17509 Open Biosystems 
2146 EZH2 V2LHS_17507 Open Biosystems 
4783 NFIL3 V2HS_243549 Open Biosystems 
4783 NFIL3 V2LHS_36553 Open Biosystems 
4783 NFIL3 V2LHS_243549 Open Biosystems 
1628 DBP V2LHS_113404 Open Biosystems 
1628 DBP V2LHS_113406 Open Biosystems 
Table 17. Expression Plasmids. 
No. Vector  Source 
1 pACT4-DM Prof. Wanker 
2 pBTM116-D9 Prof. Wanker 
3 pcMYC-CMV-D12 Prof. Wanker 
4 pFLAG-CMV-D11 Prof. Wanker 
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5 pENTR/D-TOPO  Invitrogen 
6 pDEST 26 Invitrogen 
7 pLenti6 Invitrogen 
8 pGL3-Promoter Vector Promega 
9 phRL-SV40 Vector Promega 
10 pGL3-Basic Vector Promega 
11 pGIPZ constructs Open Biosystems 
 
Expression vector maps: 
Yeast expression vectors: 
Prey configuration [39]: 
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Bait configuration [39]: 
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Mammalian expression vectors: 
MYC-fusion expression (Prof. Wanker):  
 
FLAG-fusion expression (Prof. Wanker):  
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Vector maps were taken from Ivitrogen user’s manual. 
pENTR/D-TOPO (Invitrogen): 
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pDEST 26 (Invitrogen): 
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pLenti6 (Invitrogen): 
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Reporter vectors: 
Vector maps were taken from Promega users’s manual. 
Promega Dual-Luciferase Reporter Assay System (firefly luciferase reporter): 
 
Promega Dual-Luciferase Reporter Assay System (Renilla luciferase reporter): 
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Promega Dual-Luciferase Reporter Assay System (pGL3-Basic Vector): 
 
 
pGIPZ empty vector (Open Biosystems): 
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